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ABSTRACT 
 
 
 Candida albicans is the most prevalent human fungal pathogen, found as a 
commensal organism in the mucosa, gastrointestinal, and urogenital tracts of humans.  
This pathogenic fungus causes a wide spectrum of diseases, including the mucosal 
infection oropharyngeal candidiasis (OPC) which frequently effects patients with human 
immunodeficiency virus (HIV).  The azole antifungals (such as fluconazole) are the most 
widely used and important ergosterol biosynthesis inhibitors (EBIs) for the treatment of 
Candida infections, including OPC.  However, the azoles are fungistatic against C. 
albicans and therefore have limited efficacy against this organism, especially for 
immunocompromised patients.   
 
 In C. albicans, the transcription factor Upc2 is central to the regulation of 
ergosterol biosynthesis.  UPC2 activating mutations contribute to azole resistance, 
whereas disruption increases azole susceptibility.  We further investigated the 
relationship of UPC2 to fluconazole susceptibility, particularly in azole-resistant strains.  
In addition to the reduced fluconazole minimum inhibitory concentration (MIC) 
previously observed with UPC2 disruption, we observed a reduced minimum fungicidal 
concentration (MFC) in a upc2∆/∆ mutant relative to its azole-susceptible parent SC5314.  
Moreover, upc2∆/∆ was unable to grow on solid media containing 10 µg/mL fluconazole 
and exhibited increased susceptibility and a clear zone of inhibition when subjected to 
Etest.  Time-kill analysis showed increased azole activity against upc2∆/∆ compared to 
SC5314.  UPC2 disruption in strains carrying specific resistance mutations also resulted 
in reduced MICs and MFCs.  UPC2 disruption in a highly azole-resistant clinical isolate 
containing multiple resistance mechanisms likewise resulted in a reduced MIC and MFC.  
This mutant was unable to grow on solid media containing 10 µg/mL fluconazole and 
exhibited increased susceptibility and a clear zone of inhibition when subjected to Etest.  
Time-kill analysis showed increased azole activity against the upc2∆/∆ mutant in the 
resistant background. Microarray analysis showed attenuated fluconazole induction of 
genes involved in sterol biosynthesis as well as iron transport and homeostasis in the 
absence of UPC2.  Taken together, our results demonstrate that the UPC2 transcriptional 
network is universally essential for azole resistance in C. albicans and represents an 
attractive target for enhancing azole antifungal activity.    
 
 Fungal survival in the presence of the azoles is permitted by specific signal 
transduction and transcriptional activation programs.  In an effort to identify additional 
transcriptional pathways involved in fluconazole susceptibility, we sought to identify 
transcription factors (TFs) essential for this process.  From a collection of C. albicans 
strains disrupted for genes encoding TFs (Homann et al., PLoS Genet. 2009;5:e1000783), 
4 exhibited marked reduction in MFC in both RPMI and YPD media independent of any 
noted growth defect in medium alone as compared to the parent strain.  In addition to 
UPC2, one gene of interest (GOI) (CAS5) was unable to recover from fluconazole 
exposure at concentrations as low as 2 µg/mL after 72 hours in YPD medium, showed 
reduced susceptibility and a clear zone of inhibition by Etest, was unable to grow on solid 
media containing 10 µg/mL fluconazole, and exhibited increased susceptibility by time-
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kill analysis.  CAS5 disruption in highly azole resistant clinical isolates containing 
multiple resistance mechanisms did not alter susceptibility.  However, CAS5 disruption in 
strains containing specific resistance mutations resulted in a moderate reduction in MIC 
and MFC.  Genome-wide transcriptional analysis was performed in the presence of 
fluconazole and was consistent with the suggested role of CAS5 in cell wall organization 
while also suggesting a role in iron transport and homeostasis.  These findings suggest 
that Cas5 regulates a transcriptional network that influences susceptibility of C. albicans 
to fluconazole.  Further delineation of this transcriptional network may identify targets 
for potential co-therapeutic strategies to enhance the activity to the azole class of 
antifungals. 
 
 Genome-wide expression profiling identified that ergosterol biosynthesis genes 
depend on Upc2 for their fluconazole-induceability, and cell wall maintenance genes 
depend on Cas5.  In the presence of fluconazole, the expression of iron ion transport and 
homeostasis genes were also identified to be dependent on Upc2 as well as Cas5.  The 
identification of these target genes validated the known and putative roles for Upc2 and 
Cas5, and also provided insight into novel roles for these transcription factors in azole 
susceptibility.  
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CHAPTER 1.    INTRODUCTION 
 
 
CANDIDA ALBICANS 
 
 
Physiology 
 
 Candida albicans is an opportunistic fungal pathogen commonly found as a 
commensal organisms in the oropharyngeal cavity, gastrointestinal track, and vagina of 
up to 75% of humans (1, 2).  It is a dimorphic fungus and exists as a blastospore (or yeast 
cell) at temperatures below 35°C with glucose as a carbon source and in a filamentous 
cell when above 35°C and in the presence of serum (3).  Blastospores are spherical, 
single cells that undergo mitosis by budding.  After the completion of mitosis, a septum 
forms between the two cells and separation results in two asymmetrical mother and 
daughter cells similar to Saccharomyces cerevisiae (4).  Under filamentous conditions, C. 
albicans can form hyphae or pseudohyphae.  The formation of hyphae occurs when a 
blastospore induces the elongation site and subsequently extends a germ tube and forms a 
septum without constrictions after mitosis, but the cells do not separate (5).  Instead, the 
hypha continues to elongate.  Pseudohyphae are formed when a blastospore buds but the 
cells remain attached to each other after the formation of the septum, and the daughter 
cell subsequently elongates into a shape resembling a hypha.  As the cells undergo 
mitosis, this process repeats with each terminal cell resulting in a chain of elongated cells 
(4-6). 
 
 The ability of C. albicans to change its morphology between these forms is 
considered to be a virulence factor, promoting disseminated infection and forming 
biofilms, and is regulated by various environmental signals (7-10).  Although it typically 
colonizes the mucocutaneous surfaces, the hyphal phase is able to invade into deeper 
tissues and cause damage, particularly when the host defenses are compromised (11).  C. 
albicans switches back to yeast cells once in the bloodstream in order for dissemination 
(12).  These morphologies also play a role in the formation of biofilms, which typically 
occur on the surfaces of indwelling devices such as catheters and dentures.  Biofilms 
begin forming when blastospores adhere to these devices and then form a thick hyphal 
layer, which subsequently disperses more fungal cells (13).  Biofilms have been shown to 
be resistance to antifungal drugs and is due to prevention of drug penetration by the 
extracellular matrix, drug efflux, and persister cells within the biofilms (14-18). 
 
 The yeast to hyphal transition, which occurs during fungal invasion, also 
significantly alters the composition of the cell wall.  The outermost layer of the Candida 
cell wall is composed of mannans and mannoproteins, while the inner layer is composed 
of β-1,3-glucan and chitin.  Although the outer layer of mannan masks underlying cell 
wall components such as β-1,3-glucan, they become exposed during hyphal transition at 
the bud scars and also by removal of this outer layer by heat inactivation, antifungal 
drugs, or mutations in the mannan layer (19-25).  These cell wall components are the 
main source of pathogen-associated molecular patterns (PAMPs) recognized by the 
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pattern recognition receptors (PRRs) of the cells of the immune system, and their 
interaction is critical for establishing an anti-Candida immune response (26).   
 
 
Genetics 
 
 C. albicans is a diploid yeast with no haploid stage during its cell cycle.  
Sequencing of its genome shows that it possesses 6,354 putative genes contained in 8 
chromosomes (27).  It lacks a conventional sexual cycle and instead its reproduction is 
mostly clonal.  There does exist a mating type locus on chromosome 5, but the 
occurrence of meiotic recombination is infrequent (28).  
 
 Due to its lack of a traditional sexual cycle or a haploid stage, the diploid state of 
C. albicans makes it difficult to isolate homozygous mutants carrying recessive 
mutations.  In the past, mild mutagenesis only resulted in the generation of auxotrophs 
(29, 30).  Combining mild mutagenesis with ultraviolet light increases the types of 
mutations, but also generates unwanted genomic alterations and therefore genetically 
undefined mutants.  Reliable methods for gene disruption have been developed which 
utilize electroporation transformation by homologous recombination, which occurs with a 
plasmid-resident gene, and results in chromosomal integration and ensures stable 
inheritance.   
 
 Auxotrophic strains were developed for use in transformation experiments, and 
the most common marker used is URA3 because of the ease of selection for the correct 
transformants.  The URA-blaster method of gene disruption uses this marker flanked by 
direct repeats of bacterial hisG sequences.  The cassette is constructed to contain the 5’ 
and 3’ regions of the targeted gene on either side of the hisG sequences.  Upon 
transformation into a ura- strain, one allele is replaced with the cassette by homologous 
recombination.  Positive selection for the presence of the disruption cassette in the first 
allele occurs by growth on media lacking uridine.  Counterselection then occurs by 
plating on media containing 5-fluorooronic acid (5-FOA), which only allows for the 
growth of ura- strains which arise by homologous recombination between the hisG 
sequences.  The presence of the URA3 gene, encoding orotidine 5’-phosphate 
decarboxylase, results in the conversion of 5-FOA to 5-fluorouracil, which is toxic to the 
cell.  The counterselected heterozygous cells then undergo a second round of 
transformation and selection for disruption of the second allele.  However, auxotrophic 
strains exhibit decreased virulence and limit the background from which genes may be 
deleted.  Additionally, repeated use of this method leaves behind hisG sequences, 
providing homology sites for unwanted integration events (31). 
 
 Transformation methods using a dominant resistance marker suitable for routine 
transformation of clinical isolates would be ideal.  Two such methods have been 
developed independent of auxotrophy.  These methods utilize dominant resistance 
markers conferring resistance to either mycophenolic acid or nourseothricin which are 
fused to a site-specific FLP recombinase, modified from S. cerevisiae, controlled by a 
SAP2 or MAL2 promoter respectively.  The markers are flanked by direct repeats of the 
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FLP recognition target (FRT) and cassettes are constructed to contain the 5’ and 3’ 
regions of the targeted gene on either side of the FRT sites.  After integration into the first 
allele, the promoter is induced and the FLP recombinase removes the dominant marker 
and FLP sequences.  A second round generates a mutant which differs from its 
background strain only by the lack of a gene and the presence of FRT sequences (32-34). 
 
 
Epidemiology of Infection 
 
 In recent decades, fungi have emerged as a major cause of disease particularly for 
individuals who are immunocompromised or hospitalized with a serious underlying 
disease (35-39).  This increased incidence of infections caused by fungi correlates to the 
growth of the immunocompromised and immunosuppressed patient population.  Immune 
defects caused by hematopoietic stem cell transplantation, solid organ transplantation, 
major surgery, HIV/AIDS, neoplastic disease, immunosuppressive therapy, advanced 
age, or premature birth are all high risk factors for fungal infections (37, 38, 40-44).   
 
 The most important opportunistic fungal pathogen is the Candida spp. and are the 
fourth leading cause of nosocomial blood stream infections in the United States (45).  As 
stated previously, Candida spp. are common commensal organisms in the oropharyngeal 
cavity, gastrointestinal track, and vagina of humans.  This organism is capable of 
opportunistic infection upon disruption of the normal flora by  broad spectrum 
antimicrobial treatment, a breach in the mucocutaneous barrier due to surgery or the 
presence of catheters, or defects in the host immune system caused by neutropenia, 
HIV/AIDS, chemotherapy, and organ or bone marrow transplantation (2). 
 
 The most common fungal infections that occur are invasive and mucosal 
infections.  Invasive candidiasis can occur in the bloodstream or in one or more organs 
and candidemia is the most common form of invasive candidiasis (45), typically 
occurring in hospitalized patients with serious underlying conditions.  The incidence of 
nosocomial candidiasis has steadily increased over the past three decades along with the 
widespread use of central venous catheters, broad spectrum antimicrobial agents, 
corticosteroids and cytotoxic chemotherapeutic agents.  Such immunosuppression 
impairs the ability to fight opportunistic infections.  Patients with candidemia are twice as 
likely to die during hospitalization as compared to noncandidal blood stream infections 
(46), with 10-49% mortality (47, 48). 
 
 Mucosal candidiasis mainly presents as vulvovaginal candidiasis (VVC) or 
oropharyngeal candidiasis (OPC).  VVC typically occurs in women of childbearing age, 
but also occurs due to antibiotic use, immunosuppressive therapy, hormone replacement 
therapy, and diabetes mellitus (49).  OPC can occur in elderly patients with dentures, 
providing a surface on which Candida can adhere, which is resolved by removal of the 
dentures and proper dental hygiene (50, 51).  In AIDS patients, OPC is most the 
commonly encountered opportunistic infection (52-54).  Such an infection occurs on the 
soft and hard palates, pharynx, tongue, and buccal mucosa, and is typically the first 
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clinical sign of an underlying HIV infection (55).  The occurrence of OPC increases as 
CD4+ cells decrease below 200 cells/mm3 (56).   
 
 The increasing susceptibility of HIV/AIDS patients to opportunistic fungal 
infections occurring alongside the loss in CD4+ cells implicates that the cytokines 
produced by these cells are important for immunity to Candida (57).  Indeed, functional 
cell-mediated immune responses are important for the host’s defense against Candida 
spp.  This is made evident by the engagement of PRRs on antigen presenting cells 
(APCs) by Candida, resulting in the secretion of specific cytokines which in turn promote 
the differentiation of activated CD4+ T cells into Th17 cells (58).  These cells express the 
cytokine IL-17 and signaling through the IL-17 receptor (IL-17R) is crucial for an 
effective anti-Candida immune response (59).   
 
 Due to their enhanced susceptibility, up to 90% of all AIDS patients contract OPC 
and many die as a direct consequence (56).  A significant decrease in HIV-related 
opportunistic infections, including OPC, occurred upon the advent of highly active 
antiretroviral therapy (HARRT).  However, significant morbidity associated with 
Candida continues for the HIV/AIDS patient population due to high cost, insufficient 
monitoring, and poor patient compliance (55, 60).  
 
 
Treatment of Candida Infections 
 
 Despite the wide spectrum of disease caused by C. albicans, there are few 
fundamentally different classes of clinical antifungals available for treatment due to 
limited unique and important fungal-specific targets which are not found in the host (61).  
Currently available antifungal drugs act primarily on the fungal cell wall and ergosterol 
found in the cell membrane.  The fungal cell wall displays an electron-dense fibrillar 
outer layer composed of mannoproteins and an inner layer of glucans (such as β-1,3-
glucan) and chitin which confer elasticity and tensile strength to the cell wall (62, 63).  
Ergosterol is found in the fungal cell membrane and regulates membrane fluidity and 
asymmetry, and ultimately membrane integrity and transport across the membrane (64).  
Perturbation of either of these components impacts the fungal cell’s survival.  Both 
components are exploitable drug targets as the cell wall is essential for survival, and 
human cells lack both cell walls and ergosterol.  The currently available antifungals 
which are primarily used for treatment include the polyenes, the azoles and the 
echinochandins (65). 
 
 Polyenes, such as amphotericin B (AmB), directly bind to membrane ergosterol 
and as a result cause impairment of yeast cell physiology (66-71).  Channel formation 
and subsequent membrane permeabilization is a secondary mechanism that enhances the 
antifungals activity (72).  It has a broad spectrum of action including most major fungal 
pathogens and was the sole drug available to control fungal infections for 30 years (73).  
For oral infection its use is usually limited to topical application as it is not readily 
absorbed from the gut (74).  It is primarily given intravenously (IV) for systemic 
infections but has been associated with significant nephrotoxicity.  The development of 
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lipid formulations allowed for higher doses with less toxicity but they are more costly 
(75-77).  Despite its fungicidal activity, cases of resistance have occasionally been 
reported (78). 
 
 The azoles represented a major advancement in ability to safely and effectively 
treat local and systemic fungal infections, and their high safety profile led to extensive 
use (65, 79).  Fluconazole (FLC) inhibits ergosterol production essential in cell 
membrane formation (80) by targeting the product of ERG11, a critical cytochrome P450 
enzyme of the ergosterol biosynthesis pathway known as lanosterol 14α-demethylase 
which demethylates lanosterol (81).  Inhibition of this enzyme results in depletion of 
ergosterol and accumulation of toxic sterol intermediates including 14α-methylated 
sterols which alters membrane structure and function, and ultimately disrupts its integrity 
(79, 82).  The azoles are available in both IV and oral formulations, and are currently the 
only oral option.  Oral administration of fluconazole undergoes relatively little 
metabolism, is absorbed rapidly, is less toxic than AmB and is relatively inexpensive (77, 
80, 83, 84).  One drawback is its fungistatic activity instead of being fungicidal (61, 85) 
and as a result facilitates the development of resistance (86-88). 
 
 The echinochandins, such as caspofungin, are the most recent class of antifungal 
drugs.  They act by inhibiting (1,3)-β-D-glucan synthase which is required for glucan 
synthesis, an important structure in the fungal cell wall (77).  This class of antifungal 
represents significant advancement in antifungal therapy attributed to their fungicidal 
activity, proven clinical efficacy, and limited toxicity and drug-drug interactions.  
However, they are only available IV and are associated with moderate cost which 
somewhat limits their utility. 
 
 
FUNGISTATIC AZOLE ACTIVITY AND AZOLE RESISTANCE 
 
 
Clinical Impact of Fungistatic Azole Activity 
 
 As mentioned above, the fungistatic nature of azoles limits their efficacy (61, 85).  
The fungal cells are able to grow despite the inhibitory effects of the antifungal agent 
(61).  Therefore, the inability to kill fungal cells may facilitate the development of 
resistance creating problems for treatment, especially for immunocompromised patients 
with OPC (89, 90).  OPC is typically treated with low doses of fluconazole (100 mg/day) 
over a long period of time.  Upon the occurrence of a relapse, the dosage is increased (up 
to 800 mg/day).   
 
 The incidence of OPC has decreased with the use of HARRT.  However despite 
this advancement, resistance has been shown to still occur and many resistance 
mechanisms are maintained even after the antifungal agent is no longer present (61).  
This suggests that for the treatment of fungal infection it is important that the antifungal 
agent have enhanced abilities (91-93).  As a result the development of novel co-
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therapeutic agents imparting enhanced activity upon the azoles would represent a 
favorable strategy by which to advance treatment (90, 94-96). 
 
 
Response Mechanisms That Allow Fungistatic Azole Activity 
 
 Azole antifungal inhibition of ergosterol biosynthesis pathway is not lethal in C. 
albicans, suggesting that coping mechanisms exist such as specific stress responses 
which may circumvent azole activity and permit survival of the fungal cells in the 
presence of the azoles.  Indeed, C. albicans activates specific pathways in response to 
external stresses.  Response mechanisms implicated in the fungistatic effect of the azoles 
include: increases in drug efflux pump and ergosterol biosynthesis gene expression (97), 
the Ras-cAMP-PKA pathway (98), the calcineurin pathway (99-101), the Ssk1p/Chk1p 
pathway (102), and the cell wall integrity (CWI) pathway (103-106). 
 
 Upon ketoconazole exposure, expression of genes involved in drug efflux pump 
(CDR1, CDR2, MDR1) and ergosterol biosynthesis (NCP1, MCR1, CYB5, ERG2, ERG3, 
POT14, ERG25, ERG251) were induced (97).  These efflux pumps are typically 
expressed as low or undetectable levels and become upregulated in the presence of 
certain chemicals.  Increased expression of these drug efflux pumps reduces the 
intracellular concentration of drug and therefore decreases its effect.  Also, many of the 
ergosterol biosynthesis genes identified to be induced upon ketoconazole exposure exist 
downstream from Erg11p, the azole target, and respond to ergosterol depletion by 
facilitating the production of alternate sterols including lanosterol, eburicol, obtusifoliol, 
14α-methyl fecosterol, and 14α-methylergosta-8,24(28)-dien-3β,6α-diol to be inserted 
into the cell membrane (107).  Integration of these sterols into the plasma membrane 
disrupts its integrity resulting in its altered structure and function (79, 82, 108).  Under 
these conditions, growth is inhibited but the organism remains viable (109).   
 
 Hsp90 is a molecular chaperone that stabilizes the regulators of many eukaryotic 
cellular signaling pathways, and its inhibition disrupts many cellular processes (110, 
111).  Interestingly, compromise of its function blocks the development of azole 
resistance and renders drug-resistant isolates susceptible (112), such as a resistant 
erg3Δ/Δ mutant (113).  It has also been shown to improve the efficacy of treatment in a 
murine model of disseminated infection (114).  Of the many pathways in which Hsp90 
interacts, it has been shown to play roles in some of the pathways implicated in the 
response to azoles. 
 
 Ras1 is a small GTPase that regulates the cAMP-protein kinase A (PKA) pathway 
controlling morphogenesis in response to nutrient limitation, pH, CO2, and serum (12).  
In response to these stimuli, the guanine exchange factor Cdc25 activates Ras1 to its 
GTP-bound state which continues on to stimulate Cdc35 and cAMP-associated protein 
(Cap1/Srv2) for the production of cAMP (115, 116).  This increase in intracellular cAMP 
activates the catalytic subunits of PKA which activates the transcriptional regulator of 
morphogenesis, Efg1 (117, 118).  Also playing a role in the transition from yeast to 
hyphal growth is the Hsp90 molecular chaperone.  Pharmacological disruption of Hsp90 
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function induces hyphal growth even in the absence of external cues, and therefore is a 
negative regulator of the Ras-cAMP-PKA pathway (9).  Disruption of the genes encoding 
adenyl cyclase (Cdc35) or Cap1/Srv2 renders the cells hypersusceptible to the azoles, 
with a fungicidal effect.  This has been correlated to the fungal cell’s inability to up-
regulate a multidrug transporter gene CDR1 (98), known to pump fluconazole out of the 
cell.   
 
 Calcineurin is a protein phosphatase consisting of a catalytic A (Cna1) and a 
regulatory B (Cnb1) subunit which are highly conserved between yeasts and mammals 
(119).  The molecular chaperone Hsp90 has been shown to interact with the Cna1 
subunit, stabilizing the protein for activation in response to stress (99, 120, 121).  In 
response to stress, calcineurin dephosphorylates downstream transcriptional regulators, 
including the transcription factor Crz1 which regulates genes involved in cell wall 
biosynthesis and ion homeostasis (122-125).  Calcineurin is implicated as being required 
for the fungistatic activity of the azoles (100, 126).  Hsp90 or calcineurin compromise 
imparts fungicidal activity upon the azole antifungals (114, 122, 124).  Calcineurin 
pathway mutants disrupted for the calcineurin subunit genes CNA1 and CNB1 treated in 
combination with an azole and cyclosporine A (which inhibits calcineurin) also render 
the azoles fungicidal.  This effect does not involve changes in the expression of the 
transporter genes (99-101). 
 
 The high osmolarity glycerol (HOG) pathway is mediated by the Hog1 mitogen 
activated protein kinase (MAPK) in response to osmotic and oxidative stress (127-129).  
It has also been implicated in morphogenesis and cell wall formation.  Hog1 is 
phosphorylated by the Pbs2 MAP kinase downstream from the Ssk1p/Chk1p pathway 
(102).  Environmental signals cause the Chk1 histidine kinase to autophosphorylate 
which then dephosphorylates Ssk1 and stimulates the Pbs2-Hog1 MAPK cascade (130).  
Disruption of either genes encoding the response regulator (Ssk1p) or histidine kinase 
(Chk1p) caused the fungal cells to become hypersusceptible to the azoles due to the 
inability to pump out the drug resulting in fluconazole accumulation within the cells 
(102).  Additionally, when CHK1 is disrupted, the properties of the cell surface are 
altered along with lowered glucan content (131-133).  On the other hand, disruption of 
HOG1 did not result in altered susceptibility to fluconazole, but did result in resistance 
nikkomycin Z and Congo red (127). 
 
 In S. cerevisiae, the cell wall integrity MAP kinase (CWI MAPK) pathway is the 
major contributor to cell wall assembly and maintenance (85).  Upon sensing stress at the 
surface of the fungal plasma membrane, the linear MAPK cascade amplifies the initial 
signal for transmission to downstream transcriptional regulators such as Rlm1p.  This 
regulator is responsible for the majority of the transcriptional output produced by this 
pathway (63, 103).  This pathway in conserved in C. albicans and has been previously 
suggested to be critical for the fungistatic activity of sterol biosynthesis inhibitors (104).  
CaCAS5 encodes a transcriptional regulator of the cell wall damage response and is 
postulated to be the functional equivalent of ScRlm1p (134).  When the cell wall integrity 
pathway is disrupted, specifically by disrupting the kinase genes PKC1 and MKC1, the 
cells exhibit increased fluconazole susceptibility (103, 106).  The upstream protein kinase 
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C, Pkc1p, phosphorylates the MAPK Mkc1p in response to fluconazole, but is interrupted 
by its absence.  Hsp90 depletion was also shown to destabilize Mkc1p in the same study, 
therefore blocking PKC1-signaling.  Additionally, deletion of PKC1 in a resistant 
erg3Δ/Δ mutant resulted in enhanced susceptibility (106). 
 
 The transcription factors and their target genes have yet to be identified for many 
of the pathways involved in the response to azole activity and there may be other yet to 
be identified pathways involved.  Target genes of these pathways would be useful as co-
therapeutic drug targets to improve the activity of azole against C. albicans. 
 
 
Emergence of Clinical Azole Resistance 
 
 When an infection progresses or persists despite treatment with antifungals, this is 
known as clinical resistance.  There are two forms of resistance.  Organisms that are 
resistant prior to exposure to an antifungal agent have primary or intrinsic resistance 
while secondary resistance arises after initiation of antifungal treatment (77).  Due to 
their fungistatic activity and widespread use in the treatment of fungal infections, 
antifungal drug resistance most commonly occurs for the azoles.  Their fungistatic nature 
makes it difficult to completely clear all of the fungal cells, especially in an 
immunocompromised individual, resulting in reoccurring infection.   
 
 The emergence of fluconazole resistance is attributed to many factors.  First, 
Candida infections are not usually due to newly acquired resistant strains, but rather 
commensal strains that either become more virulent or that no longer have to compete 
with other normal flora (135).  The use of low doses of fluconazole over extended periods 
of time also creates an ideal environment for the selection of resistant strains.  
Transmission between individuals also can occur, although typically among 
immunocompromised individuals (136, 137). 
 
 In order to characterize fluconazole susceptibility in the clinical setting, the 
Clinical and Laboratory Standards Institute (CLSI) Subcommittee for Antifungal 
Susceptibility Testing established standard breakpoints: sensitive ≤ 2 µg/ml, susceptible-
dose dependent (S-DD) = 4 µg/ml, resistant ≥ 8 µg/ml (138).  Appropriate measurement 
of resistance in vitro is often correlated with treatment failure (139).  However, there are 
many others factors that can impact the likelihood of therapeutic success such as clinical 
status of the patient, presence of foreign material, and location of infection (79, 140). 
 
 Due to the rise in the immunosuppressed patient population the usage of 
antifungal agents has also increased, coincidently along with a rise in resistance.  The 
azoles are the most important antifungal agent because they are relatively safe, can be 
orally delivered, and are relatively inexpensive.  Fluconazole is the most widely used 
azole for treating OPC, which is the most common AIDS-associated opportunistic 
infection (141, 142).  Repetition and lengthy duration of therapy for OPC in AIDS 
patients has led to an increased incidence of treatment failures secondary to the 
emergence of azole resistance (77, 89, 143, 144).  Recurrent OPC most often occurs 
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when CD4+ T cells drop below 50 cells/mm3.  In fact, one study identified 33% of late-
stage AIDS patients with drug-resistant Candida present in their oral cavities (145). 
 
 Other patient populations are increasingly exposed to azoles for treatment and 
prophylaxis including those undergoing aggressive cancer therapy, surgical intensive care 
unit (ICU) patients, nonneutropenic patients, and women with VVC (146-150).  
However, the increased use of the azole antifungals in the immunocompromised patient 
population has the largest effect on the frequency, morbidity, and overall response to 
therapy of fungal infections.   
 
 It is logical for resistance to antifungal agents to develop as a result of their use 
for treatment.  An additional complication of fluconazole resistance is the potential to 
develop cross-resistance to other azoles and the polyenes, as the activities of both 
antifungals are associated with ergosterol.  As a result, the ability to limit the emergence 
of resistance to these agents and the development of more potent drugs is clinically 
important.  Strategies to avoid and suppress resistance have yet to be defined, but one 
suggested method is to utilize combination therapy in order to broaden efficacy and 
preserve the utility of the azole class of antifunagls (151). 
 
 
Molecular Mechanisms of Resistance to Azoles 
 
 Several mechanisms of azole resistance have been documented in C. albicans.  
One method involves the export of the azole antifungal out of the cell by constitutive 
overexpression of efflux pumps, preventing the intracellular accumulation of effective 
concentrations.  At least two efflux systems exist in C. albicans and have been found to 
be overexpressed in resistant isolates: the ATP-binding cassette superfamily (ABC) and 
the major facilitator superfamily (MFS) (152-156).   
 
 ABC transporters rely on the binding and hydrolysis of ATP for energy and have 
a broad specificity including many of the azoles (157).  Two ABC transporters, encoded 
by CDR1 and CDR2, have been implicated in azole resistance.  In clinical matched 
isolates, increased expression of CDR1 and CDR2 is correlated with decreased azole 
susceptibility (155, 156, 158).  This was further demonstrated by experimentally 
controlling overexpression of CDR1 which conferred resistance to fluconazole (159).  
Deletion of CDR1 from a clinical isolate with resistance to several azoles resulted in a 
large reduction in resistance, while deletion of CDR2 had a lesser effect (160).   
 
 Unlike ABC transporters, MFS transporters rely on the energy of the proton 
motive force generated by the proton gradient across the cell membrane and are relatively 
specific for fluconazole and voriconazole (161).  The main MFS transporter identified to 
contribute to fluconazole resistance is Mdr1.  Increased expression of MDR1 has been 
detected in resistant isolates when compared to their susceptible matched pairs (152, 
158).  Experimental overexpression of MDR1 was unable to confer fluconazole 
resistance, because higher levels of MDR1 expression than what were achieved are 
necessary to confer resistance to fluconazole (162).  The role of MDR1 in fluconazole 
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resistance was confirmed when deletion from an MDR1-overexpressing resistant isolate 
resulted in decreased fluconazole resistance (33). 
 
 Other mechanisms by which azole resistance develops involve changes in 
lanosterol demethylase or other components of the ergosterol biosynthesis pathway.  
Inhibition of lanosterol demethylase by the azoles results in accumulation of the 
methylated toxic sterol 14α-methylergosta-8,24(28)-dien-3β,6α-diol which inhibits fungal 
cell growth (108).  In order to compensate for this loss-of-function inhibition due to azole 
activity, there exists a bypass pathway through the inactivation of ERG3 product, Δ5,6 
desaturase.  This results in the accumulation of alternate, nontoxic sterols (such as 
fecosterol) in place of the toxic sterols, allowing the organism to circumvent inhibited 
cell growth, and results in azole resistance (108, 163). 
 
 Drug target alterations also lead to resistance by decreased drug affinity, while 
still maintaining an active target.  White et al. analyzed the ERG11 sequences of 17 
sequential isolates which develop resistance and identified a point mutation resulting in a 
substitution between two residues known to be involved in interacting with the heme in 
the active site (156, 164, 165).  Such point mutations in ERG11 may result in 
conformational changes that prevent effective binding between azoles and their target 
without affecting function of the enzyme in ergosterol biosynthesis (165, 166).  Several 
point mutations have been identified in resistant isolates and lead to decreased azole 
susceptibilities (165-167).   
 
 Overexpression of ERG11 is another mechanism of resistance and results in 
overproduction of the target enzyme, lanosterol demethylase.  This increased production 
overwhelms the intracellular azole concentration such that the drug does not inhibit the 
reaction completely (152, 156, 167).  ERG11 upregulation is found to be present along 
with one of the efflux pump resistance mechanisms in at least 25% of clinical resistant 
isolates (167).   
 
 All of these mechanisms impact reduced azole susceptibility, but high-level azole 
resistance appears to accumulate gradually over time with the acquisition of multiple 
mechanisms (167, 168).  Sanglard, et al. (169) studied set of 16 sequential C. albicans 
isolated from five AIDS patients, selected based on their increasing fluconazole 
resistance following prolonged treatment.  The observed decreased in fluconazole 
accumulation was shown to be associated with a 10-fold increase in mRNA levels of 
MDR1 (normal levels for CDR1).  Additionally, White, et al. examined 17 sequential 
isolates from an HIV patient and found increases in ERG11, MDR1 and CDR1, further 
suggesting that high-level azole resistance results from contributions of several 
mechanisms (156).   
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TRANSCRIPTIONAL REGULATORS 
 
 
Transcription Factor Classes 
 
 Two major classes of transcription factors are involved in drug resistance, the first 
being the basic leucine zipper (bZip) proteins.  The bZip class is found only in eukaryotic 
cells and is characterized by a highly conserved 60-80 amino acid long basic leucine 
zipper motif shaped in a bipartite α-helix which binds the DNA major groove (170).  The 
DNA binding domain (DBD) is located in the N-terminal portion of the bZip motif and 
consists of two basic amino acid clusters which are responsible for binding to DNA.  The 
leucine zipper is located in the C-terminal portion and has leucine residues every 7 amino 
acids (170).  It is through the leucine zipper that the bZip class proteins dimerize and bind 
DNA as either homodimers or heterodimers resulting in gene transcription activation or 
repression (170, 171).   
 
 Within the bZip class, there exist 13 different families of proteins.  Two families, 
the Jun and the Fos, dimerize and form the activator protein-1 (AP-1) transcription factor 
family implicated in drug resistance (171).  These proteins bind DNA as heterodimers 
with one Jun protein and one Fos protein or homodimers with two Jun proteins.  The 
dimmers bind DNA at a specific AP-1 recognition element (ARE) motif which is found 
in the promoters and enhancers of genes involved in several cellular processes.  
 
 Fungal AP-1 transcription factors are referred to as yeast AP-1 (yAP-1) and bind 
to the yAP-1 response element (YRE) (172, 173).  Yeast bZip transcription factors differ 
by being the only bZips to contain two cysteine rich domains (CRD) located in the amino 
terminus (n-CRD) and carboxy terminus (c-CRD) of the 3’ bZip domain (174).  These 
CRDs act in the localization and activation of yAP-1 transcription factors.   
 
 The largest class of eukaryotic transcriptional regulators is the zinc finger proteins 
(175), which are defined by a zinc finger motif, structured as one α-helix and a pair of 
antiparallel β strands, containing cysteines and histidines which bind zinc atoms for 
structure, function and stabilization.  Within this class exist three families of zinc finger 
proteins: classical zinc fingers (Cys2His2) bind DNA as monomers, Cys4 zinc fingers bind 
as either homodimers or heterodimers, and zinc cluster proteins (Cys6) bind as 
monomers, homodimers and heterodimers.  The zinc cluster transcription factors have six 
cysteines bound by two zinc atoms and are exclusive to fungi (175-177). 
 
 The zinc cluster transcription factors are typically found in the nucleus and many 
are constitutively bound to their promoters (175).  These transcription factors are 
comprised of a DBD, regulatory domain, and acidic domain.  Their DBD contains zinc 
finger motif, linker, and dimerization domains.  The zinc finger motif binds as dimers in 
the DNA major groove, the linker designates DNA binding specificity, and the 
dimerization domain resembles the leucine zipper in bZip proteins (175, 178).  Their 
regulatory domain is specific to zinc cluster transcription factors and upon its deletion, 
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renders them constitutively active (179, 180).  Phosphorylation or dephosphorylation of 
the acidic domain acts as the activation domain (175). 
 
 
Transcription Factors and Fungistatic Azole Activity 
 
 Some of the transcriptional regulators of the stress responses which circumvent 
azole activity and permit survival in the presence of the azoles have been identified, but 
the direct downstream targets of many remain unclear.   
 
 EFG1 encodes a transcription factor of the basic helix-loop-helix (bHLH) class 
and is a member of the APSES family fungal-specific regulators (181, 182).  The bHLH 
domain promotes dimerization and DNA binding to the Efg1 recognition sequence (EGR 
or E-box) box, which is found in many genes involved in morphogenesis.  Indeed, EFG1 
plays a role in the induction and repression of cell wall genes in yeast and hyphal forms 
(183).  This agrees with its function downstream of the Ras-cAMP-PKA pathway.  Upon 
disruption of EFG1, an increase in membrane fluidity was observed concurrent with a 
decrease in ERG11 expression, rendering the cell hypersusceptible to fluconazole (184). 
 
 One of the downstream regulators of the calcineurin pathway is Crz1 (100).  It is a 
classical Cys2His2 zinc finger and has been found to control the expression of several 
Ca2+/calcineurin-responsive genes through CDRE sequences in their promoters (122, 
185).  It has also been documented that disruption of CRZ1 results in hypersusceptibility 
to fluconazole (100, 122).  Interestingly, disruption of the catalytic α-subunit of protein 
kinase CK2, CKA2, results in fluconazole resistance through overexpression of CDR1 
and CDR2, but subsequent CRZ1 disruption suppresses this phenotype (186).  
 
 In the S. cerevisiae CWI pathway, the transcription factor ScRlm1 plays a major 
role.  This pathway is conserved in C. albicans and the functional homolog to ScRlm1 
has been identified as Cas5, a classical Cys2His2 zinc finger protein (134, 187).  
Microarray analysis in the presence of caspofungin identified the requirement of Cas5 for 
the expression of many caspofungin-responsive genes, including those cell wall protein 
and cell wall maintenance genes.  Motifs were also identified that may represent the 
Cas5-binding sites in the promoter regions of 10 out of 13 Cas5-dependent genes 
examined.  Additionally, disruption of CAS5 resulted in hypersusceptibility to 
caspofungin, Congo red, and sodium dodecyl sulfate (134).  Due to its role in the CWI 
pathway, it is possible that it is also hypersusceptible to the azoles, similarly seen for 
other components of this pathway. 
 
 
Transcription Factors and Azole Resistance 
 
 Constitutive overexpression of the efflux pumps involved in azole-resistance is 
due to constitutively active transcription factors, as a result of gain-of-function (GOF) 
mutations.  A few of these transcription factors have been identified. 
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 The C. albicans bZip yAP-1 transcription factor, Cap1, is closely related to the S. 
cerevisiae Yap1 and has been identified to be involved in multidrug resistance (188).  
Cap1p is primarily involved in protecting the cell against oxidative stress (189-191).  
Genome-wide location and expression analysis was undertaken in order to determine 
which genes Cap1 directly binds and regulates.  Targeted groups included genes involved 
in osmotic stress response, response to drugs (including MDR1), phospholipid transport, 
and nitrogen utilization (192).  Cells disrupted for CAP1 were unable to upregulate 
MDR1 in response to fluconazole and the formation of a hyperactive Cap1, by disruption 
of the c-CRD, resulted in fluconazole resistance and increased MDR1 expression (189).  
Cap1 binds to the Yap1 response element (YRE) motif located in the MDR1 promoter, 
but the absence of this motif in a fluconazole-resistant clinical isolate did not alter MDR1 
expression, suggesting there is another regulator controlling its expression during 
resistance (193, 194).   
 
 Constitutive MDR1 overexpression resulting in multidrug resistance is due to 
GOF mutations in the zinc cluster transcription factor Mrr1.  MRR1 was identified as one 
of the genes upregulated in three MDR1-overexpressing fluconazole-resistant isolates 
when compared to their fluconazole-susceptible matched isolates.  These isolates were 
identified as being homozygous for mutated MRR1 GOF alleles (195).  Inactivation of 
this MRR1 allele resulted in the loss of MDR1 overexpression and increased fluconazole 
susceptibility.  Deletion of MRR1 reduced fluconazole resistance more than MDR1, 
suggesting that additional Mrr1p-controlled mechanisms are involved.  Meanwhile, 
introduction of the GOF allele into a fluconazole-susceptible background resulted in 
constitutive overexpression of MDR1 and multidrug resistance.  Other transcription 
factors have been implicated in the upregulation of MDR1, but Mrr1 is the central 
regulator of MDR1 expression in fluconazole resistance. 
 
 Tac1p is a zinc cluster transcription factor is another transcription factor involved 
in regulating clinical azole-resistance (196).  It binds the drug response element (DRE) 
consensus sequence located in the promoters of CDR1 and CDR2 (196, 197).  Disruption 
of TAC1 abolishes CDR1 and CDR2 expression and is hypersusceptible to fluconazole.  
Azole resistance occurs when the isolates have become homozygous for a GOF TAC1 
allele, likely because zinc cluster transcription factors act as dimers.  Such a TAC1 allele 
was isolated from an azole-resistant strain which overexpressed CDR1 and CDR2, and 
when place in the background of a susceptible strain was still able to confer resistance 
and CDR1 and CDR2 overexpression.  However, this resistance depends on the presence 
of CDR1 and CDR2 (198). 
 
 Upc2p is a zinc cluster transcription that controls inducible ergosterol gene 
expression in the presence of the azoles.  When UPC2 is disrupted in a susceptible 
background, it becomes hypersusceptible to sterol biosynthesis inhibitors (SBIs), 
including fluconazole in addition to abolished ERG gene transcription and reduced 
ergosterol levels (199, 200).  It binds to a sterol response element (SRE) motif found in 
the promoter region of ERG genes and also UPC2 itself.  Genome-wide location profiling 
identified the Upc2p gene groups targets involved in ergosterol biosynthesis (including 
ERG11), drug transport (MDR1), and transcription factors (UPC2) (201).  The first GOF 
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mutation in Upc2 was identified in matched isolates with no CDR1, CDR1, or MDR1 
overexpression by Northern blot (152).  Microarray analysis revealed that UPC2, ERG11 
and MDR1 were overexpressed in the resistant isolate, containing a G648D GOF 
mutation (202).  When the mutated GOF allele was introduced into a fluconazole-
susceptible background, both ERG11 and MDR1 were upregulated.  Other UPC2 GOF 
mutations have also been identified to confer fluconazole-resistance and increased 
ERG11 expression (203-205). 
 
 
CENTRAL HYPOTHESIS AND RESEARCH OBJECTIVES 
 
 C. albicans responds to antifungal stress through specific signal transduction and 
transcriptional activation pathways, which circumvent azole activity and permit survival 
of the fungal cells in the presence of the azoles.  Several response mechanisms have been 
identified to mediate fluconazole susceptibility.  Increased drug efflux pump expression 
results in decreased intracellular concentrations of the azoles.  Increased ERG11 
expression results in increased intracellular concentrations of lanosterol demethylase and 
therefore the amount of enzyme increases that is not bound by the azoles.  Additionally, 
increased expression of other genes involved in the ergosterol biosynthesis pathway in 
response to ergosterol depletion leads to accumulation of alternate sterols which results in 
inhibited growth but the cell remains viable.  Disruption of components of the Ras-
cAMP-PKA pathway results in decreased inducible CDR1 gene expression resulting in 
fungicidal azole activity, while disruption of the transcriptional regulator, Efg1, results in 
decreased ERG11 expression and hypersusceptibility to fluconazole.  Compromise of the 
calcineurin pathway renders the azole fungicidal and disruption of one possible 
downstream regulator, Crz1, results in fluconazole hypersusceptibility.  Disruption of 
either Ssk1 or Chk1 upstream of the HOG pathway resulted in intracellular fluconazole 
accumulation and hypersusceptibility.  Disruption of Mkc1 and Pkc1 of the CWI pathway 
results in increased susceptibility to the azoles.  The downstream transcriptional 
regulators and their target genes have yet to be identified for many of these pathways and 
there may also be novel pathways which have yet to be identified.   
 
 I hypothesized that pathways centrally involved in the response mechanisms to 
azole activity, permitting survival in their presence, require key transcriptional regulators.  
With the completion of the C. albicans genome sequencing project many genes were 
identified to code for transcription factors, and microarray technology can be used to 
identify their downstream targets.  By studying mutants deleted for specific transcription 
factors, their impact on fluconazole susceptibility can be elucidated and their fluconazole-
inducible target genes can be identified.  Among the transcription factors identified, we 
found both previously described as well as novel roles for these transcriptional regulators 
in fluconazole susceptibility.  
 
 Upc2, a zinc cluster transcription factor, has been previously identified as the 
transcriptional regulator of the ergosterol biosynthesis pathway.  The disruption of this 
transcription factor has also been shown to enhance susceptibility to fluconazole, while 
GOF mutations result in azole resistance.  My first research objective (Chapter 2) was to 
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examine susceptible and resistant strains disrupted for UPC2 by various susceptibility 
tests and gene expression analysis in an effort to elucidate the extent of its involvement in 
fluconazole susceptibility.  I hypothesized that Upc2 is essential for fluconazole 
susceptibility in both susceptible and resistant backgrounds.  Our studies showed that 
disruption of UPC2 enhanced susceptibility and overcame resistance by downregulation 
of ERG genes, specifically ERG11.  Additionally, we identified a novel role for Upc2 in 
regulating fluconazole-inducible iron homeostasis. 
 
 In research objective 2 (Chapter 3), we examined a library of mutants disrupted 
for genes encoding specific transcription factors in an effort to identify those which had 
enhanced susceptibility to fluconazole.  I hypothesized that transcriptional regulators of 
known and possibly novel pathways would be essential for responding to azole activity.  
Our studies characterized the zinc finger transcription factor Cas5 in regulating 
fluconazole susceptibility, through its role as the transcriptional regulator of the CWI 
pathway.  Gene expression profiling identified genes involved in cell wall maintenance 
whose fluconazole-induced expression was dependent on CAS5.  Additionally, we 
identified a novel role for Cas5 in iron homeostasis, similar to Upc2. 
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CHAPTER 2.    UPC2 IS UNIVERSALLY ESSENTIAL FOR AZOLE 
RESISTANCE IN CANDIDA ALBICANS 
 
 
INTRODUCTION 
 
 The increased frequency of invasive fungal infections in recent decades is directly 
related to an expansion in the immunocompromised patient population including those 
with HIV/AIDS, cancer chemotherapy patients, neutropenic patients, recipients of 
transplants with indwelling catheters, and patients receiving antibiotics (65, 206, 207).  
Candida species collectively are the fourth-leading cause of nosocomial infections in the 
United States and such infections are associated with unacceptably high rates of mortality 
(65, 208, 209).  Candida albicans is the most prevalent opportunistic human fungal 
pathogen and causes a wide variety of infections spanning from superficial, mucosal 
infections to invasive disseminated disease despite the availability of effective antifungal 
treatment.  Moreover, the most common opportunistic infection among AIDS patients is 
oropharyngeal candidiasis (OPC), and chronic cases continue despite the availability of 
highly active anti-retroviral therapy (HAART) due to poor compliance, lack of access, 
and treatment failure of HAART (52, 53, 210-212).   
 
 The azoles, particularly fluconazole, are the most widely used class of antifungals 
for the treatment of Candida infections (65, 79).  Fluconazole acts by inhibiting the 
protein product of ERG11, lanosterol 14α-demethylase, which leads to ergosterol 
depletion and accumulation of toxic methylated sterol precursors resulting in inhibition of 
growth (213).  In an immunocompromised host, the fungistatic nature of fluconazole 
limits its efficacy against this organism (61, 85).  C. albicans exhibits inhibited growth in 
the presence of this fungistatic drug and it is generally believed that such fungistatic 
activity facilitates the development of resistance creating problems for treatment, 
especially in immunocompromised patients with OPC (89, 90).  Currently known 
mechanisms of resistance to the azoles include alterations in the expression of drug efflux 
pumps (CDR1, CDR2 and MDR1) and ergosterol biosynthesis genes ERG, and mutations 
in ERG11 (77).  These mechanisms are frequently combined resulting in a stepwise 
development of resistance over time.  
 
 In C. albicans, UPC2 is a zinc-cluster transcription factor that regulates the 
expression of genes involved in ergosterol biosynthesis, including ERG11 (199, 214).  
Disruption of ERG11 or pharmacologic inhibition of the enzyme it encodes leads to 
reduced ergosterol production and the accumulation of alternate sterols including 
lanosterol, eburicol, obtusifoliol, 14α-methyl fecosterol, and 14α-methylergosta-
8,24(28)-dien-3β,6α-diol (107).  Biosynthesis of these alternate sterols does not require 
ERG11, but does require other genes in the ergosterol biosynthesis pathway, some of 
which appear to be regulated by Upc2.  We reasoned that since Upc2 is required for the 
transcriptional activation of other genes of the sterol biosynthesis pathway, the disruption 
of UPC2 might result in enhanced activity of the azole antifungals in azole-resistant as 
well as -susceptible isolates. In the present study, we further examined the role of UPC2 
in azole antifungal activity against both azole-susceptible and azole -resistant strains of 
 17 
C. albicans, in particular an azole-resistant clinical isolate and mutant strains that 
represent four of the major azole resistance mechanisms.  Taken together, our results 
indicate that the UPC2 transcriptional network is universally essential for fluconazole 
resistance in C. albicans.   
 
 
MATERIALS AND METHODS 
 
 
Strains and Growth Conditions 
 
 All C. albicans strains (Table 2-1) were stored as frozen stock in 40% glycerol at 
-80°C.  YPD (1% yeast extract, 2% peptone, and 1% dextrose) agar plates and YPD 
liquid medium were used for routine growth of strains at 30°C.  For CFU counts during 
time-kill analysis, PDA (0.4% potato starch, 2% dextrose, and 1.5% agar) plates were 
used, and cultures grown on PDA were incubated at 35°C. 
 
 
Drug Susceptibility Testing 
 
 The minimum inhibitory concentrations (MICs) of fluconazole (FLC) were 
determined by using broth microdilution as described by the Clinical and Laboratory 
Standards Institute M27-A2, modified by using YPD media, and were read both visually 
and spectrophotometrically at 24, 48, and 72 hours.  Minimum fungicidal concentrations 
(MFCs) were measured by removing 2 µl from each well of the MIC plate and plating 
onto YPD agar.  Also, serial dilutions from a 0.1 OD600 suspension were diluted 4-fold 
and 2 µl of each dilution plated onto YPD agar plates with and without 10 µg/ml 
fluconazole and then incubated at  30°C for 24 and 48 hours.  Fluconazole activity was 
also assessed by Epsilometer test strips (Etest strips) (Biomerieux) according to 
manufacturer’s instructions with the following modifications.  A standardized cell 
suspension (0.5 McFarland) was used to create a confluent lawn across YPD agar plates 
prior to Etest strip placement and then incubated at 30°C for 24 and 48 hours.  Time-kill 
analyses were performed with a 0.5 McFarland cell suspension, which was 10-fold 
diluted into YPD media with and without 10 µg/ml fluconazole and incubated at 35°C.  
Aliquots were removed at 0, 6, 12, and 24 hours, 10-fold serial diluted and plated onto 
PDA.  CFUs were counted in duplicate after 48 hours at 35°C and plotted on a log-scale 
curve versus time (215). 
 
 
Construction of ERG11 Strains with Mutant Alleles 
 
 CaERG11 coding sequences were amplified by PCR (Pfu DNA polymerase; 
Stratagene) from C. albicans genomic DNA using the primers ERG11-A and ERG11-E. 
Products were cloned into pCR-BLUNTII-TOPO using a Zero Blunt TOPO PCR Cloning 
Kit (Invitrogen) and transferred into Escherichia coli TOP10 cells with selection on LB 
agar plates containing 50 μg/ml kanamycin.  Plasmid DNA was purified (QIAprep;  
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Table 2-1. C. albicans strains used in this study 
 
 
   
Strain Designation 
Strain 
Background 
Relevant Characteristics or 
Genotype Source 
SC5314 
 
SC5314 N/A UPC2-1/UPC2-2 ATCC 
Clinical isolate 2-79 
 
2-79 N/A Susceptible isolate Redding, 1994 
Clinical isolate 12-99 
 
12-99 N/A Resistant isolate Redding, 1994 
UPC2M4A 
 
upc2Δ/Δ SC5314 upc2-1Δ::FRT/upc2-2Δ::FRT Dunkel, 2008 
UPC2M2K21A 
 
upc2Δ/Δ+UPC2 UPC2M2A upc2-1Δ::FRT/UPC2S1-1-caSAT1 Dunkel, 2008 
12-99UPC2A5C1A 
 
12-99upc2Δ/Δ 12-99 upc2Δ::FRT/upc2Δ::FRT This study 
10C1B1M1 ERG11K143R SC5314 ERG11K143R::FRT/ERG11K143R::FRT 
UPC2-1/UPC2-2 
This study 
10C1B1M1UPC2C9H ERG11upc2Δ/Δ 10C1B1M1 ERG11K143R::FRT/ERG11K143R::FRT 
upc2-1Δ::FRT/upc2-2Δ::FRT 
This study 
SCMRR1R34A MRR1P683S SC5314 MRR1P683S::FRT/MRR1P683S::FRT 
UPC2-1/UPC2-2 
Schubert, 2011 
Δupc2MRR1R34A MRR1upc2Δ/Δ SCMRR1R34A MRR1P683S::FRT/MRR1P683S::FRT 
upc2-1Δ::FRT/upc2-2Δ::FRT 
Schubert, 2011 
SCTAC1R34A TAC1G980E SC5314 TAC1G980E::FRT/TAC1G980E::FRT 
UPC2-1/UPC2-2 
Sasse, 2011 
SCupc2TAC1R34A1A14A TAC1upc2Δ/Δ SCTAC1R34A TAC1G980E::FRT/TAC1G980E::FRT 
upc2-1Δ::FRT/upc2-2Δ::FRT 
This study 
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Qiagen; Germantown, MD) and sequenced on an ABI Model 3130XL Genetic Analyzer 
using the ERG11 sequencing primers (Table 2-2), resulting in full-length sequence from 
both strands of the CaERG11 gene. The sequencing was performed using six sets of 
clones derived from three independent PCRs for each strain/isolate sequenced. 
 
 Sequenced plasmids of the ERG11 ORF whose predicted translation indicated an 
amino acid substitution were digested with restriction enzymes ApaI and XhoI, which 
excised the full-length ORF from the plasmid, and the ERG11 alleles were cloned 
upstream of the SAT1-flipper cassette into the ApaI and XhoI sites of plasmid pSFS2 
(34).  The ERG11 downstream segments were amplified with ExTaq (Takara) using 
primers ERG11-C and ERG11-D and cloned downstream of the SAT1-flipper cassette in 
pSFS2 using the NotI and SacII sites.   
 
 
Construction of UPC2 Deletion Strains 
 
 Plasmid pSFS2 contains the entire SAT1-flipper cassette (34).  The SAT1-flipper 
cassette consists of the SAT1 selectable marker which confers resistance to nourseothricin 
and the FLP flipper recombinase gene both flanked by FRT sites (flipper recombinase 
target sequences). The UPC2 deletion cassette (pUPC2M2) was developed by Dunkel et 
al, where the 5’ upstream sequence from positions -373 to +15 was cloned downstream of 
the SAT1-flipper cassette while the 3’ sequence from positions +2097 to +2437 was 
cloned upstream of the SAT1-flipper cassette (Table 2-2) (216). Upon transformation 
with the gel-purified SacI-ApaI fragment from pUPC2M2 into the parent strain the SAT1-
flipper was inserted into the coding region of one allele from positions +16 to +2096, and 
such positive transformants (NouR) were selected on YPD-nourseothricin agar plates 
containing 200μg/ml of nourseothricin. Induction of the FLP gene occurred by growing 
the transformants in YPD medium for 24 hours without selective pressure. Positive cells 
(NouS) were selected by replica plating onto YPD plates with and without 200 μg/ml of 
nourseothricin. Upon induction of the FLP gene, the cassette was excised such that only 
one copy of the FRT site remains in the locus. Another round was required to disrupt the 
second allele.  Appropriate gene disruption and complementation for two independent 
strains was confirmed by Southern hybridization (34). 
 
 
Isolation of Genomic DNA and Southern Hybridization 
 
 Genomic DNA was isolated as described previously (217).  Four µg of DNA were 
digested with an appropriate restriction endonuclease, separated on a 1% agarose gel, and 
after staining with ethidium bromide, were transferred by vacuum blotting onto a nylon 
membrane and fixed by UV cross-linking.  Southern hybridization with enhanced 
chemiluminescence-labeled probes was performed with the Amersham ECL Direct 
nucleic acid labeling and detection system according to the instructions of the 
manufacturer. 
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Table 2-2. Primers used in this study 
 
Primer Sequence 
qRT-PCR 
 ACT1-F 5'-ACGGTGAAGAAGTTGCTGCTTTAGTT-3' 
ACT1-R 5'-CGTCGTCACCGGCAAAA-3' 
BMR1-F 5'-ACATAAATACTTTGCCCATCCAGAA-3' 
BMR1-R 5'-AAGAGTTGGTTTGTAATCGGCTAAA-3' 
CDR1-F 5'-ATTCTAAGATGTCGTCGCAAGATG-3' 
CDR1-R 5'-AGTTCTGGCTAAATTCGTAATGTTTTC-3' 
CDR2-F 5'-TAGTCCATTCAACGGCAACATT-3' 
CDR2-R 5'-CACCCAGTATTTGGCATTGAAA-3' 
CFL4-F 5'-GCAATGGTTGACAGGTTGGAA-3' 
CFL4-R 5'-GCAATGTGACGATGATAAGTGACAA-3' 
ERG11-F 5'-CCCCTATTAATTTTGTTTTCCCTAATTTAC-3' 
ERG11-R 5'-CACGTTCTCTTCTCAGTTTAATTTCTTTC-3' 
FET3-F 5'-GCCGGTGTCTTAGGTTTAGCC-3' 
FET3-R 5'-CTAGCAACTCTTTCTTCAACATCGG-3' 
FRP1-F 5'-CTTCCAATACCATCCATTCACGAT-3' 
FRP1-R 5'-ATCTCCCCACTTTCAGCAAGAC-3' 
FTR1-F 5'-ATTGTTGTTTCAGTGCTTTTGGC-3' 
FTR1-R 5'-GGTCGGAACTACCACCCATAGA-3' 
  ERG11 cloning  
ERG11-F 5’-GGGCCC
ERG11-R 
TTTGAGAACAGCCACACGACAAC-3’ 
5’-CTCGAG
 
GACAAAAACCATCAACCGATTCCG-3’ 
 
ERG11 sequencing  
ERG11 seq B 5’-TATTTTCACTGCTTCAAGATCT-3’ 
ERG11 seq C 5’-CCAAAAGGTCATTATGTTTTAG-3’ 
ERG11 seq E 5’-AATGAGGTTTTTCACCTAAATG-3’ 
ERG11 seq F 5’-CCCTTTACCGAAAACTGGAGTA-3’ 
T7 5’-TAATACGACTCACTATAGGG-3’ 
M13R 5’-CAGGAAACAGCTATGACC-3’ 
  UPC2 mutant construction 
 UPC2-A 5'-GGGCCC
UPC2-B 
GAGATCTTGATGTCATTAG-3' 
5'-CTCGAG
UPC2-C 
CTATATCTTCAATGAACTG-3' 
5'-CCGCGG
UPC2-D 
ACAGGTCAATACCGCGTAG-3' 
5'-GAGCTC
Underlined sequence reflects the introduction of a restriction site sequence. 
GTTCCTCTAGTATCACTCTT-3' 
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RNA Isolation for qRT-PCR 
 
 RNA was isolated using a small-scale hot phenol method of RNA isolation 
described by Schmitt et al (218).  Briefly, overnight cultures were diluted to an OD600 of 
0.2 in 20 ml YPD and then incubated at 30○C with shaking for 3 hours.  Cells were 
collected by centrifugation, and stored at -80○C.  Cell pellets were resuspended in 950 µl 
of AE buffer and then transferred to a 2-ml RNAse-free microcentrifuge tube containing 
950 µl acid phenol (pH 4.3) with 1% SDS.  Cells were incubated at 65○C for 10 minutes 
then lysates were clarified by centrifugation.  The supernatant was then divided into two 
new 2-ml microcentrifuge tubes containing 950 µl of chloroform and mixed.  The sample 
was then subjected to centrifugation again, and the top aqueous layer was transferred to a 
new tube containing 1 ml of isopropanol and 100 µl 2M sodium acetate.  The RNA pellet 
was subsequently washed with 500 µl of 70% ethanol and collected by centrifugation.  
The RNA pellet was resuspended in DNase/RNase-free H2O.  Quantity and purity were 
determined spectrophotometrically at absorbances of A260 and A280. 
 
 
Quantitative RT-PCR 
 
 First-strand cDNAs were synthesized from 1 µg of total RNA using SuperScript 
first-strand synthesis system for RT-PCR (Invitrogen).  Gene-specific primers  
(Table 2-2) were designed using Primer Express software (Applied Biosystems) and 
synthesized by Integrated DNA Technologies (Coralville, IA).  Quantitative PCRs were 
performed in triplicate using the 7000 sequence detection system (Applied Biosystems), 
independently amplifying ACT1 (normalizing gene) and the genes of interest (GOI) as 
described previously (219). 
 
 
RNA Isolation for Microarray 
 
 RNA was isolated using a large-scale version of the hot phenol method of RNA 
isolation described by Schmitt et al. (218).  Briefly, overnight cultures were diluted to an 
OD600 of 0.005 in 100 ml YPD and then incubated at 30○C with shaking for an additional 
8 hours to an OD600 of 1.0.  Cultures were diluted again to an OD600 of 0.025 in 100 ml 
fresh YPD, allowed to incubate at 30○C with shaking for one doubling, inoculated with or 
without 10 µg/ml FLC, and then incubated at 30○C with shaking for 6 hours.  Cells were 
collected by centrifugation, and stored at -80○C.  Cell pellets were resuspended in 12 ml 
of AE buffer and then transferred to 50-ml Oak Ridge tubes treated with RNAse Away 
(Molecular BioProducts) containing 12 ml acid phenol (pH 4.3) with 1% SDS.  Cells 
were incubated at 65○C for 10 minutes then lysates were clarified by centrifugation.  The 
supernatant was then transferred to a new tube containing 15 ml of chloroform and 
mixed.  The sample was then subjected to centrifugation again, and the top aqueous layer 
was transferred to a new tube containing one volume of isopropanol and 0.1 volume 2M 
sodium acetate.  The RNA pellet was subsequently washed with 10 ml of 70% ethanol 
and collected by centrifugation.  The RNA pellet was resuspended in DNase/RNase-free 
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H2O.  Quantity and purity were determined spectrophotometrically at absorbances of A260 
and A280. 
 
 
Transcriptional Profiling 
 
 Gene expression profiles were obtained by hybridizing labeled cRNAs generated 
from C. albicans total RNA onto Affymetrix C. albicans custom expression arrays 
(CAN07; 49-5241) (216), which have been described previously (201).  Microarray 
hybridization and analysis were performed as described previously (201).  Genes were 
considered to be differentially expressed in response to drug if their expression changed 
by ≥1.5-fold in two independent experiments.  Genes induced by FLC were considered to 
be UPC2-dependent if the induction was abrogated in the deletion mutant was ≥2.0-fold 
(50%) less than the wild-type.  All microarray data is available for download from the 
NCBI at GEO (Accession number: pending). 
 
 
RESULTS 
 
 
Disruption of UPC2 Results in Enhanced Fluconazole Activity 
 
 In order to further investigate the requirement of UPC2 for susceptibility to 
fluconazole, we subjected the upc2Δ/Δ mutant derived from azole-susceptible isolate 
SC5314 to various azole susceptibility tests examining both MIC and MFC using nutrient 
rich YPD media in order to detect strong phenotypes despite existing in an environment 
that promotes growth.  Consistent with previous observations, disruption of UPC2 
resulted in a marked reduction in fluconazole MIC by broth microdilution (Table 2-3), 
Etest (Figure 2-1A), 72 hr regrowth (Figure 2-1B), and spot assay (Figure 2-1C).  
Interestingly at 24 hr in YPD, the fluconazole MFC for SC5314 was >64 μg/ml whereas 
for the upc2Δ/Δ mutant it was 0.25 μg/ml (Table 2-3).  At 48 hr the MIC, as measured by 
Etest, for SC5314 was 1.0 μg/ml and a halo of reduced growth (but not a clear zone of 
inhibition) was observed up to the Etest strip consistent with the fungistatic nature of 
fluconazole.  The 48 hr MIC by Etest for the upc2Δ/Δ mutant was 0.032 μg/ml and a 
clear zone of inhibition around the Etest strip was observed (Figure 2-1A).  We also used 
a 72 hr endpoint for a broth microdilution assay in YPD as a way to assess the ability of 
the organism to resume growth in the presence of fluconazole. SC5314 was able to 
resume growth in all concentrations of fluconazole tested whereas the upc2Δ/Δ mutant 
was not (Table 2-3, Figure 2-1B).  When plated on YPD agar plates containing 10 μg/ml 
fluconazole, growth was reduced in the presence of fluconazole for the upc2Δ/Δ mutant 
as compared to SC5314 (Figure 2-1C).  Time-kill analysis showed increased fungistatic 
activity of 10 μg/ml fluconazole against the upc2Δ/Δ mutant as compared to its parent 
strain (Figure 2-1D).  All phenotypes were reverted by reintegration of one allele of the 
disrupted gene. 
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Table 2-3. MICs and MFCs in YPD in SC5314 background 
 
 Relevant Characteristics or 
Genotype 
MIC (µg/ml)  MFC (µg/ml) 
Strain 24 hr 48 hr 72 hr  24 hr 48 hr 72 hr 
SC5314 UPC2-1/UPC2-2 0.5 0.5 >64  >64 >64 >64 
upc2Δ/Δ upc2-1Δ::FRT/upc2-2Δ::FRT ≤0.125 0.25 0.25  0.25 0.25 0.25 
upc2Δ/Δ+UPC2 upc2-1Δ::FRT/UPC2S1-1-caSAT1 0.5 0.5 >64  >64 >64 >64 
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Figure 2-1. UPC2 impacts fluconazole susceptibility in SC5314 background 
(A)  Effect of UPC2 on MIC and growth on YPD agar as determined by Etest.  A 
confluent lawn of C. albicans was streaked prior to the addition of Etest strips and then 
incubated for 48 hours.  (B)  MIC heat map of SC5314, UPC2 mutant, and complimented 
derivative.  Susceptibility was determined by broth microdilution in YPD at 72 hours.  
Growth was quantified spectrophotometrically and assigned to a colorimetric scale.  (C)  
Effect on UPC2 on the ability to grow on solid media containing fluconazole.  From 4-
fold serial dilutions of C. albicans strains, 2 µl aliquots were spotted onto YPD agar +/- 
10 µg/mL FLC and incubated for 48 hours.  (D)  Effect of fluconazole on UPC2 by time-
kill assay.  SC5314 or upc2Δ/Δ cells were diluted in YPD medium containing 
fluconazole (10 µg/mL) or the solvent, DMSO.  After 0, 6, 12, and 24 hours, samples 
from each were diluted and plated for colony forming units.  
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Disruption of UPC2 in Strains Containing Resistance Mutations in MRR1, TAC1, 
and ERG11 Also Enhances Fluconazole Activity 
 
 In order to investigate the requirement for UPC2 in the setting of specific 
mechanisms of azole resistance, independent mutants were constructed in strains 
containing two copies of a gene conferring reduced susceptibility to fluconazole: 
MRR1P683S, TAC1G980E, or ERG11K143R.  The MRR1P683S and TAC1G980E alleles contain 
gain-of-function mutations which render the transcription factors they encode 
constitutively active, resulting in upregulation of either MDR1 or CDR1 and CDR2, 
respectively, and decreased fluconazole susceptibility (195, 196, 220, 221).  The 
ERG11K143R allele contains a point mutation postulated to be located near the azole access 
channel, interfering with entry of fluconazole, resulting in decreased fluconazole 
susceptibility (222).  Again the disruption of UPC2 in each background resulted in a 
marked reduction in MIC and MFC by all methods and the trend in susceptibility seen for 
MRR1upc2Δ/Δ was consistent with what we have previously observed (214).  The MFCs 
at 24 hr in YPD for ERG11upc2Δ/Δ, MRR1upc2Δ/Δ and TAC1upc2Δ/Δ were all reduced 
from 8 μg/ml, >64 μg/ml, and >64 μg/ml in their background strains to 1 μg/ml, 4 μg/ml, 
and 2 μg/ml respectively (Table 2-4).  At 48 hr the MICs by Etest for ERG11upc2Δ/Δ, 
MRR1upc2Δ/Δ and TAC1upc2Δ/Δ were all reduced from 1.5 μg/ml, 4 μg/ml, and 8 μg/ml 
in their background strains to 0.19 μg/ml, 0.5 μg/ml, and 0.5 μg/ml respectively  
(Figure 2-2A).   Growth was also reduced when plated on YPD agar plates containing 
fluconazole 10 μg/ml for the MRR1upc2Δ/Δ and TAC1upc2Δ/Δ strains as compared to 
their background strain (Figure 2-2B).  Consistent with their fluconazole MICs, both the 
ERG11K143R strain and its upc2Δ/Δ derivative were unable to grow at this concentration 
of fluconazole.  
 
 
Disruption of Upc2 Overrides Clinical Drug Resistance 
 
 Since disruption of UPC2 in strains containing one resistance mechanism resulted 
in enhanced fluconazole activity, we wanted to further examine the extent to which 
disruption of UPC2 influences high-level azole resistance in the presence of multiple 
resistance mechanisms.  We constructed upc2Δ/Δ mutant strains in the background of an 
azole-resistant clinical isolate (12-99) known to carry four of the most common 
mechanisms of azole resistance: overexpression of CDR1 and CDR2, overexpression of 
MDR1, overexpression of ERG11, and mutation in ERG11 (223).  As was observed for 
isolate SC5314 and the isogenic resistant strains, the disruption of UPC2 resulted in a 
marked reduction in MIC and MFC by all methods.  The MFC at 24 hr in YPD for 12-99 
was >64 μg/ml whereas for 12-99upc2Δ/Δ was 16 μg/ml (Table 2-5).  The fluconazole 
MIC by Etest at 48 hr was >256 μg/ml and confluent growth was observed for 12-99, 
whereas an MIC of 1.5 μg/ml and a clear zone of inhibition was observed for 12-
99upc2Δ/Δ (Figure 2-3A).  Likewise, in broth microdilution assays after 72 hr the parent 
strain was able to grow in all concentrations of fluconazole tested whereas 12-99upc2Δ/Δ 
grew less well (Figure 2-3B).  Growth was also reduced when plated on YPD agar plates 
containing fluconazole 10 μg/ml for 12-99upc2Δ/Δ as compared to its parent strain 
(Figure 2-3C).  As was observed in the SC5314 background, time-kill analysis also  
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Table 2-4. MICs and MFCs in YPD in background of strains expressing resistance mechanisms 
 
 Relevant Characteristics or 
Genotype 
MIC (µg/ml)  MFC (µg/ml) 
Strain 24 hr 48 hr 72 hr  24 hr 48 hr 72 hr 
SC5314 
 
UPC2-1/UPC2-2 0.5 0.5 >64  >64 >64 >64 
ERG11K143R ERG11K143R::FRT/ERG11K143R::FRT 
UPC2-1/UPC2-2 
4 8 8  8 8 32 
ERG11upc2Δ/Δ ERG11K143R::FRT/ERG11K143R::FRT 
upc2-1Δ::FRT/upc2-2Δ::FRT 
0.5 1 1  1 1 1 
MRR1P683S MRR1P683S::FRT/MRR1P683S::FRT 
UPC2-1/UPC2-2 
16 >64 >64  >64 >64 >64 
MRR1upc2Δ/Δ MRR1P683S::FRT/MRR1P683S::FRT 
upc2-1Δ::FRT/upc2-2Δ::FRT 
2 2 4  4 4 4 
TAC1G980E TAC1G980E::FRT/TAC1G980E::FRT 
UPC2-1/UPC2-2 
16 >64 >64  >64 >64 >64 
TAC1upc2Δ/Δ TAC1G980E::FRT/TAC1G980E::FRT 
upc2-1Δ::FRT/upc2-2Δ::FRT 
2 2 2  2 2 2 
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Figure 2-2. UPC2 impacts fluconazole susceptibility in background of strains 
expressing resistance mechanisms 
(A)  Effect of UPC2 in resistant backgrounds on MIC and growth on YPD agar as 
determined by Etest.  A confluent lawn of C. albicans was streaked prior to the addition 
of Etest strips and then incubated for 48 hours.  (B)  Effect of UPC2 in resistance 
backgrounds on the ability to grow on solid media containing fluconazole.  From 4-fold 
serial dilutions of C. albicans strains, 2 µl aliquots were spotted onto YPD agar +/- 10 
µg/mL FLC and incubated for 48 hours. 
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Table 2-5. MICs and MFCs in YPD of strains in 12-99 background 
 
 Relevant Characteristics 
or Genotype 
MIC (µg/ml)  MFC (µg/ml) 
Strain 24 hr 48 hr 72 hr  24 hr 48 hr 72 hr 
SC5314 UPC2-1/UPC2-2 0.5 0.5 >64  >64 >64 >64 
2-79 Susceptible isolate 1 1 >64  >64 >64 >64 
12-99 Resistant isolate >64 >64 >64  >64 >64 >64 
12-99upc2Δ/Δ upc2Δ::FRT/upc2Δ::FRT 4 4 8  16 16 16 
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Figure 2-3. UPC2 impacts fluconazole susceptibility in 12-99 background 
(A)  Effect of UPC2 in 12-99 on MIC and growth on YPD agar as determined by Etest.  
A confluent lawn of C. albicans was streaked prior to the addition of Etest strips and then 
incubated for 48 hours.  (B)  MIC heat map of 2-79, 12-99, and UPC2 mutant.  
Susceptibility was determined by broth microdilution in YPD at 72 hours.  Growth was 
quantified spectrophotometrically and assigned to a colorimetric scale.  (C)  Effect of 
UPC2 in 12-99 on the ability to grow on solid media containing fluconazole.  From 4-
fold serial dilutions of C. albicans strains, 2 µl aliquots were spotted onto YPD agar +/- 
10 µg/mL FLC and incubated for 48 hours.  (D)  Effect of fluconazole on UPC2 in 12-99 
by time-kill assay. 12-99 or 12-99upc2Δ/Δ cells were diluted in YPD medium containing 
fluconazole (10 µg/mL) or the solvent, DMSO.  After 0, 6, 12, and 24 hours, samples 
from each were diluted and plated for colony forming units.  
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revealed an increased fungistatic effect for fluconazole at 10 μg/ml against 12-99upc2Δ/Δ 
(Figure 2-3D).   
 
 
Expression of ERG11, CDR1, CDR2, and MDR1 When UPC2 Is Disrupted in 
Resistant Backgrounds 
 
 In order to determine if the enhanced fluconazole activity was due to decreased 
expression ERG11 or genes encoding efflux pumps, we measured ERG11, CDR1, CDR2, 
and MDR1 mRNA abundance by qRT-PCR in the strains containing a single resistance 
mechanism, isolate 12-99 and their respective upc2Δ/Δ mutants (Figure 2-4).  As 
expected, the upc2Δ/Δ mutant constructed in the SC5314 background showed a reduction 
in baseline ERG11 expression relative to its parent strain.  This was also the case for the 
upc2Δ/Δ mutants constructed in the ERG11K143R and clinical isolate 12-99 backgrounds.  
However, both the TAC1G980E and MRR1P683S strains exhibited reduced ERG11 
expression relative to SC5314 with no appreciable additional reduction in expression 
when UPC2 was disrupted.  Disruption of UPC2 did not result in decreased expression of 
CDR1, CDR2, or MDR1 in any background.  Interestingly, disruption of UPC2 in 
ERG11upc2Δ/Δ resulted in an increase in expression of these transporter genes, the 
significance of which is unclear.  These data suggest that the enhanced activity of 
fluconazole observed in resistant strains lacking UPC2 is not due to changes in 
transporter gene expression levels, but may be associated with a reduction in ERG gene 
expression, particularly ERG11.  
 
 
Comparison of the Gene Expression Profiles of Wild-Type Strain SC5314 and 
upc2Δ/Δ Exposed to Fluconazole 
 
 In order to identify genes whose expression in response to fluconazole is 
influenced by Upc2, we compared the transcriptional profiles of SC5314 and its upc2Δ/Δ 
derivative after treatment with or without 10 μg/ml fluconazole for 6 hours.  Genes were 
considered to be differentially expressed in response to fluconazole if their expression 
changed by ≥1.5-fold in two independent experiments (Table A-1 and Table A-2).  
Fluconazole inducible genes were also considered to be UPC2-dependent if their 
induction was abrogated in the deletion mutant and was ≥2.0-fold (50%) less than 
compared to SC5314.  Using these criteria, there were 127 genes upregulated by 
fluconazole whose induction was abrogated in the absence of UPC2 (Table 2-6).  The 
most common biological processes represented by these genes included the lipid 
metabolic process, iron ion transport and iron homeostasis, transport, response to stress 
and chemical stimulus, and the oxidation-reduction process. 
 
 
Validation of Microarray Data by Real Time RT-PCR 
 
 In order to validate the differential expression of genes identified by microarray, 
we examined the mRNA abundance for 5 genes of interest using the same RNA isolated  
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Figure 2-4. Expression of ERG11, CDR1, CDR2, and MDR1 as measured by qRT-
PCR 
Expression levels for ERG11, CDR1, CDR2, and MDR1 were measured in triplicate by 
qRT-PCR and compared to the expression levels in SC5314 (A) and 2-79 (B) in YPD.  
Error bars represent the standard error of the mean. 
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Table 2-6. Genes upregulated by at least 1.5-fold by fluconazole which are dependent upon Upc2 
 
      Change in Fold Expression    
   
SC5314+FLC/  upc2Δ/Δ+FLC/  
 SC5314 (A)  upc2Δ/Δ (B)  Ratio (B/A) 
Processa orf19 Designation CGD Name Exp1 Exp2  Exp1 Exp2  Exp1 Exp2 
Lipid metabolic 
process 
orf19.1598 ERG24 2.0 1.6  0.9 0.7  0.5 0.4 
orf19.1631 ERG6 1.8 1.7  0.4 0.5  0.2 0.3 
 
orf19.2670 
 
1.6 1.8  0.4 0.7  0.2 0.4 
 
orf19.3240 ERG27 2.8 2.4  1.4 1.1  0.5 0.4 
 
orf19.4982 
 
2.1 2.3  0.7 0.8  0.3 0.4 
 
orf19.7585 INO1 9.2 20.5  0.9 0.8  0.1 0.0 
 
orf19.922 ERG11 1.6 1.5  0.8 0.7  0.5 0.4 
     
 
  
 
  Iron ion transport orf19.1415 FRE10 2.0 4.2  0.2 0.1  0.1 0.0 
 orf19.1932 CFL4 35.6 359  8.0 22  0.2 0.1 
 
orf19.4211 FET3 2.8 6.2  0.7 0.2  0.3 0.0 
 
orf19.4215 FET34 2.1 5.2  0.0 0.1  0.0 0.0 
 
orf19.5634 FRP1 8.9 8.2  0.1 0.2  0.0 0.0 
 
orf19.7219 FTR1 3.2 7.8  0.1 0.0  0.0 0.0 
     
 
  
 
  Iron ion 
homeostasis 
orf19.1264 CFL2 2.0 6.0  0.2 0.8  0.1 0.1 
orf19.1715 IRO1 4.2 8.1  2.2 1.4  0.5 0.2 
 
orf19.5636 RBT5 1.7 1.6  0.2 0.2  0.1 0.2 
 
orf19.7114 CSA1 1.7 3.2  0.7 0.6  0.4 0.2 
     
 
  
 
  Transport orf19.1352 TIM22 3.6 4.4  1.3 2.0  0.4 0.4 
 
orf19.2023 HGT7 20.8 21.6  9.4 7.8  0.5 0.4 
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Table 2-6. (Continued) 
 
   
Change in Fold Expression  
  
   
SC5314+FLC/  upc2Δ/Δ+FLC/  
  
   
SC5314 (A)  upc2Δ/Δ (B)  Ratio (B/A) 
Processa orf19 Designation CGD Name Exp1 Exp2  Exp1 Exp2  Exp1 Exp2 
 
orf19.2292 OPT4 5.2 3.7  0.0 0.0  0.0 0.0 
 
orf19.2350 
 
2.5 4.1  0.9 0.6  0.4 0.1 
 
orf19.2785 ATP7 3.1 3.1  1.3 1.5  0.4 0.5 
 
orf19.3026 MAS1 1.7 1.6  0.9 0.8  0.5 0.5 
 
orf19.3195 HIP1 1.5 2.6  0.7 0.8  0.5 0.3 
 
orf19.3232 
 
24.6 5.3  1.6 1.6  0.1 0.3 
 
orf19.3668 HGT2 48.3 35.5  20.1 12.3  0.4 0.3 
 
orf19.3746 IFC1 2.3 2.7  0.2 0.0  0.1 0.0 
 
orf19.4335 TNA1 194.9 29.8  0.4 0.2  0.0 0.0 
 
orf19.4384 HXT5 70.6 75.5  16.9 9.7  0.2 0.1 
 
orf19.4682 HGT17 45.0 24.7  4.2 4.5  0.1 0.2 
 
orf19.4690 
 
16.3 20.2  1.0 1.4  0.1 0.1 
 
orf19.5307 JEN2 10.3 2.7  0.4 1.3  0.0 0.5 
 
orf19.5753 HGT10 20.6 1.6  2.6 0.8  0.1 0.5 
 
orf19.6148 
 
4.4 47.3  2.0 13.8  0.4 0.3 
 
orf19.6249 HAK1 5.4 5.8  1.4 1.7  0.3 0.3 
 
orf19.6993 GAP2 30.6 10.6  6.0 3.0  0.2 0.3 
 
orf19.7093 HGT13 40.9 18.8  9.8 2.6  0.2 0.1 
     
 
  
 
  Response to stress orf19.1434 
 
1.7 2.7  0.8 0.9  0.5 0.3 
 orf19.3239 CTF18 2.7 2.4  1.4 0.8  0.5 0.4 
 
orf19.3672 GAL10 6.0 7.3  2.7 3.8  0.5 0.5 
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Table 2-6. (Continued) 
 
   
Change in Fold Expression  
  
   
SC5314+FLC/  upc2Δ/Δ+FLC/  
     
SC5314 (A)  upc2Δ/Δ (B)  Ratio (B/A) 
Processa orf19 Designation CGD Name Exp1 Exp2  Exp1 Exp2  Exp1 Exp2 
 
orf19.4082 DDR48 5.8 5.7  1.9 1.3  0.3 0.2 
 
orf19.4093 PES1 2.7 3.5  0.6 1.3  0.2 0.4 
 
orf19.4317 GRE3 1.5 1.5  0.3 0.7  0.2 0.5 
 
orf19.496 
 
2.6 2.3  1.1 0.6  0.4 0.3 
 
orf19.5902 RAS2 7.6 6.2  2.3 1.5  0.3 0.2 
 
orf19.7221 SET3 4.6 2.9  2.1 1.4  0.5 0.5 
 
orf19.921 HMS1 2.6 2.8  0.8 1.3  0.3 0.5 
     
 
  
 
  Response to 
chemical stimulus 
orf19.4645 BEM1 1.5 1.9  0.4 0.6  0.3 0.3 
orf19.5591 ADO1 2.4 2.9  0.7 0.8  0.3 0.3 
 orf19.6102 RCA1 2.5 3.4  1.1 1.4  0.5 0.4 
 
orf19.7374 CTA4 1.7 2.2  0.8 1.0  0.5 0.5 
     
 
  
 
  Oxidation-
reduction process 
orf19.1411 
 
2.7 4.8  1.4 1.1  0.5 0.2 
orf19.1710 ALI1 2.0 1.9  0.7 0.8  0.4 0.4 
 orf19.1940 
 
1.7 1.5  0.4 0.7  0.2 0.5 
 
orf19.2091 
 
2.2 2.3  0.8 0.9  0.4 0.4 
 
orf19.2108 SOD6 7.9 10.6  1.1 1.6  0.1 0.1 
 
orf19.4274 PUT1 6.8 8.8  2.5 0.6  0.4 0.1 
 
orf19.4747 HEM14 1.7 2.0  0.1 0.2  0.0 0.1 
     
 
  
 
  Filamentous orf19.1300 
 
2.1 4.4  0.3 0.6  0.1 0.4 
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Table 2-6. (Continued) 
 
   
Change in Fold Expression  
  
   
SC5314+FLC/  upc2Δ/Δ+FLC/  
     
SC5314 (A)  upc2Δ/Δ (B)  Ratio (B/A) 
Processa orf19 Designation CGD Name Exp1 Exp2  Exp1 Exp2  Exp1 Exp2 
growth orf19.2809 CTN3 41.1 36.9  12.6 11.5  0.3 0.3 
 
orf19.3969 SFL2 1.5 2.4  0.7 0.6  0.5 0.2 
 
orf19.5741 ALS1 66.8 79.0  4.8 3.1  0.1 0.0 
     
 
  
 
  Organelle 
organization 
orf19.109 
 
1.5 1.6  0.5 0.5  0.4 0.3 
orf19.2387 
 
1.7 1.5  0.7 0.7  0.4 0.4 
 
orf19.2984 MST1 1.9 2.0  0.7 1.0  0.4 0.5 
 
orf19.3782.2 
 
1.5 1.8  0.6 0.5  0.4 0.3 
 
orf19.4051 HTS1 1.8 1.7  0.9 0.8  0.5 0.5 
 
orf19.415 
 
2.2 2.3  1.2 1.0  0.5 0.5 
 
orf19.4273 
 
5.1 7.6  1.4 2.0  0.3 0.3 
 
orf19.4478 
 
1.6 1.8  0.5 0.8  0.3 0.5 
 
orf19.4657 
 
2.8 2.2  1.4 0.6  0.5 0.3 
 
orf19.5705 NAM2 1.6 2.0  0.7 0.7  0.4 0.3 
 
orf19.6047 TUF1 1.8 2.8  0.3 0.3  0.2 0.1 
     
 
  
 
  DNA or RNA 
metabolic process 
orf19.1956 
 
1.5 1.8  0.8 1.0  0.5 0.5 
orf19.3138 NOP1 1.5 2.4  0.7 0.7  0.5 0.3 
 orf19.7569 SIK1 1.5 2.2  0.6 0.9  0.4 0.4 
           
Translation orf19.828 
 
1.8 1.5  0.2 0.4  0.1 0.3 
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Table 2-6. (Continued) 
 
   
Change in Fold Expression  
  
   
SC5314+FLC/  upc2Δ/Δ+FLC/  
  
   
SC5314 (A)  upc2Δ/Δ (B)  Ratio (B/A) 
Processa orf19 Designation CGD Name Exp1 Exp2  Exp1 Exp2  Exp1 Exp2 
Biological process orf19.4054 CTA24 1.8 2.5  0.5 1.0  0.3 0.4 
 
orf19.6003 
 
2.4 2.1  0.9 0.7  0.4 0.4 
     
 
  
 
  Precursor 
metabolites and 
energy 
orf19.1770 CYC1 1.9 2.2  0.6 0.7  0.3 0.3 
orf19.2439.1 
 
1.6 2.6  0.8 1.2  0.5 0.5 
orf19.3290 
 
1.8 2.0  1.0 1.1  0.5 0.5 
 
orf19.5893 RIP1 1.6 2.2  0.7 0.8  0.5 0.4 
     
 
  
 
  Vitamin metabolic 
process 
orf19.2590 
 
1.8 2.8  0.0 0.2  0.0 0.1 
orf19.410.3 
 
5.6 5.7  1.0 0.8  0.2 0.1 
 
orf19.6057 
 
2.5 1.8  0.2 0.2  0.1 0.1 
     
 
  
 
  Other orf19.2836 
 
3.4 5.9  1.6 1.5  0.5 0.3 
 
orf19.3008 COQ4 2.5 1.8  0.4 0.8  0.2 0.5 
 
orf19.4899 GCA1 4.4 5.2  1.2 1.9  0.3 0.4 
 
orf19.6348 
 
3.0 2.4  0.6 1.2  0.2 0.5 
 
orf19.7263 
 
5.3 6.0  2.6 2.2  0.5 0.4 
     
 
  
 
  Unknown orf19.1070 
 
8.6 8.0  2.4 1.6  0.3 0.2 
 
orf19.1277 
 
6.6 9.3  3.4 2.7  0.5 0.3 
 
orf19.1371 
 
1.5 1.6  0.8 0.6  0.5 0.4 
 
orf19.1440 
 
2.1 2.6  0.8 0.9  0.4 0.3 
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Table 2-6. (Continued) 
 
   
Change in Fold Expression  
  
   
SC5314+FLC/  upc2Δ/Δ+FLC/  
  
   
SC5314 (A)  upc2Δ/Δ (B)  Ratio (B/A) 
Processa orf19 Designation CGD Name Exp1 Exp2  Exp1 Exp2  Exp1 Exp2 
 
orf19.1562 
 
3.7 4.5  1.7 1.3  0.5 0.3 
 
orf19.2068 
 
1.6 1.5  0.6 0.6  0.4 0.4 
 
orf19.2414 
 
3.1 3.3  0.7 1.7  0.2 0.5 
 
orf19.2691 
 
1.5 1.5  0.4 0.7  0.3 0.5 
 
orf19.2839 CIRT4B 1.6 2.6  0.7 0.6  0.4 0.2 
 
orf19.287 
 
2.8 2.9  1.4 1.5  0.5 0.5 
 
orf19.3154 
 
2.1 2.3  0.6 0.6  0.3 0.2 
 
orf19.3499 
 
79.5 20.5  10.6 10.1  0.1 0.5 
 
orf19.3881 
 
1.9 2.0  0.5 0.5  0.2 0.2 
 
orf19.4013 
 
2.6 2.2  0.3 0.4  0.1 0.2 
 
orf19.4070 
 
5.0 8.9  1.8 1.9  0.4 0.2 
 
orf19.4144 
 
2.4 3.2  0.9 0.9  0.4 0.3 
 
orf19.4391 
 
3.2 1.5  1.0 0.7  0.3 0.5 
 
orf19.4658 
 
1.6 1.8  0.5 0.8  0.3 0.5 
 
orf19.467 
 
32.3 7.1  2.8 0.8  0.1 0.1 
 
orf19.5019 
 
3.5 3.7  0.9 1.9  0.2 0.5 
 
orf19.5205 
 
3.9 4.9  1.9 2.2  0.5 0.4 
 
orf19.5547 
 
2.8 2.4  0.8 1.1  0.3 0.4 
 
orf19.5635 PGA7 4.9 4.1  0.5 0.4  0.1 0.1 
 
orf19.6186 
 
12.1 13.3  2.8 2.7  0.2 0.2 
 
orf19.6187 
 
1.7 1.7  0.9 0.7  0.5 0.4 
 
orf19.6194 
 
1.5 1.6  0.6 0.9  0.4 0.5 
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Table 2-6. (Continued) 
 
   
Change in Fold Expression  
  
   
SC5314+FLC/  upc2Δ/Δ+FLC/  
  
   
SC5314 (A)  upc2Δ/Δ (B)  Ratio (B/A) 
Processa orf19 Designation CGD Name Exp1 Exp2  Exp1 Exp2  Exp1 Exp2 
 
orf19.6690 
 
2.4 2.3  0.6 0.7  0.3 0.3 
 
orf19.670.2 
 
47.4 152.7  18.3 14.1  0.4 0.1 
 
orf19.6713 
 
2.2 3.7  0.9 0.3  0.4 0.1 
 
orf19.6905 
 
2.4 3.3  1.2 1.4  0.5 0.4 
 
orf19.6970 
 
4.5 4.4  2.0 1.8  0.4 0.4 
 
orf19.6983 
 
2.1 9.1  0.4 0.0  0.2 0.0 
 
orf19.7380 
 
3.0 3.2  1.6 1.3  0.5 0.4 
 
orf19.7567 
 
1.9 2.1  0.2 0.2  0.1 0.1 
 
orf19.7675 
 
1.7 1.9  0.8 0.8  0.5 0.4 
 
orf19.951 
 
2.3 2.4  0.8 1.2  0.3 0.5 
a Descriptions are from the Candida Genome Database (http://www.candidagenome.org). 
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for the microarray experiments.  In addition to ERG11, four others were chosen based on 
their involvement in iron transport and homeostasis. The correlation between the 
microarray data and that obtained by real time RT-PCR was good (Figure 2-5).  The 
expressions of CFL4, FET3, FRP1, and FTR1 were upregulated in the wild type SC5314 
when treated with fluconazole, but could not respond to the same extent when UPC2 was 
disrupted.  As expected, ERG11 was also shown to respond to fluconazole in a UPC2-
dependent fashion.   
 
 These data suggest that the enhanced activity of fluconazole observed in both 
susceptible and resistant strains lacking UPC2 may be due to disregulation of iron 
homeostasis, in addition to the inability to upregulate genes involved in the ergosterol 
biosynthesis pathway. 
 
 
DISCUSSION 
 
 Identifying novel drug targets that improve the efficacy of fluconazole is 
important in order to develop new therapeutic strategies to preserve the azole class of 
antifungals and overcome azole resistance.  UPC2 has been well characterized with 
regard to its impact on fluconazole susceptibility and its role regulating genes of the 
ergosterol biosynthesis pathway (199-201, 224).  Silver et al. and MacPherson et al. 
identified Upc2p as the key regulator of ergosterol metabolism in C. albicans, showing 
that azole-inducible expression of ERG2, ERG7, ERG11, and ERG25 is diminished in the 
absence of UPC2 (199, 200).  We and others have established that in some azole-resistant 
isolates specific mutations render UPC2 constitutively active, resulting in increased ERG 
gene expression (including ERG11), cellular ergosterol levels, and increased fluconazole 
resistance (156, 168, 201, 203, 204, 216, 219).  This suggests that UPC2 influences azole 
susceptibility through the regulation of this pathway. 
 
 In the present study, we observed that not only did the disruption of UPC2 result 
in enhanced fluconazole susceptibility as measured by MIC, but also resulted in a 
substantial reduction in fluconazole MFC at 24, 48, and 72 hrs.  Indeed disruption of 
UPC2 in an azole-susceptible strain prevented its regrowth in YPD medium in the 
presence of higher fluconazole concentrations after 72 hours, resulted in a clear zone of 
inhibition around a fluconazole Etest strip, and prevented growth on solid media 
containing a therapeutically relevant concentration of fluconazole (10 μg/ml).   Time-kill 
analysis also demonstrated an enhanced effect for fluconazole 10 μg/ml against the 
upc2Δ/Δ mutant as compared to its parent strain.  Taken together, these data underscore 
the contribution of the Upc2 transcriptional activation pathway to azole susceptibility. 
 
 We then wished to determine if disruption of UPC2 might have similar effects in 
fluconazole resistant isolates.  For this purpose we chose isogenic strains containing 
resistance mutations in ERG11, MRR1, or TAC1.  The strain containing the ERG11K143R 
mutation had an MIC of 8 μg/ml at 48 and 72 hours in YPD.  Consistent with this, it was 
unable to grow in the presence of 10 μg/ml fluconazole.  Although this background was 
not as highly resistant as others, its respective UPC2 deletion mutant had a marked drop  
 42 
CF
L4
FE
T3
FR
P1
FT
R1
ER
G1
1
0
5
10
15
20
40
60
80
100
SC5314+FLC/SC5314
upc2∆/∆+FLC/upc2∆/∆
R
el
at
iv
e 
Fo
ld
 C
ha
ng
e
 
 
 
Figure 2-5. Validation of fluconazole-inducible and Upc2-dependent iron gene 
expression by qRT-PCR 
Expression levels for CFL4, FET3, FRP1, FTR1, and ERG11 were measured in triplicate 
by qRT-PCR and compared to the expression levels in SC5314 in YPD.  Shown are the 
relative n-fold changes in gene expression in the in SC5314 and upc2Δ/Δ treated with 
fluconazole (FLC).  Error bars represent the standard error of the mean.  
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in both fluconazole MIC and MFC.  The MRR1P683S and TAC1G980E resistant strains both 
had an MIC and MFC of >64 μg/ml at 48 and 72 hours in YPD medium which was 
reduced markedly in the respective upc2Δ/Δ mutants at all time points.  This trend in 
susceptibility is consistent with what has been previously observed for this 
MRR1P683Supc2Δ/Δ mutant (214).  However, unlike the halo of reduced confluent growth 
observed around the Etest strip with clinical isolate SC5314 (and generally observed with 
other C. albicans isolates), such growth was not observed with these resistant strains 
despite higher MICs and MFCs of >64 μg/ml.  It has recently been shown that the 
MRR1P683S and TAC1G980E constructed mutants exhibit a fitness defect associated with 
introduction of these specific resistance mutations, whereas clinical isolates carrying such 
mutations appear to have regained fitness (225).  Such clinical isolates have likely 
evolved compensatory mutations which mitigate these fitness defects.  This may explain 
the unusual growth pattern of these mutants when subjected to susceptibility testing by 
Etest. Despite the absence of reduced confluent growth, the upc2Δ/Δ mutants in each 
background showed increased susceptibility to fluconazole by Etest and an inability to 
grow in the presence of fluconazole at 10 μg/ml.  Therefore, the loss of UPC2 in strains 
containing a single mechanism of resistance also resulted in enhanced susceptibility to 
fluconazole and to a greater extent than that observed for their susceptible parent strain 
SC5314. 
 
 The same phenotype was also observed upon disruption of UPC2 in a highly 
resistant clinical isolate, 12-99, which carries all four of the most common mechanisms 
of resistance. 12-99upc2Δ/Δ exhibited a substantial reduction in fluconazole resistance as 
compared to isolate 12-99.  Although 12-99upc2Δ/Δ was able to resume growth in lower 
concentrations of fluconazole at 72 hours in broth microdilution plates, it was not able to 
grow to the extent of 12-99 or its susceptible matched isolate, 2-79, both of which were 
able to grow even in the highest concentration of fluconazole.  Similarly to what was 
observed for upc2Δ/Δ in the SC5314 background, fluconazole exhibited a greater 
fungistatic effect against 12-99upc2Δ/Δ as compared to its parent azole-resistant isolate.  
Indeed the loss of UPC2 allowed fluconazole to overcome all four mechanisms of 
fluconazole resistance operative in isolate 12-99, and resulted in greater fluconazole 
susceptibility than was seen with its susceptible matched isolate, 2-79.  Moreover, this 
resulted in a more pronounced effect by MFC, 72 hour regrowth, and time kill analysis 
than was observed for the susceptible wild type strain, SC5314.  
 
 One hypothesis for how the disruption of UPC2 overcomes drug resistance is that 
it influences the expression of the efflux pump genes CDR1, CDR2, and MDR1 in these 
strains. Indeed, it has been shown that in C. albicans Upc2 binds to the promoters of 
CDR1 and MDR1 and can regulate their expression  (201).  However, the expression of 
these genes was not affected in the absence of UPC2 in both the constructed mutant 
strains or resistant clinical isolate 12-99.  The disruption of UPC2 had such an effect on 
susceptibility that even with constitutive upregulation of these efflux pumps, the strains 
were no longer resistant to fluconazole.  CDR1 and CDR2 remained upregulated in 
TAC1G980E and 12-99 as did MDR1 in MRR1P683S and 12-99.   
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 Another possible explanation for the increased susceptibility to fluconazole 
observed in the upc2Δ/Δ mutants is a reduction in baseline or inducible expression of 
genes involved in sterol biosynthesis.  In the presence of fluconazole, the ERG11 gene 
product, lanosterol demethylase, is inhibited leading to the accumulation of toxic sterol 
precursors and the production of alternate sterols such as lanosterol, eburicol, 
obtusifoliol, 14α-methyl fecosterol and 14α-methylergosta-8,24(28)-dien-3β,6α-diol 
(107). Integration of these sterols into the plasma membrane disrupts its integrity 
resulting in its altered structure and function (79, 82, 226).  Under these conditions, 
growth is inhibited but the organism remains viable (109).  Fluconazole treatment also 
induces the expression of ERG11 and other genes of the ergosterol biosynthesis pathway 
leading to increased production of not only lanosterol demethylase, but enzymes involved 
in alternate sterol production (227).  However when UPC2 is disrupted, ERG11 
expression would be reduced which would diminish the amount of drug target expressed 
in the cell.  Expression of genes encoding enzymes needed for the biosynthesis of 
alternative sterols would also be reduced, further compromising the organism in the face 
of fluconazole exposure.  Indeed expression of ERG11 was reduced in ERG11upc2Δ/Δ, 
MRR1upc2Δ/Δ and TAC1upc2Δ/Δ as well as 12-99upc2Δ/Δ as measured by real-time 
RT-PCR, and inducible expression of ERG6, ERG24, and ERG27 (as well as ERG11) 
was reduced in the upc2Δ/Δ mutant as compared to its parent strain SC5314 upon 
exposure to fluconazole as measured by microarray analysis.  ERG6 and ERG27 both 
encode enzymes believed to be involved in the production of alternate sterols  
(Figure 2-6).  
 
 Of particular interest, another core set of fluconazole-induced genes we found to 
be dependent upon UPC2 included those in the gene ontology process categories of iron 
transport (CFL4, FET3, FET34, FRE10, FRP1, FTR1) and iron homeostasis (CFL2, 
CSA1, IRO1, RBT5).  Iron starvation has been shown to enhance the susceptibility of C. 
albicans to fluconazole (228-231).  Prasad et al. observed that an ftr1Δ/Δ mutant, which 
is defective in high-affinity iron uptake, also exhibited enhanced susceptibility to 
fluconazole (228).  Upon examination of ERG11 mRNA abundance and membrane 
ergosterol levels of the ftr1Δ/Δ mutant, a reduction in ERG11 expression and ergosterol 
content was observed compared to wild-type cells which led to increased membrane 
fluidity and consequently increased passive diffusion of fluconazole.  In contrast ERG3, 
which acts in the biosynthesis of 14α-methylergosta-8,24(28)-dien-3β,6α-diol (232), was 
upregulated.  This phenotype reverted upon the addition of iron to the medium.  A similar 
observation has been made in Cryptococcus neoformans where disruption of the genes 
encoding the ferroxidase (CFO1) and an iron permease (CFT1) of the high-affinity 
reductive iron uptake system, resulted in increased susceptibility to azole antifungals 
(233).   
 
 As many enzymes in the ergosterol biosynthesis pathway require iron, it is 
tempting to speculate that decreased iron uptake, as suggested by the diminished 
expression of iron transport and homeostasis genes exhibited by the upc2Δ/Δ mutant 
relative to its parent strain in the presence of fluconazole, would have a significant impact 
on the activity of these enzymes.  This, combined with decreased expression of the genes 
encoding enzymes involved in ergosterol biosynthesis, (ERG11 in particular), may   
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Figure 2-6. Sterol biosynthesis pathway in C. albicans 
Genes in boldface were found to be responsive to fluconazole in a Upc2-dependent 
manner.  Dotted lines denote multiple enzymatic steps (232, 234, 235). 
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account for the substantial effect on fluconazole susceptibility observed in these strains 
upon disruption of UPC2.  While further investigation is needed to determine which 
Upc2 targets influence susceptibility to the azole antifungals, our findings suggest that 
the Upc2 and the transcriptional activation pathway it regulates represents a potential 
target for overcoming azole antifungal resistance in C. albicans.   
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CHAPTER 3.    CAS5 IMPACTS THE ACTIVITY OF FLUCONAZOLE 
AGAINST CANDIDA ALBICANS 
 
 
INTRODUCTION 
 
 Candida albicans is the most prevalent opportunistic human fungal pathogen, 
causing mucosal, cutaneous and systemic infections including oropharyngeal candidiasis 
(OPC), which is the most common opportunistic infection among AIDS patients (65).  
Candida species collectively are also the fourth-leading cause of nosocomial infections 
and are associated with high mortality rates (208, 209).  The azole antifungals, 
particularly fluconazole (FLC), are the most widely used for treatment of Candida 
infections (65).  However, C. albicans exhibits inhibited growth in the presence of azole 
antifungals, thus these agents are fungistatic against this organism (206).  Identifying 
strategies to impart increased susceptibility to the azoles could improve their efficacy 
against C. albicans and may also diminish the development of resistance. 
 
 In C. albicans inhibition of the ergosterol biosynthesis pathway is not lethal 
suggesting that specific stress responses may circumvent or counter the activity of the 
azoles.  Such an adaptive response would permit fungal survival in the presence of these 
antifungal agents.  Indeed, in response to antifungal stress, specific signal transduction 
and transcriptional activation programs are affected (97).  Drug efflux pump and 
ergosterol biosynthesis gene expression (236), the Ras-cAMP-PKA pathway (98), the 
calcineurin pathway (99-101), the Ssk1p/Chk1p pathway (102), and the cell wall integrity 
pathway (105, 237) have all been implicated as stress responses upon azole exposure yet 
the transcriptional activation pathways involved in these processes have yet to be 
identified.  Moreover, it is likely that additional biological processes influence 
susceptibility to the azole antifungals.  
 
 Recently a library of C. albicans TF mutants was created and examined in 55 
different growth conditions.  Phenotypic profiling in response to various stress agents, 
including fluconazole, identified the possible biological roles of many previously 
uncharacterized TFs (187).  While initial screens identified several TFs that affect 
fluconazole susceptibility, we undertook a more comprehensive analysis of this library in 
order to identify transcriptional activation programs that influence fluconazole activity 
and would therefore be implicated in the mechanisms by which C. albicans survives in 
the presence of the azoles.  We identified one TF in particular, Cas5, whose disruption 
results enhanced azole activity indicating a role for the Cas5 transcriptional network in 
the susceptibility of C. albicans to the azole antifungal agents.  
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MATERIALS AND METHODS 
 
 
Strains and Growth Conditions 
 
 All C. albicans strains (Table 3-1) were stored as frozen stock in 40% glycerol at 
-80°C.  YPD (1% yeast extract, 2% peptone, and 1% dextrose) agar plates and YPD 
liquid medium were used for routine growth of strains at 30°C.  For colony forming unit 
(CFU) counts during time-kill analysis, PDA (0.4% potato starch, 2% dextrose, and 1.5% 
agar) plates were used, and cultures grown on PDA were incubated at 35°C. 
 
 
Drug Susceptibility Testing 
 
 The minimum inhibitory concentrations (MICs) of fluconazole were determined 
by using broth microdilution as described by the Clinical and Laboratory Standards 
Institute M27-A2, modified by using both RPMI and YPD media, and were read both 
visually and spectrophotometrically at 24, 48, and 72 hours.  Minimum fungicidal 
concentrations (MFCs) were measured by removing 2 µl from each well of the MIC plate 
and plating onto SD or YPD agar, respectively.  Also, serial dilutions from a 0.1 OD600 
suspension were diluted 4-fold and 2 µl of each dilution plated onto YPD agar plates with 
and without 10 µg/ml fluconazole and then incubated at  30°C for 24 and 48 hours.  
Fluconazole activity was also assessed by Epsilometer test strips (Etest strips) 
(Biomerieux) according to manufacturer’s instructions with the following modifications.  
A standardized cell suspension (0.5 McFarland) was used to create a confluent lawn 
across YPD agar plates prior to Etest strip placement and then incubated at 30°C for 24 
and 48 hours.  Time-kill analyses were performed with a 0.5 McFarland cell suspension, 
which was 10-fold diluted into YPD media with and without 10 µg/ml fluconazole and 
incubated at 35°C.  Aliquots were removed at 0, 6, 12, and 24 hours, 10-fold serial 
diluted and plated onto PDA.  CFUs were counted in duplicate after 48 hours at 35°C and 
plotted on a log-scale curve versus time (238). 
 
 
Construction of Gene Deletion Strains 
 
 Plasmid pBSS2 contains the entire SAT1-flipper disruption cassette from pSFS2 
in a pBluescript vector backbone.  The SAT1-flipper cassette consists of the SAT1 
selectable marker which confers resistance to nourseothricin and the FLP flipper 
recombinase gene both flanked by FRT sites (flipper recombinase target sequences).  The 
target gene’s 5’ flanking sequence was cloned upstream of the SAT1-flipper cassette 
while the 3’ flanking sequence was cloned downstream of the SAT1-flipper cassette 
(Table 3-2).  Upon transformation into the SC5314 strain the SAT1-flipper was inserted 
into the coding region of one allele, and such positive transformants (NouR) were selected 
on YPD-nourseothricin agar plates containing 200 μg/ml of nourseothricin.  Induction of 
the FLP gene occurred by growing the transformants in YPD medium for 24 hours 
without selective pressure.  Positive cells (NouS) were selected by replica plating onto
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Table 3-1. C.albicans strains used in this study 
 
Strain Designation 
Strain 
Background 
Relevant Characteristics or 
Genotype Source 
SC5314 SC5314 N/A CAS5/CAS5 CZF1/CZF1 
MKC1/MKC1 RPN4/RPN4 
ATCC 
SCCAS5A5A66C 
 
cas5Δ/Δ SC5314 cas5Δ::FRT/cas5Δ::FRT This study 
SCCAS5A5A66C1B 
 
cas5Δ/Δ+CAS5 SCCAS5A5A66C cas5Δ::FRT/CAS5-caSAT1 This study 
SCRPN4A1A21C 
 
rpn4Δ/Δ SC5314 rpn4Δ::FRT/rpn4Δ::FRT This study 
SCRPN4A1A21C6A 
 
rpn4Δ/Δ+RPN4 SCRPN4A1A21C rpn4Δ::FRT/RPN4-caSAT1 This study 
SCCZF1G1D12 
 
czf1Δ/Δ SC5314 czf1Δ::FRT/czf1Δ::FRT This study 
SCMKC1B5A4A 
 
mkc1Δ/Δ SC5314 mkc1Δ::FRT/mkc1Δ::FRT This study 
SCMKC1B5A4A9A 
 
mkc1Δ/Δ+MKC1 SCMKC1B5A4A mkc1Δ::FRT/MKC1-caSAT1 This study 
Clinical isolate2-79 
 
2-79 N/A Susceptible isolate Redding, 1994 
Clinical isolate12-99 
 
12-99 N/A Resistant isolate Redding, 1994 
12-99CAS5A1A72 
 
12-99cas5Δ/Δ 12-99 cas5Δ::FRT/cas5Δ::FRT This study 
G2 
 
G2 G1 Susceptible isolate Franz, 1998 
G5 
 
G5 G2 Resistant isolate Franz, 1998 
G5CAS5B16D3D 
 
G5cas5Δ/Δ G5 cas5Δ::FRT/cas5Δ::FRT This study 
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Table 3-1. (Continued) 
 
Strain Designation 
Strain 
Background 
Relevant Characteristics or 
Genotype Source 
Gu2 
 
Gu2 Gu1 Susceptible isolate Franz, 1999 
Gu5 
 
Gu5 Gu2 Resistant isolate Franz, 1999 
Gu5CAS5A23A4A 
 
Gu5cas5Δ/Δ Gu5 cas5Δ::FRT/cas5Δ::FRT This study 
S1 
 
S1 N/A Susceptible isolate Franz, 1999 
S2 
 
S2 S1 Resistant isolate Franz, 1999 
S2CAS5B6C5A 
 
S2cas5Δ/Δ S2 cas5Δ::FRT/cas5Δ::FRT This study 
SCUPC2R14A 
 
UPC2G648D SC5314 UPC2G648D::FRT/UPC2G648D::FRT 
CAS5/CAS5 
Heilmann, 2010 
SCUPC2R14ACAS5A5A21Y UPC2cas5Δ/Δ SCUPC2R14A UPC2G648D::FRT/UPC2G648D::FRT 
cas5Δ::FRT/cas5Δ::FRT 
This study 
10C1B1M1 ERG11K143R SC5314 ERG11K143R::FRT/ERG11K143R::FRT 
CAS5/CAS5 
Chapter 2 
10C1B1M1CAS5-1A51B ERG11cas5Δ/Δ 10C1B1M1 ERG11K143R::FRT/ERG11K143R::FRT 
cas5Δ::FRT/cas5Δ::FRT 
This study 
SCMRR1R34A MRR1P683S SC5314 MRR1P683S::FRT/MRR1P683S::FRT 
CAS5/CAS5 
Schubert, 2011 
SCMRR1R34ACAS5-2A3 MRR1cas5Δ/Δ SCMRR1R34A MRR1P683S::FRT/MRR1P683S::FRT 
cas5Δ::FRT/cas5Δ::FRT 
This study 
SCTAC1R34A TAC1G980E SC5314 TAC1G980E::FRT/TAC1G980E::FRT 
CAS5/CAS5 
Sasse, 2011 
SCTAC1R34ACAS5-2A1 TAC1cas5Δ/Δ SCTAC1R34A TAC1G980E::FRT/TAC1G980E::FRT 
cas5Δ::FRT/cas5Δ::FRT 
This study 
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Table 3-2. Primers used in this study 
 
Method Primer Sequence 
qRT-PCR ACT1-F 5'-ACGGTGAAGAAGTTGCTGCTTTAGTT-3' 
 ACT1-R 5'-CGTCGTCACCGGCAAAA-3' 
 BMR1-F 5'-ACATAAATACTTTGCCCATCCAGAA-3' 
 BMR1-R 5'-AAGAGTTGGTTTGTAATCGGCTAAA-3' 
 CDR1-F 5'-ATTCTAAGATGTCGTCGCAAGATG-3' 
 CDR1-R 5'-AGTTCTGGCTAAATTCGTAATGTTTTC-3' 
 CDR2-F 5'-TAGTCCATTCAACGGCAACATT-3' 
 CDR2-R 5'-CACCCAGTATTTGGCATTGAAA-3' 
 CFL4-F 5'-GCAATGGTTGACAGGTTGGAA-3' 
 CFL4-R 5'-GCAATGTGACGATGATAAGTGACAA-3' 
 ERG11-F 5'-CCCCTATTAATTTTGTTTTCCCTAATTTAC-3' 
 ERG11-R 5'-CACGTTCTCTTCTCAGTTTAATTTCTTTC-3' 
 ERG26-F 5'-ATTAGAGTGTGCGATGCCATT-3' 
 ERG26-R 5'-CGTCGTCGTAGTCGTCAC-3' 
 FTR1-F 5'-ATTGTTGTTTCAGTGCTTTTGGC-3' 
 FTR1-R 5'-GGTCGGAACTACCACCCATAGA-3' 
 PGA13-F 5'-CTCCGAAGAAGAAGGAAGCGT-3' 
 PGA13-R 5'-GGTGAAATCAGTGACGGTGACTT-3' 
 PGA31-F 5'-CTTTCCTTTGATGGTTCCGACT-3' 
 PGA31-R 5'-GGGTCATTGATGTTCTTGGCA-3' 
Mutant 
construction 
CAS5-A 5'-TTCAACTTCAAGGTACC
CAS5-B 
TGTTGATATTCTA-3' 
5'-CTAACGGTCTCGAG
 
AAATTTTGTGATAGTT-3' 
CAS5-C 5'-ATTGTGGTAACCGCGG
 
TAATCGTAAAGATA-3' 
CAS5-D 5'-GCATATTTAGGAGCTC
 
CTAGTGGTGATTTA-3' 
CAS5-E 5'-GCATACTGCATATTTAGCTCGAG
 
CTAGTGG-3' 
RPN4-A 5'-AGATCAATATAGGGCCC
 
TAAAGGACATCTT-3' 
RPN4-B 5'-GTGTATTATTGGCTCGAG
 
TAAAAGTGTTGT-3' 
RPN4-C 5'-TAGATTTAATCCGCGG
 
AGCTAAAGAGAATG-3' 
RPN4-D 5'-CTGGTGAAGAGCTC
 
TAAAGTGATATTATTG-3' 
RPN4-E 5'-CTGGTGAAGAACTCGAG
 
AGTGATATTATTG-3' 
CZF1-A 5'-GCAAAATTCAAAGGGCCC
 
GACCTAATTC-3' 
CZF1-B 5'-GTGGTTGTGCTCGAG
 
GAGAGGTATTGG-3' 
CZF1-C 5'-CAATTGAAGCGGCCGC
 
GTTTGGTAGAATC-3' 
CZF1-D 5'-GTCAACTTTTGCCGCGG
 
CACACACGTAAA-3' 
MKC1-A 5'-TTTGATAATAAAAAGGGGCCC
 
TTGAGAA-3' 
MKC1-B 5'-GATAAATTCCTGGCTCGAG
 
ACCTTATTTAC-3' 
MKC1-C 5'-AAGAGTATATAAAGCCCGCGG
 
AAGAGCTTG-3' 
MKC1-D 5'-AACAAGACTGAGCTC
 
AACAAAAGAAATGTA-3' 
MKC1-E 5'-AACAAGACTGAACTCGAG
Underlined sequence reflects the introduction of a restriction site sequence. 
AAAAGAAATGTA-3' 
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YPD plates with and without 200 μg/ml of nourseothricin.  Upon induction of the FLP 
gene, the cassette was excised such that only one copy of the FRT site remains in the 
locus. Another round was required to disrupt the second allele (34). 
 
 For gene complementation, the target gene’s open reading frame (ORF) ± ~1kb 
was cloned in place of the target gene’s 5’ flanking sequence in the aforementioned 
disruption cassette.  Upon transformation into the SC5314 strain, one allele of the gene’s 
coding region was inserted into the original locus in conjunction with the SAT1-flipper, 
and such positive transformants (NouR) were selected on YPD-nourseothricin agar plates 
containing 200 μg/ml of nourseothricin.  Induction of the FLP gene occurred by growing 
the transformants in YPD medium for 24 hours without selective pressure.  Positive cells 
(NouS) were selected on by replica plated onto YPD plates with and without 200 μg/ml of 
nourseothricin.  Upon induction of the FLP gene, the cassette is excised such that only 
the gene’s allele with a downstream FRT was left in the locus.  Appropriate gene 
disruption and complementation was confirmed by Southern hybridization (34). 
 
 
Isolation of Genomic DNA and Southern Hybridization 
 
 Genomic DNA was isolated as described previously (217).  Four µg of DNA were 
digested with an appropriate restriction endonuclease, separated on a 1% agarose gel, and 
after staining with ethidium bromide, were transferred by vacuum blotting onto a nylon 
membrane and fixed by UV cross-linking.  Southern hybridization with enhanced 
chemiluminescence-labeled probes was performed with the Amersham ECL Direct 
nucleic acid labeling and detection system according to the instructions of the 
manufacturer. 
 
 
RNA Isolation for qRT-PCR 
 
 RNA was isolated using a small-scale hot phenol method of RNA isolation 
described by Schmitt et al (218).  Briefly, overnight cultures were diluted to an OD600 of 
0.2 in 20 ml YPD and then incubated at 30○C with shaking for 3 hours.  Cells were 
collected by centrifugation, and stored at -80○C.  Cell pellets were resuspended in 950 µl 
of AE buffer and then transferred to a 2-ml RNase-free microcentrifuge tube containing 
950 µl acid phenol (pH 4.3) with 1% SDS.  Cells were incubated at 65○C for 10 minutes 
then lysates were clarified by centrifugation.  The supernatant was then divided into two 
new 2-ml microcentrifuge tubes containing 950 µl of chloroform and mixed.  The sample 
was then subjected to centrifugation again, and the top aqueous layer was transferred to a 
new tube containing 1 ml of isopropanol and 100 µl 2M sodium acetate.  The RNA pellet 
was subsequently washed with 500 µl of 70% ethanol and collected by centrifugation.  
The RNA pellet was resuspended in DNase/RNase-free H2O.  Quantity and purity were 
determined spectrophotometrically at absorbances of A260 and A280. 
 
 
 53 
Quantitative RT-PCR 
 
 First-strand cDNAs were synthesized from 1 µg of total RNA using SuperScript 
first-strand synthesis system for qRT-PCR (Invitrogen).  Gene-specific primers  
(Table 3-2) were designed using Primer Express software (Applied Biosystems) and 
synthesized by Integrated DNA Technologies (Coralville, IA).  Quantitative PCRs were 
performed in triplicate using the 7000 sequence detection system (Applied Biosystems), 
independently amplifying ACT1 (normalizing gene) and the genes of interest (GOI) as 
described previously (219). 
 
 
RNA Isolation for Microarray 
 
 RNA was isolated using a large-scale version of the hot phenol method of RNA 
isolation described by Schmitt et al. (218).  Briefly, overnight cultures were diluted to an 
OD600 of 0.005 in 100 ml YPD and then incubated at 30○C with shaking for an additional 
8 hours to an OD600 of 1.0.  Cultures were diluted again to an OD600 of 0.025 in 100 ml 
fresh YPD, allowed to incubate at 30○C with shaking for one doubling, inoculated with or 
without 10 µg/ml fluconazole, and then incubated at 30○C with shaking for 6 hours.  
Cells were collected by centrifugation, and stored at -80○C.  Cell pellets were 
resuspended in 12 ml of AE buffer and then transferred to a 50-ml Oak Ridge tubes 
treated with RNAse Away (Molecular BioProducts) containing 12 ml acid phenol (pH 
4.3) with 1% SDS.  Cells were incubated at 65○C for 10 minutes then lysates were 
clarified by centrifugation.  The supernatant was then transferred to a new tube 
containing 15 ml of chloroform and mixed.  The sample was then subjected to 
centrifugation again, and the top aqueous layer was transferred to a new tube containing 
one volume of isopropanol and 0.1 volume 2M sodium acetate.  The RNA pellet was 
subsequently washed with 10 ml of 70% ethanol and collected by centrifugation.  The 
RNA pellet was resuspended in DNase/RNase-free H2O.  Quantity and purity were 
determined spectrophotometrically at absorbances of A260 and A280. 
 
 
Transcriptional Profiling 
 
 Gene expression profiles were obtained by hybridizing labeled cRNAs generated 
from C. albicans total RNA onto Affymetrix C. albicans custom expression arrays 
(CAN07; 49-5241) (216), which have been described previously (201).  Microarray 
hybridization and analysis were performed as described previously (201).  Genes were 
considered to be differentially expressed in response to drug if their expression changed 
by ≥1.5-fold in two independent experiments.  Genes induced by fluconazole were 
considered to be CAS5-dependent if the induction was abrogated in the deletion mutant 
was ≥2.0-fold (50%) less than the wild-type.  All microarray data is available for 
download from the NCBI at GEO (Accession number: pending). 
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RESULTS 
 
 
Disruption of Cas5 Enhances Fluconazole Activity against C. albicans 
 
 In order to identify transcriptional activation programs that influence azole 
susceptibility of C. albicans to the azole antifungals, we first screened a collection of TF 
deletion mutants for those that displayed a increase in fluconazole susceptibility as 
measured by broth microdilution in RPMI medium (187).  In order to detect marked 
reductions in MIC, a lower range of fluconazole concentrations from 0.0071825 to 4 
μg/ml were used, and 19 TFs were identified from the library with reductions in 
fluconazole MIC in RPMI medium.  These hits were then rescreened for those that also 
displayed a reduction in fluconazole MFC in both RPMI and YPD media (Table B-1).  
We identified four TF mutants that met the criteria: CAS5, RPN4, UPC2 and CZF1 
(Table 3-3).  The observation that disruption of UPC2 increased susceptibility to 
fluconazole was not surprising as this has been reported previously (199, 200), validating 
the results of our screen.  The remaining three TF deletion mutants which exhibited a 
reduction in MFC in both RPMI and YPD were prioritized as being of greatest interest 
and independent mutants were generated in the SC5314 background (Table 3-4).  In 
order to determine the extent to which disruption of these TF genes impacts fluconazole 
susceptibility, the deletion mutants were subjected to various susceptibility tests using the 
nutrient rich YPD media in order to detect strong phenotypes despite existing in an 
environment that promotes growth.   
 
 CAS5 and RPN4 disruption had a moderate impact on fluconazole MIC, and a 
marked impact on MFC by broth microdilution (Table 3-4) and Etest (Figure 3-1A), 
while CZF1 had no impact by all methods.  The fluconazole MFC at 24 hours in YPD for 
SC5314 was >64 μg/ml whereas the cas5Δ/Δ, rpn4Δ/Δ, and czf1Δ/Δ mutants were 1, 16, 
and >64 μg/ml respectively (Table 3-4), indicating that CZF1 could not be independently 
confirmed as influencing susceptibility to fluconazole and therefore did not proceed 
through any further examination.  For SC5314, the 48 hour MIC by Etest was 1.0 μg/ml 
and a halo of reduced growth was observed up to the Etest strip consistent with the 
fungistatic nature of fluconazole.  At 48 hours, the MICs by Etest for the cas5Δ/Δ and 
rpn4Δ/Δ mutant were 0.25 μg/ml and 1.5 μg/ml respectively.  A large clear zone of 
inhibition was observed for cas5Δ/Δ but was smaller for rpn4Δ/Δ (Figure 3-1A).  Using 
a 72 hour endpoint for a broth microdilution assay in YPD as a way to assess the ability 
of the organism to resume growth in the presence of fluconazole we found that SC5314 
and rpn4Δ/Δ were able to resume growth in all concentrations of fluconazole tested 
whereas the cas5Δ/Δ mutant only grew at the lowest concentrations (Figure 3-1B).  
When plated on YPD agar plates containing 10 μg/ml of fluconazole, growth was 
reduced for the cas5Δ/Δ mutant, but only slightly for rpn4Δ/Δ, as compared to SC5314 
(Figure 3-1C).  Time-kill analysis showed increased fungistatic activity for 10 μg/ml 
fluconazole against the cas5Δ/Δ mutant, but not rpn4Δ/Δ, as compared to their parent 
strain (Figure 3-1D).  RPN4 was not pursued in further analysis due to its minimal 
impact at the therapeutically relevant concentration of fluconazole, 10 μg/ml.  All 
phenotypes were reverted by reintegration of one allele of the disrupted gene.  
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Table 3-3. Library hits with reduced MICs and MFCs in both RPMI and YPD 
 
  
orf19 Designation 
MIC (µg/ml)  MFC (µg/ml) 
Clone ID CGD RPMI YPD  RPMI YPD 
WT -- -- 0.25 0.5  >4 >64 
TF3 RPN4 orf19.1069 0.0625 0.25  0.125 32 
TF33 CAS5 orf19.4670 0.125 0.25  4 2 
TF77 UPC2 orf19.391 0.03125 0.125  1 1 
TF104 CZF1 orf19.3127 0.0625 0.5  0.25 8 
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Table 3-4. MICs and MFCs in YPD in SC5314 background 
 
 Relevant Characteristics 
or Genotype 
MIC (µg/ml)  MFC (µg/ml) 
Strain 24 hr 48 hr 72 hr  24 hr 48 hr 72 hr 
SC5314 CAS5/CAS5 CZF1/CZF1 
MKC1/MKC1 RPN4/RPN4 
0.5 0.5 >64  >64 >64 >64 
cas5Δ/Δ 
 
cas5Δ::FRT/cas5Δ::FRT 0.5 1 1  1 1 1 
cas5Δ/Δ+CAS5 
 
cas5Δ::FRT/CAS5-caSAT1 0.5 0.5 >64  >64 >64 >64 
rpn4Δ/Δ 
 
rpn4Δ::FRT/rpn4Δ::FRT 0.5 1 >64  8 8 8 
rpn4Δ/Δ+RPN4 
 
rpn4Δ::FRT/RPN4-caSAT1 0.5 0.5 >64  >64 >64 >64 
czf1Δ/Δ 
 
czf1Δ::FRT/czf1Δ::FRT 0.5 0.5 >64  >64 >64 >64 
mkc1Δ/Δ 
 
mkc1Δ::FRT/mkc1Δ::FRT 0.5 0.5 1  1 1 1 
mkc1Δ/Δ+MKC1 
 
mkc1Δ::FRT/MKC1-caSAT1 0.5 0.5 >64  >64 >64 >64 
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Figure 3-1. Effects of CAS5 and RPN4 on fluconazole susceptibility in SC5314 
background 
(A)  Effect on MIC and growth on YPD agar as determined by Etest.  A confluent lawn 
of C. albicans was streaked prior to the addition of Etest strips and then incubated for 48 
hours.  (B)  MIC heat map of SC5314, mutants, and complimented derivative.  
Susceptibility was determined by broth microdilution in YPD at 72 hours.  Growth was 
quantified spectrophotometrically and assigned to a colorimetric scale.  (C)  Effect on the 
ability to grow on solid media containing fluconazole.  From 4-fold serial dilutions of C. 
albicans strains, 2 µl aliquots were spotted onto YPD agar +/- 10 µg/mL FLC and 
incubated for 48 hours.  (D)  Effect of fluconazole by time-kill assay.  SC5314, cas5Δ/Δ, 
or rpn4Δ/Δ cells were diluted in YPD medium containing FLC (10 µg/mL) or the 
solvent, DMSO.  After 0, 6, 12, and 24 hours, samples from each were diluted and plated 
for colony forming units.  
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MKC1 Disruption Does Not Fully Phenocopy CAS5 
 
 The cell wall integrity (CWI) pathway has been previously shown to be critical 
for the activity of sterol biosynthesis inhibitors and is specific to fungal cells (103-105).  
This pathway is conserved in C. albicans from Saccharomyces cerevisiae and in C. 
albicans the transcription factor Cas5p is postulated to be the functional equivalent of the 
S. cerevisiae CWI transcriptional regulator Rlm1 (134, 239).  Looking upstream of Rlm1 
in the CWI pathway is Slt2, a stress-activated kinase phosphorylated by Pkc1p.  The 
functional equivalent of this protein in C. albicans is Mkc1 and is required for the 
maintenance of cell wall integrity as well as the azole stress response in C. albicans (103, 
240, 241).  In order to determine if deletion of MKC1 in SC5314 phenocopies deletion of 
CAS5, we similarly tested an mkc1Δ/Δ mutant for susceptibility to fluconazole.   
 
 Disruption of MKC1 had no change in fluconazole MIC at 24 or 48 hours, but a 
marked impact on MFC by broth microdilution (Table 3-4), and MIC by Etest  
(Figure 3-2A).  The fluconazole MFC at 24 hours in YPD for SC5314 was >64 μg/ml 
whereas the mkc1Δ/Δ mutant was 1 μg/ml (Table 3-4).  At 48 hours, the MIC by Etest 
for SC5314 was 0.5 μg/ml and a halo of reduced growth was observed up to the Etest 
strip consistent with the fungistatic nature of fluconazole.  Meanwhile, the mkc1Δ/Δ 
mutant had an MIC by Etest of 0.25 μg/ml and a large clear zone of inhibition was 
observed (Figure 3-2A).  We also used a 72 hour endpoint for a broth microdilution 
assay as a way to assess the ability of the organism to regrow in the presence of 
fluconazole.  SC5314 and mkc1Δ/Δ+MKC1 were able to resume growth in all 
concentrations of fluconazole tested whereas the mkc1Δ/Δ mutant only grew at the lowest 
concentrations (Figure 3-2B).  When plated on YPD agar plates containing 10 μg/ml 
fluconazole, growth was reduced in the presence of fluconazole for the mkc1Δ/Δ mutant 
as compared to SC5314 (Figure 3-2C).  Time-kill analysis showed slightly increased 
activity of 10 μg/ml fluconazole against the mkc1Δ/Δ mutant as compared to the parent 
strain, but some regrowth was observed after 24 hours (Figure 3-2D).  All phenotypes 
were reverted by reintegration of one allele of the disrupted gene. 
 
 
Disruption of Cas5 Does Not Override Combinations of Clinical Drug Resistance 
Mechanisms 
 
 In order to examine the extent at which Cas5p is involved, we constructed 
cas5Δ/Δ mutant strains in the background of an azole-resistant clinical isolate (12-99) 
known to carry four of the most common mechanisms of azole resistance: overexpression 
of CDR1 and CDR2, overexpression of MDR1, overexpression of ERG11, and a mutation 
in ERG11 (242).  The disruption of CAS5 in isolate 12-99 did not result in a reduction in 
MIC or MFC, and therefore was not able to overcome the combined mechanisms of 
resistance operative in this isolate (Table 3-5).  At 48 hours, the MIC by Etest for 12-99 
was >256 μg/ml and confluent growth was observed up to the Etest strip consistent with 
the resistance of 12-99 to fluconazole, and the same was observed for 12-99cas5Δ/Δ, 
although this strain exhibited slower growth (data not shown).  Time-kill analysis  
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Figure 3-2. MKC1 effects fluconazole susceptibility in SC5314 background 
(A)  Effect of MKC1 on MIC and growth on YPD agar as determined by Etest.  A 
confluent lawn of C. albicans was streaked prior to the addition of Etest strips and then 
incubated for 48 hours.  (B)  MIC heat map of SC5314, mutant, and complimented 
derivative.  Susceptibility was determined by broth microdilution in YPD at 72 hours.  
Growth was quantified spectrophotometrically and assigned to a colorimetric scale.  (C)  
Effect of MKC1 on the ability to grow on solid media containing fluconazole.  From 4-
fold serial dilutions of C. albicans strains, 2 µl aliquots were spotted onto YPD agar +/- 
10 µg/mL FLC and incubated for 48 hours.  (D)  Effect of fluconazole on MKC1 in time-
kill assay.  SC5314 or mkc1Δ/Δ cells were diluted in YPD medium containing FLC (10 
µg/mL) or the solvent, DMSO.  After 0, 6, 12, and 24 hours, samples from each were 
diluted and plated for colony forming units.  
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Table 3-5. MICs and MFCs in YPD in background of clinical resistant strains 
 
  MIC (µg/ml)  MFC (µg/ml) 
Strain 
Relevant Characteristics 
or Genotype 24 hr 48 hr 72 hr 
 
24 hr 48 hr 72 hr 
SC5314 CAS5/CAS5 0.5 0.5 >64  >64 >64 >64 
2-79 Susceptible isolate 1 1 >64  >64 >64 >64 
12-99 Resistant isolate >64 >64 >64  >64 >64 >64 
12-99cas5Δ/Δ cas5Δ::FRT/cas5Δ::FRT >64 >64 >64  >64 >64 >64 
G2 Susceptible isolate 1 >64 >64  >64 >64 >64 
G5 Resistant isolate >64 >64 >64  >64 >64 >64 
G5cas5Δ/Δ cas5Δ::FRT/cas5Δ::FRT 32 32 32  >64 >64 >64 
Gu2 Susceptible isolate 0.5 1 >64  >64 >64 >64 
Gu5 Resistant isolate >64 >64 >64  >64 >64 >64 
Gu5cas5Δ/Δ cas5Δ::FRT/cas5Δ::FRT >64 >64 >64  >64 >64 >64 
S1 Susceptible isolate 2 >64 >64  >64 >64 >64 
S2 Resistant isolate >64 >64 >64  >64 >64 >64 
S2cas5Δ/Δ cas5Δ::FRT/cas5Δ::FRT 64 >64 >64  >64 >64 >64 
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revealed an overall growth defect but this did not alter the effect of fluconazole against 
12-99cas5Δ/Δ at 10 μg/ml (Figure 3-3). 
 
 Isolate 12-99 simultaneously overexpresses CDR1 and CDR2 as well as MDR1 
(156).  Since previous studies have shown that azole resistant isolates usually do not 
simultaneously overexpress these transporter genes (154, 167, 243), CAS5 was also 
disrupted in the clinical isolates S2, G5, and Gu5.  Isolate S2 has been previously shown 
to have a G464S amino acid substitution in Upc2p which renders it constitutively active, 
resulting in upregulation of ERG11 and increased fluconazole resistance (195, 202).  
Isolate G5 has a G997V amino acid substitution in Mrr1p, resulting in increased MDR1 
expression and is also homozygous for an ERG11 mutation (152, 195).  Isolate Gu5 
displays increased expression of CDR1 and CDR2 (153).  As with isolate 12-99, the 
disruption of CAS5 in these three clinical isolates did not markedly alter the MIC or MFC 
in these resistant backgrounds when examined by broth microdilution (Table 3-5).  The 
only change observed was a 24 hour MIC of 32 μg/ml for G5cas5Δ/Δ reduced from >64 
μg/ml by broth microdilution, and a 48 hour Etest MIC of 24 μg/ml reduced from >256 
μg/ml (data not shown). 
 
 
Disruption of CAS5 in Strains Containing Resistance Mutations in MRR1, TAC1, 
and ERG11 Impacts Fluconazole Susceptibility 
 
 Since the deletion of CAS5 was unable to override the common resistance 
mechanisms acting together we sought to investigate the requirement for CAS5 for 
specific mechanisms of resistance.  Independent mutants were constructed in background 
strains containing two copies of a gene conferring reduced susceptibility to fluconazole: 
MRR1P683S, TAC1G980E, UPC2G648D or ERG11K143R.  The MRR1P683S, TAC1G980E and 
UPC2G648D alleles contain gain-of-function mutations which render the transcription 
factors they encode constitutively active, resulting in upregulation of MDR1, CDR1 and 
CDR2, and ERG11 respectively, and decreased fluconazole susceptibility (195, 196, 202, 
220, 221).  The ERG11K143R allele contains a point mutation postulated to be located near 
the azole access channel, interfering with entry of fluconazole, resulting in decreased 
fluconazole susceptibility (222).  Interestingly, we observed the UPC2cas5Δ/Δ mutant 
cells to be larger than those of the parent strain and also to be elongated and clumped 
together.  As a result, susceptibility testing for this strain was inconsistent due to the 
extreme variability in optical density versus cell density, and therefore could not be 
reported.  The disruption of CAS5 in each remaining background did not markedly impact 
the MICs at 24 hours, but did result in a reduction in MIC at later time points by all 
methods.  The MFCs at 48 hours in YPD for ERG11cas52Δ/Δ, MRR1cas5Δ/Δ and 
TAC1cas5Δ/Δ were all reduced from 8 μg/ml, >64 μg/ml, and >64 μg/ml in their 
background strains to 4 μg/ml, 8 μg/ml, and 16 μg/ml respectively (Table 3-6).  At 48 
hours the MICs by Etest for ERG11cas5Δ/Δ, MRR1cas5Δ/Δ and TAC1cas5Δ/Δ were all 
reduced from 1.5 μg/ml, 6 μg/ml, and 8 μg/ml in their background strains to 0.5 μg/ml, 
1.5 μg/ml, and 6 μg/ml respectively (Figure 3-4A).  When plated on YPD agar plates 
containing 10 μg/ml fluconazole, growth was slightly reduced in the presence of  
  
 64 
 
0 6 12 18 24
101
102
103
104
105
106
107
108
109
12-99+DMSO
12-99+FLC
12-99cas5∆/∆+DMSO
12-99cas5∆/∆+FLC
Limit of Quantification
Time (hrs)
CF
U
/m
L
 
 
 
Figure 3-3. Effect of fluconazole on CAS5 in 12-99 by time-kill assay 
12-99 or 12-99cas5Δ/Δ cells were diluted in YPD medium containing FLC (10 µg/mL) 
or the solvent, DMSO.  After 0, 6, 12, and 24 hours, samples from each were diluted and 
plated for colony forming units. 
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Table 3-6. MICs and MFCs in YPD in background of strains expressing resistance mechanisms 
 
  MIC (µg/ml)  MFC (µg/ml) 
Strain 
Relevant Characteristics or 
Genotype 24 hr 48 hr 72 hr 
 
24 hr 48 hr 72 hr 
SC5314 
 
CAS5/CAS5 0.5 0.5 >64  >64 >64 >64 
ERG11K143R ERG11K143R::FRT/ERG11K143R::FRT 
CAS5/CAS5 
4 8 8  4 8 8 
ERG11cas5Δ/
Δ 
ERG11K143R::FRT/ERG11K143R::FRT 
cas5Δ::FRT/cas5Δ::FRT 
4 4 4  4 4 4 
MRR1P683S MRR1P683S::FRT/MRR1P683S::FRT 
CAS5/CAS5 
8 16 >64  >64 >64 >64 
MRR1cas5Δ/Δ MRR1P683S::FRT/MRR1P683S::FRT 
cas5Δ::FRT/cas5Δ::FRT 
8 8 8  8 8 8 
TAC1G980E TAC1G980E::FRT/TAC1G980E::FRT 
CAS5/CAS5 
8 16 >64  >64 >64 >64 
TAC1cas5Δ/Δ TAC1G980E::FRT/TAC1G980E::FRT 
cas5Δ::FRT/cas5Δ::FRT 
8 16 16  16 16 16 
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Figure 3-4. CAS5 slightly impacts fluconazole susceptibility in background of 
strains expressing resistance mechanisms 
(A)  Effect of CAS5 in isogenic resistant backgrounds on MIC and growth on YPD agar 
as determined by Etest.  A confluent lawn of C. albicans was streaked prior to the 
addition of Etest strips and then incubated for 48 hours.  (B)  Effect of CAS5 on the 
ability of isogenic strains to grow on solid media containing fluconazole.  From 4-fold 
serial dilutions of C. albicans strains, 2 µl aliquots were spotted onto YPD agar +/- 10 
µg/mL FLC and incubated for 48 hours. 
  
 67 
fluconazole for the cas5Δ/Δ mutants compared to their respective backgrounds  
(Figure 3-4B).    
 
 
Expression of ERG11, CDR1, CDR2, and MDR1 When CAS5 Is Disrupted in 
Resistant Backgrounds 
 
 One possible explanation for the enhanced fluconazole activity could be 
decreased expression of ERG11 or genes encoding the Cdr1 and Cdr2 or Mdr1 efflux 
pumps. In order to determine if this was the case, we measured ERG11, CDR1, CDR2, 
and MDR1 mRNA abundance by qRT-PCR in the strains containing a single resistance 
mechanism and their respective cas5Δ/Δ mutants (Figure 3-5).  Interestingly, the 
cas5Δ/Δ mutant constructed in the SC5314 background showed a slight reduction in 
baseline ERG11 expression.  This was also the case for the cas5Δ/Δ mutants constructed 
in the ERG11K143R, MRR1P683S, TAC1G980E and UPC2G648D backgrounds.  Disruption of 
CAS5 did not result in decreased CDR1 expression, except slightly in the TAC1G980E 
background.  Alternatively, disruption of CAS5 increased CDR2 expression in all 
backgrounds.  Meanwhile MDR1 expression also increased in the SC5314, ERG11K143R, 
and TAC1G980E backgrounds but decreased in the MRR1P683S background.  The 
significance of the increased expression of these transporter genes is unclear.  These data 
suggest that the enhanced activity of fluconazole observed in resistant strains lacking 
CAS5 is not due to decreased expression of transporters gene expression levels.  Instead, 
the observed phenotypes may be associated with a reduction in ERG gene expression, 
particularly ERG11. 
 
 
Comparison of the Gene Expression Profiles of Wild-Type Strain SC5314 and 
cas5Δ/Δ Exposed to Fluconazole 
 
 In order to identify genes whose expression in response to fluconazole is 
influenced by Cas5, we compared the transcriptional profiles of SC5314 and its cas5Δ/Δ 
derivative after treatment with or without 10 μg/ml fluconazole for 6 hours.  Genes were 
considered to be differentially expressed in response to fluconazole if their expression 
changed by ≥1.5-fold in two independent experiments (Table A-1 and Table A-2).  
Fluconazole inducible genes were also considered to be CAS5-dependent if their 
induction was abrogated in the deletion mutant and was ≥2.0-fold (50%) less than 
compared to SC5314.  Using these criteria, there were 209 genes upregulated by 
fluconazole whose induction was abrogated in the absence of CAS5 (Table 3-7).  The 
most common biological processes represented by these genes include transport, response 
to chemical stimulus, oxidation-reduction process, filamentous growth, lipid metabolic 
process and cell wall organization.  Interestingly, there were also 6 genes involved in iron 
ion transport, binding, and homeostasis. 
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Figure 3-5. Expression of CDR1, CDR2, ERG11, and MDR1 by qRT-PCR 
Expression levels for ERG11, CDR1, CDR2, and MDR1 were measured in triplicate by 
qRT-PCR and compared to the expression levels in SC5314 in YPD.  Error bars represent 
the standard error of the mean. 
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Table 3-7. Genes upregulated by at least 1.5-fold by fluconazole which are dependent upon Cas5 
 
      Change in Fold Expression      
   
SC5314+FLC/  cas5Δ/Δ+FLC/  
Ratio (B/A) SC5314 (A)  cas5Δ/Δ (B)  
Processa orf19 Designation CGD Name Exp1 Exp2  Exp1 Exp2  Exp1 Exp2 
Lipid metabolic 
process 
orf19.10 ALK8 9.0 8.1  3.0 3.5  0.3 0.4 
orf19.2248 ARE2 1.7 1.6  0.7 0.7  0.4 0.4 
 
orf19.2670 
 
1.6 1.8  0.4 0.4  0.3 0.2 
 
orf19.2909 ERG26 2.4 1.7  0.9 0.9  0.4 0.5 
 
orf19.4897 SFH5 2.4 2.4  1.3 1.2  0.5 0.5 
 
orf19.4982 
 
2.1 2.3  0.9 0.6  0.4 0.3 
 
orf19.5640 PEX5 2.2 2.6  0.9 0.9  0.4 0.3 
 
orf19.5751 ORM1 3.3 3.6  1.6 1.7  0.5 0.5 
 
orf19.6594 PLB3 2.1 3.4  1.1 0.9  0.5 0.3 
     
 
  
 
  Cell wall 
organization 
orf19.212 VPS28 1.7 2.1  0.5 0.5  0.3 0.3 
orf19.5302 PGA31 17.6 4.1  2.1 1.5  0.1 0.4 
 
orf19.5644 
 
2.3 3.5  1.1 1.0  0.5 0.3 
 
orf19.6102 RCA1 2.5 3.4  1.2 1.2  0.5 0.4 
 
orf19.6420 PGA13 15.6 30.6  2.4 2.3  0.2 0.1 
 
orf19.6481 YPS7 1.6 2.3  0.4 0.4  0.3 0.2 
 
orf19.719 
 
1.8 3.3  1.0 1.0  0.5 0.3 
     
 
  
 
  Cellular membrane 
organization 
orf19.3412 ATG15 2.0 2.6  0.7 1.0  0.4 0.4 
orf19.5644 
 
2.3 3.5  1.1 1.0  0.5 0.3 
 
orf19.669 PRM1 2.2 2.8  0.6 0.4  0.3 0.1 
     
 
  
 
  Iron ion transport orf19.1415 FRE10 2.0 4.2  0.9 2.3  0.5 0.5 
 
orf19.1932 CFL4 35.6 359  2.4 6.6  0.1 0.0 
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Table 3-7. (Continued) 
 
   
Change in Fold Expression  
  
   
SC5314+FLC/  cas5Δ/Δ+FLC/  
  
   
SC5314 (A)  cas5Δ/Δ (B)  Ratio (B/A) 
Processa orf19 Designation CGD Name Exp1 Exp2  Exp1 Exp2  Exp1 Exp2 
 
orf19.4215 FET34 2.1 5.2  0.2 0.5  0.1 0.1 
 
orf19.7219 FTR1 3.2 7.8  0.5 1.1  0.1 0.1 
     
 
  
 
  Iron ion binding orf19.1411 
 
2.7 4.8  1.1 0.9  0.4 0.2 
     
 
  
 
  Iron ion homeostasis orf19.1264 CFL2 2.0 6.0  0.6 0.5  0.3 0.1 
    
 
  
 
  Transport orf19.111 CAN2 1.7 13.0  0.7 1.5  0.4 0.1 
 
orf19.1252 YME1 1.9 3.0  1.0 0.7  0.5 0.2 
 
orf19.1313 CDR3 1.9 2.1  0.9 1.0  0.5 0.5 
 
orf19.1352 TIM22 3.6 4.4  0.9 1.1  0.2 0.3 
 
orf19.1563 ECM3 1.5 1.5  0.4 0.6  0.3 0.4 
 
orf19.1867 
 
2.6 4.2  0.7 0.6  0.3 0.2 
 
orf19.2073 
 
1.5 1.6  0.6 0.5  0.4 0.3 
 
orf19.2292 OPT4 5.2 3.7  1.2 1.0  0.2 0.3 
 
orf19.2350 
 
2.5 4.1  0.6 1.0  0.3 0.3 
 
orf19.2810 AAP1 18.9 19.6  7.5 8.8  0.4 0.4 
 
orf19.2946 HNM4 8.4 4.9  2.9 2.5  0.3 0.5 
 
orf19.3015 ARX1 2.7 3.9  1.3 1.7  0.5 0.4 
 
orf19.3195 HIP1 1.5 2.6  0.6 0.7  0.4 0.3 
 
orf19.3232 
 
24.6 5.3  2.6 1.0  0.1 0.2 
 
orf19.3574 MDJ2 5.6 3.1  2.0 1.2  0.4 0.4 
 
orf19.4041 PEX4 4.9 4.3  1.3 1.5  0.3 0.4 
 
orf19.4090 
 
2.1 1.7  1.1 0.8  0.5 0.5 
 
orf19.4372 
 
1.8 3.0  0.6 0.6  0.3 0.2 
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Table 3-7. (Continued) 
 
   
Change in Fold Expression  
  
   
SC5314+FLC/  cas5Δ/Δ+FLC/  
  
   
SC5314 (A)  cas5Δ/Δ (B)  Ratio (B/A) 
Processa orf19 Designation CGD Name Exp1 Exp2  Exp1 Exp2  Exp1 Exp2 
 
orf19.4384 HXT5 70.6 75.5  11.1 23.4  0.2 0.3 
 
orf19.4546 HOL4 4.3 5.1  1.7 2.3  0.4 0.4 
 
orf19.4682 HGT17 45 24.7  7.0 7.3  0.2 0.3 
 
orf19.4887 ECM21 2.7 3.1  0.8 1.0  0.3 0.3 
 
orf19.5539 
 
1.6 1.6  0.7 0.8  0.5 0.5 
 
orf19.5902 RAS2 7.6 6.2  0.8 1.1  0.1 0.2 
 
orf19.5958 CDR2 2.1 2.5  0.9 1.0  0.4 0.4 
 
orf19.6117 
 
1.5 2.3  0.6 0.4  0.4 0.2 
 
orf19.6249 HAK1 4.4 10.7  2.1 3.2  0.5 0.3 
 
orf19.6648 SDA1 3.2 6.8  1.6 3.2  0.5 0.4 
 
orf19.6993 GAP2 21.7 8.6  3.0 4.5  0.1 0.5 
 
orf19.7056 
 
6.2 120.3  2.5 2.7  0.4 0.0 
 
orf19.7093 HGT13 30.7 13.2  2.0 1.5  0.1 0.1 
 
orf19.7094 HGT12 423.2 19.8  8.0 1.9  0.0 0.1 
     
 
  
 
  Response to stress orf19.1434 
 
1.7 2.7  0.8 1.0  0.5 0.4 
 
orf19.211 
 
1.7 2.4  0.7 0.7  0.4 0.3 
 
orf19.3239 CTF18 2.7 2.4  1.0 1.1  0.4 0.5 
 
orf19.4383 
 
2.8 2.6  0.9 0.8  0.3 0.3 
 
orf19.5069 
 
14.9 15.5  5.9 7.1  0.4 0.5 
     
 
  
 
  Response to 
chemical stimulus 
orf19.2060 SOD5 33.2 14.2  5.4 6.1  0.2 0.4 
orf19.2838 
 
2.5 2.9  0.8 0.7  0.3 0.3 
 
orf19.2876 CBF1 2.3 3.2  0.5 0.5  0.2 0.2 
 
orf19.3159 UTP20 3.8 8.9  1.9 3.5  0.5 0.4 
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Table 3-7. (Continued) 
 
   
Change in Fold Expression  
  
   
SC5314+FLC/  cas5Δ/Δ+FLC/  
  
   
SC5314 (A)  cas5Δ/Δ (B)  Ratio (B/A) 
Processa orf19 Designation CGD Name Exp1 Exp2  Exp1 Exp2  Exp1 Exp2 
 
orf19.3736 KAR4 2.8 2.6  1.2 1.0  0.4 0.4 
 
orf19.4015 CAG1 3.1 3.6  0.8 0.7  0.3 0.2 
 
orf19.4317 GRE3 1.5 1.5  0.8 0.6  0.5 0.4 
 
orf19.4318 MIG1 1.7 2.1  0.7 1.0  0.4 0.5 
 
orf19.5326 
 
1.5 1.9  0.6 0.7  0.4 0.4 
 
orf19.5591 ADO1 2.4 2.9  1.1 1.5  0.4 0.5 
 
orf19.6202 RBT4 3.3 6.2  1.6 2.2  0.5 0.3 
 
orf19.6881 YTH1 1.9 2.0  0.9 0.9  0.4 0.4 
 
orf19.7316 
 
2.0 2.3  0.7 0.8  0.3 0.3 
 
orf19.7384 NOG1 3.7 7.2  1.2 2.1  0.3 0.3 
     
 
  
 
  Oxidation-reduction 
process 
orf19.1117 
 
5.7 2.3  0.7 1.1  0.1 0.5 
orf19.1473 
 
35.0 15.0  3.8 4.8  0.1 0.3 
 
orf19.2108 SOD6 7.9 10.6  1.6 1.1  0.2 0.1 
 
orf19.3538 FRE9 4.7 14.9  2.5 3.6  0.5 0.2 
 
orf19.3707 YHB1 3.0 2.8  0.9 0.6  0.3 0.2 
 
orf19.4747 HEM14 1.7 2.0  0.6 0.4  0.3 0.2 
 
orf19.4871 ERO1 1.9 1.9  0.9 0.6  0.5 0.3 
 
orf19.5879 
 
3.3 2.9  1.5 1.2  0.5 0.4 
 
orf19.638 FDH1 11.7 19.5  4.4 3.9  0.4 0.2 
 
orf19.6837 FMA1 1.5 1.5  0.7 0.7  0.5 0.4 
 
orf19.7111.1 SOD3 40.5 69.2  9.4 15  0.2 0.2 
 
orf19.7314 CDG1 7.5 6.0  1.0 0.6  0.1 0.1 
 
orf19.742 ALD6 11.5 10.4  4.1 1.7  0.4 0.2 
 
orf19.7551 ALO1 1.5 2.8  0.7 0.6  0.5 0.2 
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Table 3-7. (Continued) 
 
   
Change in Fold Expression  
  
   
SC5314+FLC/  cas5Δ/Δ+FLC/  
  
   
SC5314 (A)  cas5Δ/Δ (B)  Ratio (B/A) 
Processa orf19 Designation CGD Name Exp1 Exp2  Exp1 Exp2  Exp1 Exp2 
Filamentous growth orf19.2397.3 
 
2.0 4.3  0.9 1.2  0.5 0.3 
 orf19.4055  
1.9 2.5  0.9 0.7  0.5 0.3 
 
orf19.4815 YTM1 2.3 3.2  0.6 1.4  0.3 0.4 
 
orf19.4928 SEC2 2.0 2.1  0.4 0.4  0.2 0.2 
 
orf19.5741 ALS1 66.8 79.0  22.6 21  0.3 0.3 
 
orf19.5798 LIG4 1.8 2.6  0.9 0.8  0.5 0.3 
 
orf19.6595 RTA4 10.4 15..0  3.0 2.9  0.3 0.2 
 
orf19.6888 
 
4.3 5.7  1.4 1.1  0.3 0.2 
 
orf19.7313 SSU1 4.5 4.8  1.3 1.1  0.3 0.2 
 
orf19.7374 CTA4 1.7 2.2  0.8 1.1  0.5 0.5 
 
orf19.7436 AAF1 2.0 4.4  1.0 1.2  0.5 0.3 
 
orf19.795 VPS36 2.0 2.5  0.6 0.6  0.3 0.3 
     
 
  
 
  Biofilm formation orf19.6090 
 
1.9 2.4  0.6 0.6  0.3 0.2 
     
 
  
 
  Pathogenesis orf19.5542 SAP6 5.9 4.3  2.1 1.4  0.4 0.3 
 
orf19.5585 SAP5 3.7 3.0  0.9 1.0  0.2 0.3 
 
orf19.5716 SAP4 4.8 3.2  2.1 1.5  0.4 0.5 
     
 
  
 
  Organelle 
organization 
orf19.3135 
 
2.3 2.6  1.2 1.1  0.5 0.4 
orf19.4862.2 PET100 1.7 1.8  0.8 0.9  0.5 0.5 
 
orf19.6225.1 
 
1.9 1.9  0.9 0.7  0.5 0.4 
     
 
  
 
  RNA metabolic 
process 
orf19.1915 MPP10 3.8 4.5  2.1 2.5  0.5 0.5 
orf19.1923 RRN3 5.7 23.0  2.9 3.8  0.5 0.2 
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Table 3-7. (Continued) 
 
   
Change in Fold Expression  
  
   
SC5314+FLC/  cas5Δ/Δ+FLC/  
  
   
SC5314 (A)  cas5Δ/Δ (B)  Ratio (B/A) 
Processa orf19 Designation CGD Name Exp1 Exp2  Exp1 Exp2  Exp1 Exp2 
 
orf19.2115 
 
1.9 2.8  0.9 1.5  0.5 0.5 
 
orf19.2137 
 
1.9 2.3  0.6 0.8  0.3 0.4 
 
orf19.3962 HAS1 1.7 2.3  0.7 0.8  0.4 0.4 
 
orf19.501 
 
2.4 3.3  1.0 1.4  0.4 0.4 
 
orf19.5614 
 
7.9 7.7  3.9 4.1  0.5 0.5 
 
orf19.7062 RPA135 2.0 5.6  0.9 1.6  0.5 0.3 
     
 
  
 
  Biological process orf19.2064 
 
1.9 3.0  0.9 0.8  0.5 0.3 
 
orf19.2242 PRB1 1.7 1.5  0.7 0.6  0.4 0.4 
 
orf19.2710 
 
2.6 1.8  1.0 0.9  0.4 0.5 
 
orf19.3547 
 
5.3 5.9  1.1 1.7  0.2 0.3 
 
orf19.467 WOR3 32.3 7.1  3.0 2.9  0.1 0.4 
 
orf19.5045 PTP2 6.0 10.4  2.5 2.0  0.4 0.2 
 
orf19.6225 PCL7 1.5 2.0  0.8 0.8  0.5 0.4 
     
 
  
 
  Cellular protein 
modification 
orf19.5236 
 
1.7 2.2  0.5 0.4  0.3 0.2 
orf19.540 
 
1.7 1.7  0.9 0.6  0.5 0.4 
 
orf19.7547 
 
2.9 3.0  1.1 1.4  0.4 0.5 
     
 
  
 
  Carbohydrate 
metabolic process 
orf19.4899 GCA1 4.8 4.4  0.9 1.2  0.2 0.3 
orf19.7434 GLG2 37.5 16.1  7.5 8.7  0.2 0.5 
 
orf19.7514 PCK1 6.0 8.6  1.9 1.4  0.3 0.2 
     
 
  
 
  Other orf19.1369 
 
2.9 2.3  1.2 1.0  0.4 0.4 
 
orf19.2046 POT1-2 1.5 2.2  0.5 0.4  0.3 0.2 
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Table 3-7. (Continued) 
 
   
Change in Fold Expression  
  
   
SC5314+FLC/  cas5Δ/Δ+FLC/  
  
   
SC5314 (A)  cas5Δ/Δ (B)  Ratio (B/A) 
Processa orf19 Designation CGD Name Exp1 Exp2  Exp1 Exp2  Exp1 Exp2 
 
orf19.278 
 
2.5 2.7  1.4 1.5  0.5 0.5 
 
orf19.410.3 RIB4 5.6 5.7  0.6 0.5  0.1 0.1 
 
orf19.4551 CTN1 22.4 26.6  11.3 14.3  0.5 0.5 
 
orf19.5159 DUG3 1.8 3.6  0.9 0.7  0.5 0.2 
 
orf19.5206 
 
5.2 4.0  1.4 1.7  0.3 0.4 
 
orf19.5454 DAL1 3.7 6.6  1.7 1.9  0.5 0.3 
 
orf19.6057 
 
2.5 1.8  0.9 1.0  0.3 0.5 
 
orf19.6997 ATO5 2.5 2.6  0.8 0.7  0.3 0.3 
 
orf19.972 
 
1.9 2.9  0.8 0.6  0.4 0.2 
     
 
  
 
  Unknown orf19.1277 
 
6.6 9.3  1.5 1.5  0.2 0.2 
 
orf19.1766 
 
26.6 340.0  3.3 5.7  0.1 0.0 
 
orf19.1800  
 
4.1 3.8  2.1 1.8  0.5 0.5 
 
orf19.1939  
 
2.3 1.6  0.6 0.8  0.3 0.5 
 
orf19.2059 
 
2.6 2.3  0.2 0.3  0.1 0.1 
 
orf19.2210  
 
2.3 4.3  1.0 1.9  0.4 0.5 
 
orf19.2398  
 
2.5 3.8  1.3 1.7  0.5 0.5 
 
orf19.2414  
 
3.1 3.3  1.1 0.6  0.4 0.2 
 
orf19.2691  
 
1.5 1.5  0.5 0.7  0.3 0.4 
 
orf19.2812 
 
1.8 1.8  0.8 1.0  0.4 0.5 
 
orf19.2836 
 
11.7 21.9  3.1 4.8  0.3 0.2 
 
orf19.2839 CIRT4B 1.6 2.6  0.4 0.3  0.2 0.1 
 
orf19.2878 PGA15 6.0 8.1  3.1 2.4  0.5 0.3 
 
orf19.296 
 
3.1 1.7  1.5 0.9  0.5 0.5 
 
orf19.2962 
 
2.3 2.2  0.7 0.8  0.3 0.4 
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Table 3-7. (Continued) 
 
   
Change in Fold Expression  
  
   
SC5314+FLC/  cas5Δ/Δ+FLC/  
  
   
SC5314 (A)  cas5Δ/Δ (B)  Ratio (B/A) 
Processa orf19 Designation CGD Name Exp1 Exp2  Exp1 Exp2  Exp1 Exp2 
 
orf19.3004  
 
1.5 2.0  0.6 0.6  0.4 0.3 
 
orf19.3021 
 
2.6 2.0  1.2 0.9  0.5 0.5 
 
orf19.3245  
 
2.2 2.3  1.2 1.1  0.5 0.5 
 
orf19.3302  
 
1.5 2.1  0.7 0.8  0.5 0.4 
 
orf19.3309  
 
1.5 1.7  0.8 0.6  0.5 0.3 
 
orf19.3310  
 
1.8 1.9  0.8 0.6  0.4 0.3 
 
orf19.3499  
 
79.5 20.5  5.9 7.6  0.1 0.4 
 
orf19.3512 CSP1 2.6 2.8  0.9 1.2  0.4 0.4 
 
orf19.3621 
 
3.2 5.2  0.7 0.7  0.2 0.1 
 
orf19.376 
 
2.9 3.4  1.1 1.5  0.4 0.4 
 
orf19.3881  
 
1.9 2.0  0.7 0.6  0.4 0.3 
 
orf19.3910  
 
3.1 2.6  1.1 0.9  0.4 0.3 
 
orf19.4013  
 
2.6 2.2  0.6 0.6  0.2 0.3 
 
orf19.4014  
 
1.9 1.6  0.8 0.8  0.4 0.5 
 
orf19.4144  
 
2.4 3.2  1.2 1.6  0.5 0.5 
 
orf19.4214  
 
30.5 19.5  0.5 1.2  0.0 0.1 
 
orf19.4264  
 
2.5 3.2  1.2 1.0  0.5 0.3 
 
orf19.4286 
 
1.9 2.9  0.3 0.4  0.2 0.1 
 
orf19.4404 PGA49 7.3 1.6  1.1 0.8  0.2 0.5 
 
orf19.4450.1 
 
3.6 4.5  1.0 0.7  0.3 0.2 
 
orf19.4539  
 
1.8 1.7  0.9 0.5  0.5 0.3 
 
orf19.4569  
 
1.8 2.0  0.8 0.8  0.4 0.4 
 
orf19.4596  
 
3.5 4.9  1.0 1.1  0.3 0.2 
 
orf19.4607  
 
5.6 7.0  0.5 0.3  0.1 0.0 
 
orf19.4608 PDC12 7.1 16.7  0.5 0.3  0.1 0.0 
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Table 3-7. (Continued) 
 
   
Change in Fold Expression  
  
   
SC5314+FLC/  cas5Δ/Δ+FLC/  
  
   
SC5314 (A)  cas5Δ/Δ (B)  Ratio (B/A) 
Processa orf19 Designation CGD Name Exp1 Exp2  Exp1 Exp2  Exp1 Exp2 
 
orf19.4658  
 
5.0 6.6  2.5 3.1  0.5 0.5 
 
orf19.4691  
 
16.6 24.8  4.2 3.4  0.3 0.1 
 
orf19.4872  
 
8.2 19.2  1.2 1.3  0.1 0.1 
 
orf19.5019  
 
2.8 3.4  1.4 1.8  0.5 0.5 
 
orf19.5282  
 
2.4 2.7  0.5 0.4  0.2 0.2 
 
orf19.5626  
 
3.6 4.0  1.5 1.4  0.4 0.3 
 
orf19.6084 
 
123.7 19.7  11.8 9.8  0.1 0.5 
 
orf19.6186  
 
12.1 13.3  2.4 2.0  0.2 0.1 
 
orf19.6248  
 
3.1 12.1  0.7 1.2  0.2 0.1 
 
orf19.633  
 
1.5 1.6  0.8 0.5  0.5 0.3 
 
orf19.6353 
 
1.8 2.0  0.7 0.6  0.4 0.3 
 
orf19.6484 
 
19.5 30.0  2.2 4.3  0.1 0.1 
 
orf19.6527  
 
1.5 1.8  0.8 0.7  0.5 0.4 
 
orf19.6678  
 
3.1 5.1  1.2 1.4  0.4 0.3 
 
orf19.6690 
 
2.4 2.3  0.7 0.6  0.3 0.3 
 
orf19.670.2  
 
47.4 152.7  10.8 16.1  0.2 0.1 
 
orf19.6766 NOP13 5.1 5.3  1.7 2.6  0.3 0.5 
 
orf19.6905  
 
2.4 3.3  0.5 0.4  0.2 0.1 
 
orf19.6970  
 
4.5 4.4  2.3 2.4  0.5 0.5 
 
orf19.6983  
 
2.1 9.1  1.0 1.3  0.5 0.1 
 
orf19.7011  
 
2.2 4.7  1.1 2.3  0.5 0.5 
 
orf19.7043  
 
3.9 2.8  0.9 1.0  0.2 0.4 
 
orf19.7229 IML2 2.8 3.3  1.4 1.4  0.5 0.4 
 
orf19.7550 IFA14 2.3 1.7  1.0 0.7  0.4 0.4 
 
orf19.7567  
 
2.5 2.4  1.1 0.8  0.4 0.3 
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Table 3-7. (Continued) 
 
   
Change in Fold Expression  
  
   
SC5314+FLC/  cas5Δ/Δ+FLC/  
  
   
SC5314 (A)  cas5Δ/Δ (B)  Ratio (B/A) 
Processa orf19 Designation CGD Name Exp1 Exp2  Exp1 Exp2  Exp1 Exp2 
 
orf19.893 PGA17 12.3 5.5  1.4 1.1  0.1 0.2 
 
orf19.951 
 
2.3 2.4  0.4 0.4  0.2 0.2 
 
orf19.994   
 
2.0 2.7  0.7 1.3  0.4 0.5 
a Descriptions are from the Candida Genome Database (http://www.candidagenome.org). 
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Validation of Microarray Data by Real Time RT-PCR 
 
 In order to validate the differential expression of genes identified by microarray, 
we examined the mRNA abundance for 5 genes of interest using the same RNA isolated 
for the microarray experiments.  PGA13 was chosen because it is involved in cell wall 
organization and was also identified by Bruno et al. to be Cas5-dependent (134).  In 
addition, four others were chosen based on their involvement in cell wall organization 
(PGA31), iron ion transport (CFL4, FTR1) and lipid metabolic process (ERG26).  The 
correlation between the microarray data and the real time RT-PCR was good  
(Figure 3-6).  The expressions of CFL4, ERG26, FTR1, PGA13, and PGA31 were 
upregulated in the wild type SC5314 when treated with fluconazole, but could not 
respond to the same extent when CAS5 was disrupted.   
 
 
DISCUSSION 
 
 Identifying transcriptional networks that are central to azole antifungal 
susceptibility would be instructive for developing co-therapeutic strategies that would 
enhance their activity against C. albicans.  Several signal transduction and transcriptional 
activation programs have been identified to respond to antifungal stress, but the 
transcription factors and their respective target genes have yet to be identified for many 
of these processes (98-102, 105, 236, 237).  In the present study, we screened a library of 
C. albicans mutants disrupted for genes encoding TFs in order to identify those which 
exhibit increased susceptibility to fluconazole.  We observed that disruption of CAS5 
resulted in a slightly enhanced MIC, but also resulted in a substantial reduction in 
fluconazole MFC at 24, 48, and 72 hours.  Indeed disruption of CAS5 in an azole 
susceptible strain prevented its regrowth in YPD medium in the presence of higher 
fluconazole concentrations after 72 hours, resulted in a clear zone of inhibition around a 
fluconazole Etest strip, and prevented growth on solid media containing a therapeutically 
relevant concentration of fluconazole (10 μg/ml).   Time-kill analysis also demonstrated 
an enhanced effect of 10 μg/ml fluconazole against the cas5Δ/Δ mutant as compared to 
its parent strain.  The disruption of RPN4 did not display as strong of an effect, 
suggesting that RPN4 influences fungistatic azole activity to a lesser extent, while CZF1 
disruption had no impact on susceptibility.  As previously observed for disruption of 
UPC2 (Chapter 2), CAS5 disruption strongly impacts fluconazole susceptibility. 
 
 We then sought to determine if disruption of MKC1, involved in the CWI 
pathway, would have the same impact on fluconazole susceptibility as seen upon 
disruption of CAS5, as Cas5 has been postulated to be the transcriptional regulator of the 
CWI pathway (134).  We observed that disruption of MKC1 did have an effect on 
fluconazole susceptibility, but not as pronounced as was observed for disruption CAS5.  
Disruption of MKC1 did result in a clear zone of inhibition around a fluconazole Etest 
strip, prevented its regrowth in YPD medium in the presence of higher fluconazole 
concentrations after 72 hours, and prevented growth on solid media containing a 
therapeutically relevant concentration of fluconazole (10 μg/ml).  Time-kill analysis also 
demonstrated a slightly enhanced effect of 10 μg/ml fluconazole against the mkc1Δ/Δ  
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Figure 3-6. Validation of fluconazole-inducible and Cas5-dependent gene 
expression by qRT-PCR 
Expression levels for CFL4, ERG26, FTR1, PGA13 and PGA31 were measured in 
triplicate by qRT-PCR and compared to the expression levels in SC5314 in YPD.  Shown 
are the relative n-fold changes in gene expression in the in SC5314 and cas5Δ/Δ treated 
with fluconazole (FLC).  Error bars represent the standard error of the mean. 
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mutant compared to its parent strain, but was still able to grow above its starting 
inoculum.  This suggests that MKC1 plays a smaller role in fluconazole susceptibility and 
Cas5p may represent a different or redundant pathway. 
 
 Our observations for MKC1 are similar to those of others.  Epp et al. observed a 
reduction in fluconazole MIC from 2 μg/ml to 1 μg/ml at 24 hours, >128 μg/ml to 2 
μg/ml at 48 hours, but after 72 hours both its parent and the mkc1Δ/Δ mutant had an MIC 
of >128 μg/ml.  This trend of regrowth after extended time periods was also seen when 
plated on YPD plates containing 2 μg/ml fluconazole.  After 2 days (48 hours) the 
mkc1Δ/Δ mutant was unable to grow in the presence of fluconazole compared to the 
parent strain, but after 6 days the mutant showed signs of growth (244).  LaFayette et al. 
also observed a decrease in ergosterol biosynthesis inhibitor MICs for mkc1Δ/Δ but its 48 
hour MFC was comparable to wild type (106).  Taken together, these findings suggest a 
partial role for Mkc1p in the susceptibility of C. albicans to the azoles. 
 
 Upon disruption of CAS5 in fluconazole resistant clinical isolates, 12-99, G5, 
Gu5, and S2, which carry combinations of the four most common mechanisms of 
resistance, there was no marked change in susceptibility, except slightly in the G5 
background.  The disruption of CAS5 in isogenic strains containing specific resistance 
mutations in ERG11, MRR1, or TAC1, resulted in slightly increased susceptibility.  
However, he strain containing the UPC2G648D GOF mutation rendered irregular cell shape 
and size.  This phenotype was also present when CAS5 was disrupted from strains 
constructed to contain UPC2G648S or UPC2A643V alleles.  This may suggest a relationship 
between the two TFs.  When UPC2 is constitutively active, ergosterol biosynthesis genes 
are upregulated and cellular ergosterol content increases (205), consequently impacting 
membrane fluidity which affects cell wall composition (245).  CAS5 is the putative 
transcriptional regulator of the cell wall integrity pathway (134), and upon its disruption 
in the presence of a UPC2 GOF mutation, it is possible the cell cannot effectively 
regulate the morphology of its cell wall and membrane.  Also, the similarity of Cas5p- 
and Upc2p-dependent genes (discussed below) suggests cross talk between the two 
transcription factors.  Studies to examine such a relationship may uncover other currently 
unknown roles for each TF. 
 
 The strain containing the ERG11K143R mutation had an MIC of 4 μg/ml at 24 
hours, and 8 μg/ml at 48 and 72 hours in YPD.  Although this background was not as 
highly resistant as others, its respective CAS5 deletion mutant had a drop in both 
fluconazole MIC and MFC at 48 and 72 hours.  The MRR1P683S and TAC1G980E resistant 
strains both had MICs of 8 μg/ml at 24 hours, 16 μg/ml at 48 hours and >64 μg/ml at 72 
hours, and MFCs of >64 μg/ml at all time points in YPD medium.  These values dropped 
moderately in the respective cas5Δ/Δ mutants.  A halo of reduced confluent growth was 
observed around the Etest strip for the MRR1P683S and TAC1G980E constructed mutants, 
but not the ERG11K143R background.  Fitness defects have been shown to be associated 
with the introduction of resistance mutations and may explain the growth of ERG11K143R 
when examined by Etest (225).  Despite the absence of reduced confluent growth, the 
casΔ/Δ mutants in each background showed increased susceptibility to fluconazole by 
Etest and a decreased ability to grow in the presence of fluconazole at 10 μg/ml.  
 82 
Although the loss of CAS5 in strains containing a single mechanism of resistance resulted 
in slightly enhanced susceptibility to fluconazole, this modest effect is not practical for 
clinical applications in overcoming resistance.  The differences in susceptibility observed 
for the mutants constructed in the azole-resistant clinical isolates versus the isogenic 
strains may be due to the suggestion that clinical isolates have compensatory mutations 
mitigating any decrease in fitness resulting from such resistance mutations (225).   
 
 We then sought to determine if CAS5 might influence fluconazole susceptibility 
through altered expression of the efflux pump genes CDR1, CDR2, and MDR1.  The 
expression of CDR1 was not affected in the absence of CAS5, except for slightly in the 
TAC1G980E background.  However, CDR2 and MDR1 expression was upregulated in most 
backgrounds, except for MRR1P683S where MDR1 expression was downregulated.  The 
change in susceptibility for the MRR1P683S background may be due to decreased MDR1 
expression, but CDR2 expression is upregulated in this background.  Therefore, the 
moderate effect on susceptibility observed upon disruption of CAS5 does not appear to be 
due to altered expression of the efflux pumps. 
 
 Another hypothesis for the increased susceptibility to fluconazole of the cas5Δ/Δ 
mutants is changes in cell wall structure.  Previous reports have shown that when the cell 
wall integrity pathway is disrupted, specifically by disrupting the protein kinase gene 
MKC1, the cell exhibits increased susceptibility to fluconazole (105, 237).  In response to 
fluconazole, the upstream kinase Pkc1p phosphorylates Mkc1p, but is interrupted by its 
absence.  Cas5p has been postulated to be the functional equivalent of the Saccharomyces 
cerevisiae cell wall integrity downstream transcriptional regulator ScRlm1p (134).  As 
previous reports have suggested that cell wall integrity is critical for the fungistatic effect 
of sterol biosynthesis inhibitors (246), this implicates that when CAS5 is disrupted the 
integrity of the cell wall is compromised and results in increased susceptibility.  Indeed, 
expression of cellular cell wall integrity genes measured by microarray analysis was 
reduced in the cas5Δ/Δ mutant as compared to its parent strain SC5314 upon exposure to 
fluconazole.  PGA13, PGA31, RCA1, VPS7, VPS28, orf19.5644, and orf19.719 genes are 
all involved in cell wall integrity.  Interestingly, the gene ontology process categories of 
iron ion transport and iron ion homeostasis were also found to be dependent upon CAS5.  
This is consistent with the involvement of cell wall proteins in iron acquisition (247).   
 
 Previous studies by our group also identified a similar set of iron ion transport and 
iron ion homeostasis genes to be dependent upon UPC2 (Chapter 2) (Table 3-8), 
suggesting crosstalk between the two transcription factors.  Indeed upon disruption of 
CAS5, the baseline expression of ERG11 was reduced in all resistant backgrounds as 
measured by real-time RT-PCR.  Additionally, several genes involved in the lipid 
metabolic process were also identified to be Cas5-dependent, including ERG26 of the 
ergosterol biosynthesis pathway, a process that is regulated by Upc2 (199, 221).  ERG26 
encodes for C-4 sterol decarboxylase and has been found to be an essential gene in C. 
albicans (248).  Therefore, inhibition of this step may represent a potential drug target.   
 
 These data suggest that the enhanced activity of fluconazole observed in both 
susceptible and resistant strains lacking CAS5 may be due to deregulation of iron ion  
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Table 3-8. Genes upregulated by at least 1.5-fold by fluconazole which are dependent upon Cas5 and Upc2 
 
      Change in Fold Expression         
 
   
SC5314+FLC/  cas5Δ/Δ+FLC/  upc2Δ/Δ+FLC/  CAS5 Ratio 
(B/A) 
 UPC2 Ratio 
C/A) 
 orf19 
Designation 
 
SC5314 (A)  cas5Δ/Δ (B)  upc2Δ/Δ (C)   
Processa 
CGD 
Name Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
Lipid metabolic 
process 
orf19.2670 
 
1.6 1.8  0.4 0.4  0.4 0.7  0.3 0.2  0.2 0.4 
orf19.4982 
 
2.1 2.3  0.9 0.6  0.7 0.8  0.4 0.3  0.3 0.4 
     
 
  
 
  
 
  
 
  Iron ion transport orf19.1415 FRE10 2.0 4.2  0.9 2.3  0.2 0.1  0.5 0.5  0.1 0.0 
 
orf19.1932 CFL4 35.6 359.0  2.4 6.6  8.0 22.0  0.1 0.0  0.2 0.1 
 
orf19.4215 FET34 2.1 5.2  0.2 0.5  0.0 0.1  0.1 0.1  0.0 0.0 
 
orf19.7219 FTR1 3.2 7.8  0.5 1.1  0.1 0.0  0.1 0.1  0.0 0.0 
     
 
  
 
  
 
  
 
  Iron ion homeostasis orf19.1264 CFL2 2.0 6.0  0.6 0.5  0.2 0.8  0.3 0.1  0.1 0.1 
     
 
  
 
  
 
  
 
  Transport orf19.1352 TIM22 3.6 4.4  0.9 1.1  1.3 2.0  0.2 0.3  0.4 0.4 
 
orf19.2292 OPT4 5.2 3.7  1.1 1.0  0.0 0.0  0.2 0.3  0.0 0.0 
 
orf19.2350 
 
2.5 4.1  0.6 1.0  0.9 0.6  0.3 0.3  0.4 0.1 
 
orf19.3195 HIP1 1.5 2.6  0.6 0.7  0.7 0.8  0.4 0.3  0.5 0.3 
 
orf19.3232 
 
24.6 5.3  2.6 1.0  1.6 1.6  0.1 0.2  0.1 0.3 
 
orf19.4384 HXT5 70.6 75.5  11.1 23.4  16.9 9.7  0.2 0.3  0.2 0.1 
 
orf19.4682 HGT17 45.0 24.7  7.0 7.3  4.2 4.5  0.2 0.3  0.1 0.2 
 
orf19.6249 HAK1 4.4 10.7  2.1 3.2  2.0 2.6  0.5 0.3  0.5 0.2 
 
orf19.6993 GAP2 21.7 8.6  3.0 4.5  3.6 2.5  0.1 0.5  0.2 0.3 
     
 
  
 
  
 
  
 
  Response to stress orf19.1434 
 
1.7 2.7  0.8 1.0  0.8 0.9  0.5 0.4  0.5 0.3 
 
orf19.3239 CTF18 2.7 2.4  1.0 1.1  1.4 0.8  0.4 0.5  0.5 0.4 
 
orf19.4317 GRE3 1.5 1.5  0.8 0.6  0.3 0.7  0.5 0.4  0.2 0.5 
 
orf19.5902 RAS2 7.6 6.2  0.8 1.1  2.3 1.5  0.1 0.2  0.3 0.2 
     
 
  
 
  
 
  
 
  Response to 
chemical stimulus 
orf19.5591 ADO1 2.4 2.9  1.1 1.5  0.7 0.8  0.4 0.5  0.3 0.3 
orf19.6102 RCA1 2.5 3.4  1.2 1.2  1.1 1.4  0.5 0.4  0.5 0.4 
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Table 3-8. (Continued) 
 
   
Change in Fold Expression         
 
   
SC5314+FLC/  cas5Δ/Δ+FLC/  upc2Δ/Δ+FLC/  CAS5 Ratio 
(B/A) 
 UPC2 Ratio 
C/A) 
   
SC5314 (A)  cas5Δ/Δ (B)  upc2Δ/Δ (C)   
Processa 
orf19 
Designation 
CGD 
Name Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
 
orf19.7374 CTA4 1.7 2.2  0.8 1.1  0.8 1.0  0.5 0.5  0.5 0.5 
     
 
  
 
  
 
  
 
  Oxidation-reduction 
process 
orf19.1411 
 
2.7 4.8  1.1 0.9  1.4 1.1  0.4 0.2  0.5 0.2 
orf19.2108 SOD6 7.9 10.6  1.6 1.1  1.1 1.6  0.2 0.1  0.1 0.1 
 
orf19.4747 HEM14 1.7 2.0  0.6 0.4  0.1 0.2  0.3 0.2  0.0 0.1 
     
 
  
 
  
 
  
 
  Filamentous growth orf19.5741 ALS1 66.8 79.0  22.6 21.0  4.8 3.1  0.3 0.3  0.1 0.0 
     
 
  
 
  
 
  
 
  Biofilm formation orf19.4899 GCA1 4.8 4.4  0.9 1.2  0.2 0.6  0.2 0.3  0.0 0.1 
     
 
  
 
  
 
  
 
  Other orf19.410.3 RIB4 5.6 5.7  0.6 0.5  1.0 0.8  0.1 0.1  0.2 0.1 
 
orf19.467 WOR3 32.3 7.1  3.0 2.9  2.8 0.8  0.1 0.4  0.1 0.1 
 
orf19.6057 
 
2.5 1.8  0.9 1.0  0.2 0.2  0.3 0.5  0.1 0.1 
     
 
  
 
  
 
  
 
  Unknown orf19.1277 
 
6.6 9.3  1.5 1.5  3.4 2.7  0.2 0.2  0.5 0.3 
 
orf19.2414 
 
3.1 3.3  1.1 0.6  0.7 1.7  0.4 0.2  0.2 0.5 
 
orf19.2691 
 
1.5 1.5  0.5 0.7  0.4 0.7  0.3 0.4  0.3 0.5 
 
orf19.2836 
 
11.7 21.9  3.1 4.8  1.6 1.2  0.3 0.2  0.1 0.1 
 
orf19.2839 CIRT4B 1.6 2.6  0.4 0.3  0.7 0.6  0.2 0.1  0.4 0.2 
 
orf19.3499 
 
79.5 20.5  5.9 7.6  10.6 10.1  0.1 0.4  0.1 0.5 
 
orf19.3881 
 
1.9 2.0  0.7 0.6  0.5 0.5  0.4 0.3  0.2 0.2 
 
orf19.4013 
 
2.6 2.2  0.6 0.6  0.3 0.4  0.2 0.3  0.1 0.2 
 
orf19.4144 
 
2.4 3.2  1.2 1.6  0.9 0.9  0.5 0.5  0.4 0.3 
 
orf19.4658 
 
5.0 6.6  2.5 3.1  2.4 1.1  0.5 0.5  0.5 0.2 
 
orf19.5019 
 
2.8 3.4  1.4 1.8  0.9 1.3  0.5 0.5  0.3 0.4 
 
orf19.6186 
 
12.1 13.3  2.4 2.0  2.8 2.7  0.2 0.1  0.2 0.2 
 
orf19.6690 
 
2.4 2.3  0.7 0.6  0.6 0.7  0.3 0.3  0.3 0.3 
 
orf19.670.2 
 
47.4 152.7  10.8 16.1  18.3 14.1  0.2 0.1  0.4 0.1 
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Table 3-8. (Continued) 
 
   
Change in Fold Expression         
 
   
SC5314+FLC/  cas5Δ/Δ+FLC/  upc2Δ/Δ+FLC/  CAS5 Ratio 
(B/A) 
 UPC2 Ratio 
C/A) 
   
SC5314 (A)  cas5Δ/Δ (B)  upc2Δ/Δ (C)   
Processa 
orf19 
Designation 
CGD 
Name Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
 
orf19.6905 
 
2.4 3.3  0.5 0.4  1.2 1.4  0.2 0.1  0.5 0.4 
 
orf19.6970 
 
4.5 4.4  2.3 2.4  2.0 1.8  0.5 0.5  0.4 0.4 
 
orf19.6983 
 
2.1 9.1  1.0 1.3  0.4 0.0  0.5 0.1  0.2 0.0 
 
orf19.7567 
 
2.5 2.4  1.1 0.8  0.2 0.5  0.4 0.3  0.1 0.2 
 
orf19.951 
 
2.3 2.4  0.4 0.4  0.8 1.2  0.2 0.2  0.3 0.5 
a Descriptions are from the Candida Genome Database (http://www.candidagenome.org). 
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transport and ERG26 expression, in addition to the inability to upregulate genes involved 
in the cell wall integrity pathway.  Delineation of which downstream targets influence 
azole susceptibility would identify potential targets for co-therapeutic strategies rendering 
enhanced activity to the azoles, and as a result may mitigate the development of 
resistance. 
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CHAPTER 4.    DISCUSSION 
 
 
 Candida albicans is the most prevalent human fungal pathogen and causes a wide 
spectrum of diseases (65).  Despite this there are few fundamentally different classes of 
clinical antifungals available for treatment, due to limited unique and important fungal 
targets which are not found in the host (61).  Currently available antifungal drugs act 
primarily on the fungal cell wall and ergosterol found in the cell membrane.  Perturbation 
of either of these structures or their components impacts the fungal cell’s survival.  
Fungal cell walls display an electron-dense fibrillar outer layer composed of 
mannoproteins, and an inner layer of glucans and chitin conferring elasticity and tensile 
strength to the cell wall (62, 63).  Ergosterol is found in the fungal cell membrane and 
regulates fluidity and ultimately membrane integrity (64).  Both are exploitable drug 
targets as the cell wall is essential for survival, and human cells lack both cell walls and 
ergosterol. 
 
 The azole antifungals (such as fluconazole) are the most widely used and 
important ergosterol biosynthesis inhibitors (EBIs) for the treatment of Candida 
infections (65).  This class of antifungals acts by inhibiting the product of ERG11, a 
critical cytochrome P450 enzyme of the ergosterol biosynthesis pathway, known as 
lanosterol 14α-demethylase.  Inhibition of this enzyme results in accumulation of sterol 
intermediates and altered cell membrane structure and function (79, 82).  Despite their 
overall success in treatment, the azoles are fungistatic against C. albicans and therefore 
have limited efficacy against this organism, especially for immunocompromised patients, 
and the development of resistance can occur (61, 85, 206).  The lack of lethality caused 
by sterol biosynthesis inhibition may be due to adaptive responses which circumvent 
azole activity and permit fungal survival in the presence of the azoles.  Indeed, various 
pathways have been shown to be critical for the fungistatic activity of azole antifungals.   
 
 We hypothesized that the transcriptional regulators of these pathways are required 
for the response to the azoles in both susceptible and resistant strains.  Identification of 
their downstream targets would be useful as novel targets for the development of 
cotherapeutic strategies to improve the efficacy of fluconazole treatment.  By studying 
mutants of specific transcription factors we were able to identify those whose disruption 
results in enhanced susceptibility in both susceptible and resistant strains.  Using C. 
albicans Affymetrix microarrays we were able to examine the genome-wide expression 
profile of these mutants and their background strains for fluconazole-inducible genes 
whose expressions are TF-dependent.  
 
 Liu et al. recently examined the genome-wide expression profile in response to 
ketoconazole exposure and observed an induction of genes involved in ergosterol 
biosynthesis (97).  Many of these genes exist upstream from Erg11p, the azole target, and 
respond to ergosterol depletion by facilitating the production of alternate sterols including 
lanosterol, eburicol, obtusifoliol, 14α-methyl fecosterol, and 14α-methylergosta-
8,24(28)-dien-3β,6α-diol to be inserted into the cell membrane (107) (Figure 4-1).  
Integration of these sterols into the plasma membrane disrupts its integrity resulting in its   
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Figure 4-1. An alternate sterol biosynthesis pathway in C. albicans 
Alternate sterols produced in response to azole inhibition.  Genes in boldface have been 
shown to be influenced by iron.  Dotted lines denote multiple enzymatic steps (232, 234, 
235). 
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altered structure and function (79, 82, 108).  Under these conditions, growth is inhibited 
but the organism remains viable (109).   
 
 The transcriptional regulator of the ergosterol biosynthesis pathway is Upc2, 
controlling inducible ergosterol genes expression in response to the azoles.  Upon 
disruption of UPC2, the cells become hypersusceptible to fluconazole, ERG gene 
inducible transcription is abolished, and as a result ergosterol levels are reduced (199, 
200).  Our first objective was to better characterize the role of UPC2 in fluconazole 
susceptibility in both azole-susceptible and azole-resistant strains.  In addition to previous 
observations of reduced fluconazole MIC for a upc2Δ/Δ mutant as compared to its azole-
susceptible parent strain, we observed a reduced MFC when disrupted from the azole-
susceptible parent SC5314 as well as the highly azole-resistant parent 12-99, which 
carries the four most common mechanisms of resistance.  Disruption in both backgrounds 
prevented its regrowth after 72 hours in the presence of higher fluconazole concentrations 
in YPD medium, resulted in a clear zone of inhibition around a fluconazole Etest strip, 
and prevented growth on solid YPD medium containing a therapeutically relevant 
concentration of fluconazole (10 μg/ml).  An enhanced effect for fluconazole was also 
demonstrated by time-kill analysis for the upc2Δ/Δ mutants as compared to their 
respective parent strains.  The same phenotype was also observed upon disruption of 
UPC2 in isogenic strains containing resistance mutations in ERG11, MRR1, and TAC1.  
The upc2Δ/Δ mutants in each background showed increased susceptibility to fluconazole 
by Etest and an inability to grow on solid media containing fluconazole.  
 
 C. albicans Upc2 has been shown to bind the promoters of CDR1 and MDR1 
(201). However, the observed effect on fluconazole susceptibility occurred without any 
change in expression of the efflux pump genes CDR1, CDR2, or MDR1 and therefore is 
not the cause for how the disruption of UPC2 overcomes drug resistance.  UPC2 
disruption did result in reduced ERG11 expression compared to both azole-susceptible 
and azole-resistant parent strains as measured by real-time RT-PCR, and inducible 
expression of ERG6, ERG24, and ERG27 (as well as ERG11) was reduced in the 
upc2Δ/Δ mutant as compared to its parent strain SC5314 upon exposure to fluconazole as 
measured by microarray analysis.  Such changes in expression would diminish the 
intracellular drug target and as well as the biosynthesis of alternative sterols, 
compromising the organism in the presence of fluconazole. 
 
 Interestingly, genes involved in iron transport (CFL4, FET3, FET34, FRE10, 
FRP1, FTR1) and homeostasis (CFL2, CSA1, IRO1, RBT5) were also found to be 
dependent upon UPC2 for their induction in response to fluconazole.  Before being taken 
up by the cell, ferric iron must be solubilized to its ferrous form by a cell surface ferric 
reductase (FRE1, also known as FRE10), and when iron availability is low it is then 
taken up by the high-affinity iron uptake system including a membrane permease (FTR1) 
and a multicopper oxidase (FET3) (249-251) (Figure 4-2).  Disruption of FTR1 and iron 
starvation have previously been shown to enhance fluconazole susceptibility in C. 
albicans (228-231) and the iron uptake system has been proposed as an alternative target 
for combination antifungal treatment (233).  Iron deprived cells also have decreased 
amounts of both ergosterol and sterol intermediates when compared to iron sufficient  
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Figure 4-2. High-affinity ion uptake in yeast 
Extracellular ferric iron is reduced to ferrous iron by a ferric reductase (Fre1).  A 
multicopper oxidase (Fet3) oxidizes the iron back to its ferric form which is then 
transported into the cell by an iron permease (Ftr1) (252). 
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cells (228, 253).  This may be due to the inactivity of enzymes in the ergosterol  
biosynthesis pathways which require iron for their function.  ERG11 and ERG5 encode 
cytochrome P450 enzymes and their active sites contain a heme iron.  Also, the 
expressions ERG11 and ERG3 have been shown to be iron regulated, and while ERG25 
expression is not regulated by iron, it is an iron containing gene identified to be essential 
to viability (253-256).  Since many enzymes in the ergosterol biosynthesis pathway 
require iron, reduced expression of iron transport and homeostasis genes would impact 
the activity of ergosterol biosynthesis enzymes in response to fluconazole.  Therefore, the 
enhanced effect of fluconazole upon the disruption of UPC2 may be due to this effect in 
combination with decreased expression of the ERG genes.  Indeed, a upc2Δ/Δ mutant has 
been shown to be highly susceptible to Malachite green, a compound which depletes 
intracellular iron (257).   
 
 We then sought out to identify other transcription factors that had similar effects 
on fluconazole susceptibility as UPC2 by screening a library of mutants disrupted for 
genes encoding transcription factors (187).  Our results in Chapter 3 showed that the TF 
Cas5 was identified to be hypersusceptible to fluconazole, and independent disruption of 
CAS5 from the azole-susceptible parent SC5314 also exhibited increased susceptibility to 
fluconazole.  The fluconazole MIC was slightly reduced and a substantial reduction was 
observed for the fluconazole MFC.  Disruption of CAS5 prevented regrowth after 72 
hours in the presence of higher fluconazole concentrations in YPD medium, resulted in a 
clear zone of inhibition around a fluconazole Etest strip, and prevented growth on solid 
YPD medium containing a therapeutically relevant concentration of fluconazole (10 
μg/ml).  An enhanced effect for fluconazole was also demonstrated by time-kill analysis 
as compared to the parent strain.  This phenotype was not as strong when disrupted in 
isogenic strains containing resistance mutations in ERG11, MRR1, and TAC1 and had no 
effect on azole-resistant clinical isolates.  Of note, the cas5Δ/Δ mutant derived from a 
strain containing resistance mutations in UPC2 resulted in altered cell shape and size, 
suggesting a relationship between the two transcription factors, but was unable to be 
quantified due to cell density irregularities.  The cas5Δ/Δ mutants in the ERG11, MRR1, 
and TAC1 backgrounds showed slightly increased susceptibility to fluconazole by Etest 
and reduced inability to grow on solid media containing fluconazole.  The effect of CAS5 
on fluconazole susceptibility was not shown to be due to decreased expression of the 
CDR1, CDR2, and MDR1 efflux pump genes.  Although the resulting modest effect on 
resistance is not practical for clinical application, it is important to note the enhanced 
effect in the susceptible background which would improve efficacy of treatment.  As a 
result, it may also impact the development of resistance.  
 
 The cas5Δ/Δ mutants in the ERG11, MRR1, and TAC1 backgrounds did exhibit a 
decrease in ERG11 expression, adding evidence to a possible relationship between Cas5p 
and Upc2, as inducible ERG11 expression is controlled by Upc2.  Additionally, inducible 
expression of several genes involved in the lipid metabolic process (including ERG26) 
were reduced in the cas5Δ/Δ mutant as compared to its parent strain SC5314 upon 
exposure to fluconazole as measured by microarray analysis.  ERG26 encodes for C-4 
sterol decarboxylase which is an essential enzyme in C. albicans for viability (248).  As 
previously mentioned, decreased expression ERG11 would diminish the target of the 
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azoles and decreased ERG26 expression would impact the biosynthesis of alternative 
sterols, compromising the ability of this response mechanism to circumvent the activity 
of fluconazole.  Another striking similarity to UPC2 was the dependence of iron ion 
transport (CFL4, FET34, FRE10, FTR1), binding (orf19.1411), and homeostasis (CFL2) 
genes on Cas5 by microarray analysis. Many of these genes were previously identified to 
also be dependent upon Upc2 (Chapter 2).  The disruption of cell membrane integrity by 
fluconazole also impacts cell wall integrity (258).  Since cell membrane and wall proteins 
such as Cfl2p, Cfl4p, Fet3p, Fet34p, Fre10p, and Ftr1p are involved in iron acquisition 
(247), it is reasonable for a relationship to exist in regulating iron acquisition and cell 
wall maintenance genes. 
 
 Cas5 has been postulated to be the transcriptional regulator of the CWI pathway 
(239), which is required to maintain cell shape and integrity (134).  The specificity of the 
CWI pathway to fungal cells and its role in responding to fluconazole activity makes it an 
attractive system for which novel co-therapeutic agents could be designed to act 
synergistically with fluconazole (103, 104).  When the cas5Δ/Δ mutant was compared to 
its parent strains by microarray analysis, several genes involved in cell wall organization 
were identified to dependent upon Cas5 for their induction in response to fluconazole.  
Included were the genes PGA13, PGA31, RCA1, VPS28, YPS7, orf19.5644, and 
orf19.719.  Previous studies also identified that the expression of PGA13 was dependent 
upon Cas5 in response to caspofungin (134).  PGA13 encodes a GPI protein which is 
highly expressed during cell wall regeneration (259), and its deletion results in slightly 
enhanced susceptibility to fluconazole and caspofungin (260).  The deletion of VPS28 has 
also been shown to result in hypersusceptibility to both the azole (fluconazole, 
voriconazole) and echinocandin antifungals (caspofungin, micafungin) (261).  Since 
many of these genes encode proteins contributing to cell wall integrity, it suggests that 
when CAS5 is disrupted the integrity of the cell wall is compromised.  This, combined 
with decreased iron uptake, which occurs at the cell surface, may account for the 
observed increase in fluconazole susceptibility. 
 
 Ciclopirox olamine was introduced more than 3 decades ago as a topical 
antifungal agent with a very broad spectrum of activity (262).  Although its mechanism 
of action is poorly understood, the chelation of metal ions and the inhibition of iron-
dependent enzymes have been shown to play a role (263).  Upon exposure to ciclopirox 
olamine, the expression of genes encoding drug efflux pumps (CDR1, CDR2), iron 
permease (FTR1), iron transporter (FTH1), and iron reductase (CFL1) were induced, 
while the addition of iron(III) chloride reversed this effect.  The iron chelator bipyridine 
also induced a similar pattern of gene expression (262).  Additionally, no cases of 
resistance have been reported to ciclopirox olamine.  This may be due to its fungicidal 
mode of action or an irreversible binding of the drug to intracellular structures, 
preventing its export by efflux pumps (264).  To examine if resistance could be 
developed in vitro, cells were grown in the presence of ciclopirox olamine for 6 months.  
Expression of CDR1 and CDR2 increased, but there was no decrease in susceptibility or 
development of resistance (262).  A later study showed similar gene expression changes 
in response to ciclopirox olamine, but mutants disrupted for CDR1 and CDR2, as well as 
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a clinically azole-resistant isolate overexpressing CDR1 and CDR2, had no change in 
susceptibility to ciclopirox olamine (265).   
 
 Further emphasis for targeting the iron uptake system in combination with 
antifungal treatment was provided by the observation that doxycycline acts 
synergistically with fluconazole (266).  Doxycycline is an antimicrobial with iron-
chelating activity (267-270).  The combination of doxycycline with fluconazole resulted 
in fungicidal activity, and prevented the development of fluconazole resistance.  It was 
also effective against a highly fluconazole-resistant clinical isolate, FH5, with an 
isochromosome 5L duplication resulting in 4 copies of ERG11 and 4 copies of 
constitutively active TAC1 (271).  These effects were reversed upon the addition of iron 
to the growth medium.  High levels of doxycycline alone did impact growth of the 
susceptible strain SC5314, but had not impact on the azole-resistant isolate.  
Interestingly, growth of an S. cerevisiae strain with constitutive ERG11 overexpression 
was able to resume in the presence of these two drugs.  However, overexpression of 
ERG11 in C. albicans did not restore growth (266).  Since the Erg11 protein binds heme, 
and azoles interact with the heme iron (272), iron depletion could decrease the activity of 
both Erg11 and the azoles.  Further study is necessary in order to determine the extent of 
iron’s role in fluconazole susceptibility. 
 
 By studying transcription factor mutants in both azole-susceptible and azole-
resistant backgrounds, we were able to identify the involvement of high-affinity transport 
pathway in the response to azoles, as well as expanding upon pathways previously 
identified.  We successfully identified UPC2 and CAS5 in the regulation of iron ion 
transport, binding, and homeostasis in addition to the role of Upc2 as the regulator of 
ergosterol biosynthesis and Cas5 of cell wall integrity in the presence of fluconazole.  
Disruption of the transcription factor, Upc2p, was also shown to overcome high levels of 
azole resistance.  Our results demonstrate the importance of using TF mutants for 
identifying transcriptional pathways functioning in both susceptible and resistant 
response mechanisms to fluconazole. 
 
 The discovery of the role of iron transport and homeostasis may allow for the 
development of more efficient combination therapy with fluconazole.  The combination 
of iron deprivation and cell wall disruption may be important for preventing the 
development of azole resistance from the time of therapy initiation.  Additionally, 
targeting both high-affinity iron transport and ergosterol biosynthesis may be able to 
overcome the existence of resistance as well as hinder its development.   
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APPENDIX A.  UPC2 SUPPLEMENTAL DATA 
 
 
Table A-1. Genes upregulated by at least 1.5-fold by fluconazole in SC5314 
 
      Change in Fold Expression 
   
SC5314+FLC
/SC5314 
 cas5Δ/Δ+FLC
/cas5Δ/Δ 
 upc2Δ/Δ+FLC/
upc2Δ/Δ 
orf19 
Designation 
CGD 
Name Processa Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
orf19.7094 HGT12 carbohydrate transport  423.2 19.8  8.0 1.9  13.5 140.0 
orf19.4335 TNA1 anion transport  194.9 29.8  2.5 42.4  0.4 0.2 
orf19.6084 
  
123.7 19.7  11.8 9.8  62.0 51.5 
orf19.4527 HGT1 carbohydrate transport  115.9 120.9  98.6 141.2  59.1 88.7 
orf19.4476 
 
cellular aldehyde metabolic process 104.5 102.1  114.2 83.9  419.7 228.8 
orf19.3499 
  
79.5 20.5  5.9 7.6  10.6 10.1 
orf19.3923 PGA37 
 
73.2 6.3  7.7 22.1  91.4 58.4 
orf19.6311 
  
72.8 23.5  382.3 60.5  98.1 13.7 
orf19.4384 HXT5 high-affinity hexose transport 70.6 75.5  11.1 23.4  16.9 9.7 
orf19.5741 ALS1 cell adhesion 66.8 79.0  22.6 21.0  4.8 3.1 
orf19.3908 
  
51.0 14.6  5.4 9.0  512.3 140.7 
orf19.3668 HGT2 carbohydrate transport 48.3 35.5  10.1 19.8  20.1 12.3 
orf19.670.2 
  
47.4 152.7  10.8 16.1  18.3 14.1 
orf19.4682 HGT17 carbohydrate transport  45.0 24.7  7.0 7.3  4.2 4.5 
orf19.1438 
 
oxidation-reduction process 42.4 13.5  36.3 29.8  17.4 9.8 
orf19.2809 CTN3 acetyl-CoA metabolic process  41.1 36.9  33.4 30.6  12.6 11.5 
orf19.7093 HGT13 carbohydrate transport  40.9 18.8  5.9 11.3  9.8 2.6 
orf19.7111.1 SOD3 response to oxidative stress 40.5 69.2  9.4 15.0  46.5 99.8 
orf19.7434 GLG2 glycogen biosynthetic process 37.5 16.1  7.5 8.7  47.7 39.9 
orf19.1932 CFL4 siderophore-iron transport  35.6 359.0  2.4 6.6  8.0 22.0 
orf19.1473 
 
oxidation-reduction process 35.0 15.0  3.8 4.8  30.4 41.0 
orf19.2060 SOD5 cellular copper ion homeostasis  33.2 14.2  5.4 6.1  14.2 28.1 
orf19.467 
  
32.3 7.1  3.0 2.9  2.8 0.8 
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        Change in Fold Expression 
   
SC5314+FLC
/SC5314 
 cas5Δ/Δ+FLC
/cas5Δ/Δ 
 upc2Δ/Δ+FLC/
upc2Δ/Δ 
orf19 
Designation 
CGD 
Name Processa Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
orf19.6993 GAP2 gamma-aminobutyric acid transport  30.6 10.6  3.5 10.0  6.0 3.0 
orf19.4214 
  
30.5 19.5  0.5 1.2  0.3 12.5 
orf19.6486 LDG3 
 
29.6 3.1  8.1 4.2  15.7 11.4 
orf19.4773 AOX2 aerobic respiration 29.5 24.9  15.4 14.1  122.1 50.4 
orf19.2652 TEF4 translational elongation 27.8 15.2  15.3 25.5  9.5 8.5 
orf19.1344 
  
27.1 12.6  13.1 32.5  53.0 6.3 
orf19.3232 
 
anion transport  24.6 5.3  2.6 1.0  1.6 1.6 
orf19.4551 CTN1 acetyl-CoA metabolic process  22.4 26.6  11.3 14.3  17.4 75.7 
orf19.1655 PXP2 fatty acid beta-oxidation  22.1 31.9  19.5 19.9  95.6 41.4 
orf19.3982 
 
sucrose catabolic process  21.1 5.4  2.5 3.2  44.9 44.0 
orf19.2023 HGT7 glucose transport 20.8 21.6  9.4 7.8  0.5 0.4 
orf19.5753 HGT10 carbohydrate transport  20.6 1.6  2.9 2.9  2.6 0.8 
orf19.6484 
  
19.5 30.0  2.2 4.3  240.3 97.9 
orf19.344 
  
19.0 6.9  13.6 8.9  152.4 53.0 
orf19.2810 AAP1 amino acid transport  18.9 19.6  7.5 8.8  32.9 13.3 
orf19.6919 
  
18.1 4.5  1.4 10.1  21.7 54.8 
orf19.5302 PGA31 fungal-type cell wall organization  17.6 4.1  2.1 1.5  9.9 3.4 
orf19.7197 
 
DNA replication initiation  17.0 6.6  2.0 7.3  11.6 22.6 
orf19.3924 
  
16.8 4.1  8.5 4.7  3.2 3.2 
orf19.4691 
  
16.6 24.8  4.2 3.4  4.0 59.6 
orf19.4690 
 
manganese ion transport  16.3 20.2  7.8 23.4  1.0 1.4 
orf19.6420 PGA13 filamentous growth 15.6 30.6  2.4 2.3  87.4 117.0 
orf19.5069 
 
meiotic DNA recombinase assembly 14.9 15.5  5.9 7.1  28.3 16.1 
orf19.740 HAP41 regulation of transcription from RNA polymerase II promoter 14.3 10.7  12.7 23.5  14.3 2.5 
orf19.5037 HRQ2 
 
13.5 9.7  8.4 12.3  14.4 4.8 
orf19.7566 
 
amino acid transport 13.4 7.0  6.9 11.2  11.3 5.3 
orf19.3627 
  
12.6 5.5  10.1 10.8  26.6 13.5 
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Designation 
CGD 
Name Processa Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
orf19.893 PGA17 
 
12.3 5.5  1.4 1.1  32.2 3.5 
orf19.6186 
  
12.1 13.3  2.4 2.0  2.8 2.7 
orf19.1765 
  
11.7 7.6  4.4 6.9  22.8 13.6 
orf19.638 FDH1 formate metabolic process  11.7 19.5  4.4 3.9  9.0 29.2 
orf19.742 ALD6 ethanol metabolic process  11.5 10.4  4.1 1.7  3.5 6.8 
orf19.3986 PPR1 regulation of transcription, DNA-dependent  10.9 5.3  9.9 10.3  10.7 3.2 
orf19.7296 
  
10.6 11.5  11.8 8.6  55.8 13.6 
orf19.2717 SAS10 endonucleolytic cleavage of rRNA 10.4 2.5  4.4 3.5  4.7 14.9 
orf19.6595 RTA4 filamentous growth  10.4 15.0  3.0 2.9  17.8 34.3 
orf19.1763 IFR1 oxidation-reduction process 10.3 11.8  15.9 7.9  53.4 50.8 
orf19.5307 JEN2 lactate transport  10.3 2.7  2.0 3.1  0.4 1.3 
orf19.7504 
  
10.1 4.9  12.6 25.3  23.1 5.3 
orf19.6793 
  
10.0 7.7  8.6 15.5  118.0 36.1 
orf19.3733 IDP2 glutamate biosynthetic process 9.7 14.9  10.8 12.9  12.6 18.2 
orf19.1363 
 
ascospore formation  9.5 29.7  11.0 10.3  70.4 1188.0 
orf19.7585 INO1 inositol biosynthetic process 9.2 20.5  21.8 19.6  0.9 0.8 
orf19.2049 
  
9.1 5.6  8.5 5.2  59.6 21.2 
orf19.10 ALK8 fatty acid omega-oxidation 9.0 8.1  3.0 3.5  133.9 183.6 
orf19.5634 FRP1 high-affinity iron ion transport  8.9 8.2  7.5 7.3  0.1 0.2 
orf19.1070 
  
8.6 8.0  5.4 4.6  2.4 1.6 
orf19.4802 FTH1 high-affinity iron ion transport  8.5 9.9  5.9 7.1  14.3 6.5 
orf19.2946 HNM4 choline transport  8.4 4.9  2.9 2.5  18.4 2.9 
orf19.6844 ICL1 glyoxylate cycle  8.2 8.2  17.3 23.3  17.4 50.8 
orf19.4872 
  
8.2 19.2  1.2 1.3  25.8 10.2 
orf19.2108 SOD6 oxidation-reduction process 7.9 10.6  1.6 1.1  1.1 1.6 
orf19.1345 LIP8 lipid catabolic process  7.9 6.2  1.3 4.3  107.5 3.9 
orf19.5614 
 
cell wall organization  7.9 7.7  3.9 4.1  11.8 6.5 
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CGD 
Name Processa Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
orf19.3740 PGA23 response to drug  7.9 6.7  9.2 9.1  29.1 10.1 
orf19.4706 
  
7.7 6.2  15.1 12.7  17.5 6.6 
orf19.5902 RAS2 Ras protein signal transduction 7.6 6.2  0.8 1.1  2.3 1.5 
orf19.7314 CDG1 L-cysteine metabolic process 7.5 6.0  1.0 0.6  1.7 5.0 
orf19.4404 PGA49 
 
7.3 1.6  1.1 0.8  15.4 4.7 
orf19.4608 PDC12 
 
7.1 16.7  0.5 0.3  14.1 12.6 
orf19.4274 PUT1 glutamate biosynthetic process  6.8 8.8  15.1 21.1  2.5 0.6 
orf19.94 
  
6.8 6.6  17.5 25.8  12.3 6.2 
orf19.1826 MDM34 regulation of transcription, DNA-dependent  6.8 9.3  7.3 13.6  21.5 5.5 
orf19.1277 
  
6.6 9.3  1.5 1.5  3.4 2.7 
orf19.5447 HGT19 carbohydrate transport 6.6 8.1  7.8 18.5  9.8 3.9 
orf19.6828 
 
rRNA processing  6.5 3.5  1.5 2.8  2.5 3.9 
orf19.2747 RGT1 filamentous growth  6.4 4.6  5.3 43.8  97.4 10.4 
orf19.7056 
 
amino acid transmembrane transport 6.2 120.3  2.5 2.7  94.2 9.2 
orf19.7131 
 
carnitine biosynthetic process  6.2 6.8  6.2 7.8  3.6 1.8 
orf19.5959 NOP14 response to drug  6.1 4.0  5.3 4.6  9.0 7.7 
orf19.3672 GAL10 fungal-type cell wall biogenesis  6.0 7.3  14.2 6.9  2.7 3.8 
orf19.5045 PTP2 osmosensory signaling pathway  6.0 10.4  2.5 2.0  23.0 20.2 
orf19.3615 
  
6.0 5.4  8.2 8.1  12.8 10.9 
orf19.2878 PGA15 
 
6.0 8.1  3.1 2.4  7.7 6.7 
orf19.7514 PCK1 gluconeogenesis 6.0 8.6  1.9 1.4  9.3 13.0 
orf19.5542 SAP6 adhesion to host  5.9 4.3  2.1 1.4  9.5 7.9 
orf19.3684 
 
ascospore formation  5.9 2.1  11.2 11.3  9.1 15.4 
orf19.2247 
  
5.9 5.6  5.5 1.3  88.0 0.7 
orf19.2515 
  
5.9 9.0  6.7 7.1  13.4 7.9 
orf19.2952 EXG2 cell wall organization  5.8 4.1  2.6 3.0  7.0 4.2 
orf19.7077 
 
iron ion transport 5.8 5.5  4.1 4.1  90.1 64.1 
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CGD 
Name Processa Exp1 Exp2 
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orf19.4082 DDR48 hyphal growth  5.8 5.7  9.3 6.9  1.9 1.3 
orf19.1117 
 
NADH regeneration 5.7 2.3  0.7 1.1  1.3 2.0 
orf19.1923 RRN3 transcription from RNA polymerase I promoter  5.7 23.0  2.9 3.8  13.4 3.5 
orf19.1237 ARO9 aromatic amino acid family catabolic process to alcohol 5.6 9.5  6.9 5.0  18.6 12.6 
orf19.1069 RPN4 proteasomal ubiquitin-dependent protein catabolic process  5.6 6.0  5.7 5.5  20.2 12.7 
orf19.6920 
  
5.6 1.9  7.3 6.0  31.0 20.1 
orf19.410.3 
 
riboflavin biosynthetic process  5.6 5.7  0.6 0.5  1.0 0.8 
orf19.3574 MDJ2 protein import into mitochondrial matrix 5.6 3.1  2.0 1.2  2.1 3.6 
orf19.4607 
  
5.6 7.0  0.5 0.3  5.8 24.3 
orf19.5000 CYB2 lactate metabolic process  5.5 3.3  3.3 3.3  4.2 6.2 
orf19.6249 HAK1 potassium ion transport 5.4 5.8  2.7 3.8  1.4 1.7 
orf19.449 
 
metabolic process 5.4 5.6  5.2 5.9  3.4 1.6 
orf19.3934 CAR1 arginine catabolic process to ornithine 5.4 3.2  7.8 10.6  2.5 2.5 
orf19.3547 
 
regulation of transcription, mating-type specific  5.3 5.9  1.1 1.7  2.7 3.8 
orf19.918 CDR11 multidrug transport 5.3 11.0  4.1 3.1  9.8 10.1 
orf19.7263 
 
cellular process 5.3 6.0  5.0 4.5  2.6 2.2 
orf19.5206 
 
box H/ACA snoRNP assembly  5.2 4.0  1.4 1.7  4.7 6.2 
orf19.2292 OPT4 oligopeptide transport  5.2 3.7  1.1 1.0  0.0 0.0 
orf19.4273 
 
aerobic respiration 5.1 7.6  3.9 5.1  1.4 2.0 
orf19.3931 SFC1 fumarate transport  5.1 5.2  9.9 13.9  6.9 3.4 
orf19.6766 NOP13 
 
5.1 5.3  1.7 2.6  4.7 9.8 
orf19.3434 TRY5 positive regulation of cell-substrate adhesion 5.0 7.3  6.8 7.5  6.9 3.1 
orf19.4070 
  
5.0 8.9  3.0 2.5  1.8 1.9 
orf19.3670 GAL1 galactose catabolic process  5.0 8.2  12.9 7.4  4.7 2.7 
orf19.5094 BUL1 protein polyubiquitination  5.0 5.7  3.2 3.0  4.9 5.3 
orf19.4658 
  
5.0 6.6  2.5 3.1  2.4 1.1 
orf19.5353 
  
4.9 8.8  10.4 14.0  4.5 0.8 
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CGD 
Name Processa Exp1 Exp2 
 
Exp1 Exp2 
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orf19.4041 PEX4 protein autoubiquitination  4.9 4.3  1.3 1.5  3.5 6.8 
orf19.6886 
 
maturation of rRNA 4.9 4.9  2.5 4.6  16.5 16.7 
orf19.5635 PGA7 
 
4.9 4.1  2.8 3.0  0.5 0.4 
orf19.677 CHO1 filamentous growth  4.9 5.5  7.6 9.8  16.7 3.3 
orf19.1377 IPK2 arginine metabolic process 4.9 3.4  4.6 7.4  16.4 13.3 
orf19.7552 
 
endonucleolytic cleavage of rRNA 4.9 4.6  2.9 5.5  6.2 7.3 
orf19.5716 SAP4 adhesion to host 4.8 3.2  2.1 1.5  6.4 4.8 
orf19.3538 FRE9 siderophore-iron transport  4.7 14.9  2.5 3.6  12.6 4.3 
orf19.4711 
  
4.7 4.8  3.6 3.3  13.7 6.0 
orf19.6840 
  
4.7 3.0  12.1 18.1  34.7 10.0 
orf19.4056 GAT2 filamentous growth  4.6 5.1  2.7 3.9  2.9 0.6 
orf19.7221 SET3 filamentous growth 4.6 2.9  7.6 15.7  2.1 1.4 
orf19.6970 
  
4.5 4.4  2.3 2.4  2.0 1.8 
orf19.7313 SSU1 filamentous growth  4.5 4.8  1.3 1.1  6.8 4.0 
orf19.5850 NOC2 filamentous growth  4.5 4.8  2.1 3.5  8.7 9.5 
orf19.6148 
 
microtubule nucleation  4.4 47.3  4.6 5.2  2.0 13.8 
orf19.4899 GCA1 biofilm formation 4.4 5.2  3.7 3.2  1.2 1.9 
orf19.5874 
  
4.4 6.6  31.0 10.4  14.5 8.2 
orf19.7503 CDA2 ascospore wall assembly 4.4 2.4  3.8 1.5  6.4 14.0 
orf19.6306 
 
carnitine biosynthetic process  4.4 2.7  4.7 5.0  7.1 3.6 
orf19.3369 MOH1 
 
4.3 8.1  6.4 5.9  18.6 13.3 
orf19.3902 
  
4.3 4.5  2.8 1.6  10.4 32.6 
orf19.6888 
 
filamentous growth  4.3 5.7  1.4 1.1  8.8 11.4 
orf19.2542 
  
4.3 2.1  2.2 3.3  0.5 3.7 
orf19.4546 HOL4 drug transport  4.3 5.1  1.7 2.3  6.9 4.1 
orf19.7500 PXA1 fatty acid transport  4.3 5.2  4.3 6.3  8.2 4.7 
orf19.3121 GST1 regulation of nitrogen utilization  4.2 2.7  5.8 19.0  1.5 7.8 
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Exp1 Exp2 
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orf19.1715 IRO1 cellular iron ion homeostasis  4.2 8.1  2.7 2.3  2.2 1.4 
orf19.4128 
  
4.2 3.4  2.0 3.4  2.0 2.1 
orf19.6169 ATO1 
 
4.2 4.3  2.4 1.8  24.8 33.3 
orf19.5125 
  
4.2 4.5  3.5 2.8  10.6 9.1 
orf19.6254 ANT1 ATP transport  4.2 2.3  2.8 3.2  5.4 4.0 
orf19.711 
  
4.1 4.1  9.8 6.2  8.9 5.2 
orf19.1350 
 
cell redox homeostasis 4.1 4.2  6.6 5.8  25.2 19.6 
orf19.1800 
 
protein targeting to vacuole 4.1 3.8  2.1 1.8  6.4 4.0 
orf19.499 
 
translational readthrough  4.1 4.2  11.2 14.9  24.8 5.4 
orf19.1609 
 
endonucleolytic cleavage of rRNA 4.1 5.0  3.4 3.5  3.8 6.6 
orf19.695 RGS2 termination of G-protein coupled receptor signaling pathway 4.1 5.8  3.3 3.4  5.8 5.2 
orf19.4894 
  
4.1 3.8  7.6 6.6  7.0 8.9 
orf19.7457 
  
4.1 2.4  4.6 4.4  11.2 12.7 
orf19.76 SPB1 maturation ofrRNA 4.1 5.3  2.8 4.0  3.9 7.7 
orf19.5735.3 
  
4.0 3.1  4.1 3.4  2.9 2.5 
orf19.7306 
 
pyridoxal biosynthetic process 4.0 3.9  5.1 5.9  11.6 15.6 
orf19.2706 CRH11 cell wall organization 4.0 3.3  4.1 2.7  3.9 2.3 
orf19.3483 
 
phosphatidylglycerol catabolic process  4.0 2.4  2.0 2.0  5.1 8.4 
orf19.7449 
 
mitochondrial genome maintenance 3.9 2.1  2.0 3.0  1.9 2.6 
orf19.5759 SNQ2 filamentous growth  3.9 6.9  5.4 8.0  4.2 2.0 
orf19.5205 
  
3.9 4.9  1.1 0.6  1.9 2.2 
orf19.7043 
  
3.9 2.8  0.9 1.0  2.4 2.1 
orf19.1488 
  
3.9 2.2  2.6 3.8  2.1 3.5 
orf19.6554 
 
calcium ion homeostasis 3.9 3.8  6.8 7.5  7.6 3.9 
orf19.2724 
  
3.9 4.1  8.5 16.0  4.8 3.2 
orf19.720 GST3 regulation of nitrogen utilization 3.8 3.4  11.8 13.2  58.6 32.7 
orf19.1915 MPP10 endonucleolytic cleavage of rRNA 3.8 4.5  2.1 2.5  11.3 6.2 
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orf19.6555 
 
protein import into mitochondrial intermembrane space 3.8 3.4  2.9 4.8  2.4 1.2 
orf19.90 
  
3.8 3.1  2.6 3.6  4.3 2.4 
orf19.4873 
  
3.8 13.5  14.6 7.1  57.4 24.8 
orf19.1704 FOX3 fatty acid beta-oxidation  3.8 2.7  5.0 7.0  6.9 4.3 
orf19.7260 
 
oxidation-reduction process 3.8 3.5  2.8 3.3  2.3 2.8 
orf19.6000 CDR1 multidrug transport  3.8 6.1  2.6 4.7  6.8 3.3 
orf19.286 
 
autophagy  3.8 2.2  1.4 1.8  2.7 3.7 
orf19.4779 
 
drug transport  3.8 4.7  2.8 3.4  9.7 8.8 
orf19.3829 PHR1 cell wall organization  3.8 5.0  2.8 3.8  14.9 7.0 
orf19.3159 UTP20 endonucleolytic cleavage of rRNA 3.8 8.9  1.9 3.5  5.4 2.7 
orf19.5585 SAP5 pathogenesis  3.7 3.0  0.9 1.0  1.4 2.3 
orf19.3077 VID21 histone acetylation  3.7 4.3  2.7 3.4  3.8 2.8 
orf19.7156 FAA2-3 lipid metabolic process 3.7 2.8  1.7 2.2  14.4 8.4 
orf19.5565 
 
valine metabolic process 3.7 2.2  9.7 5.5  7.0 11.5 
orf19.7384 NOG1 ribosomal large subunit biogenesis  3.7 7.2  1.2 2.1  13.9 5.4 
orf19.5454 DAL1 allantoin assimilation pathway 3.7 6.6  1.7 1.9  11.1 3.9 
orf19.7635 DRS1 response to drug 3.7 5.2  2.0 5.3  16.5 6.7 
orf19.6838 
 
fatty acid catabolic process  3.7 2.1  2.5 3.2  6.2 7.5 
orf19.3418 
 
arginine catabolic process to ornithine  3.7 2.2  3.0 2.3  11.4 7.6 
orf19.7053 GAC1 meiosis  3.7 5.8  4.6 4.5  10.4 2.1 
orf19.5248 MSO1 ascospore-type prospore membrane assembly 3.7 2.7  2.8 3.8  3.5 3.2 
orf19.4445 
 
filamentous growth  3.7 4.1  2.6 3.3  39.0 56.8 
orf19.7422 
 
rRNA modification 3.7 3.9  2.0 2.5  4.1 5.4 
orf19.1944 GPR1 filamentous growth  3.7 4.6  2.5 5.5  10.5 3.2 
orf19.1562 
  
3.7 4.5  3.9 4.6  1.7 1.3 
orf19.4743 AFG1 
 
3.7 4.6  2.8 2.5  9.3 5.9 
orf19.3435 
  
3.6 4.2  4.3 6.0  8.1 3.4 
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orf19.1352 TIM22 protein import into mitochondrial inner membrane  3.6 4.4  0.9 1.1  1.3 2.0 
orf19.1523 FMO1 cellular response to drug 3.6 5.6  2.5 4.3  4.3 5.7 
orf19.6606 
  
3.6 2.7  3.4 10.0  2.6 2.9 
orf19.2859 SRP40 nucleocytoplasmic transport  3.6 2.9  3.3 4.9  1.3 4.3 
orf19.1728 
  
3.6 2.3  43.7 33.3  15.7 5.0 
orf19.4450.1 
  
3.6 4.5  1.0 0.7  2.4 10.6 
orf19.7042 
  
3.6 2.3  9.4 7.6  5.8 4.7 
orf19.5626 
  
3.6 4.0  1.5 1.4  3.6 2.3 
orf19.2492 STE3 cytogamy  3.6 3.4  2.7 3.8  3.3 1.6 
orf19.3710 YHB5 response to stress  3.5 4.0  12.2 12.4  8.2 4.5 
orf19.1727 PMC1 cellular calcium ion homeostasis  3.5 3.6  5.0 7.9  8.3 3.0 
orf19.5019 
  
3.5 3.7  1.7 2.1  0.9 1.9 
orf19.7300 
  
3.5 4.8  4.4 3.5  9.7 16.9 
orf19.2400 
 
nuclear mRNA splicing, via spliceosome 3.5 1.5  0.9 1.2  1.5 2.3 
orf19.5962 SNF3 carbohydrate transport  3.5 3.0  4.7 7.1  5.9 2.1 
orf19.4596 
  
3.5 4.9  1.0 1.1  5.6 5.2 
orf19.4505 ADH3 fermentation  3.5 1.6  5.8 2.4  2.0 1.4 
orf19.4450 ZCF23 regulation of transcription, DNA-dependent 3.5 3.3  3.5 8.7  22.9 2.3 
orf19.3261 ATO9 
 
3.4 3.7  1.1 2.8  2.5 2.9 
orf19.2836 
 
carbon utilization 3.4 5.9  3.7 4.3  1.6 1.5 
orf19.661 KRR1 endonucleolytic cleavage of rRNA 3.4 3.0  3.2 4.6  4.0 4.8 
orf19.7424 NSA2 maturation of rRNA)  3.4 2.8  2.1 3.1  2.6 4.0 
orf19.6109 TUP1 filamentous growth  3.4 3.2  3.1 3.1  4.2 2.1 
orf19.2504 BMS1 ribosome assembly  3.4 4.1  2.1 3.2  2.8 3.2 
orf19.3646 CTR1 high-affinity iron ion transport  3.4 9.1  3.1 4.9  10.9 10.4 
orf19.3606 
  
3.4 3.2  2.1 3.7  2.8 2.3 
orf19.2832 INN1 chromosome organization  3.4 3.9  2.9 3.7  10.3 10.2 
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orf19.7298 CHS2 cell wall chitin biosynthetic process  3.4 4.0  4.9 7.1  10.5 3.5 
orf19.6589 
 
regulation of cell size  3.4 4.5  3.8 6.6  1.6 3.7 
orf19.1646 
 
endonucleolytic cleavage of rRNA 3.4 3.1  1.8 2.8  2.8 5.4 
orf19.1424 
 
oxalate transport 3.4 4.7  2.5 3.2  4.7 2.5 
orf19.3815 
 
ubiquitin-dependent protein catabolic process 3.3 4.2  3.2 4.3  9.2 6.2 
orf19.1481 HAP42 regulation of transcription, DNA-dependent 3.3 4.1  3.8 6.0  2.7 2.0 
orf19.5604 MDR1 multidrug transport 3.3 1.7  9.7 4.0  4.4 1.1 
orf19.6202 RBT4 pathogenesis  3.3 6.2  1.6 2.2  5.7 2.2 
orf19.6725 FUM12 fumarate metabolic process  3.3 6.4  3.8 6.4  5.7 2.5 
orf19.2067 
 
intracellular sequestering of iron ion  3.3 3.3  2.4 2.8  4.0 4.8 
orf19.4077 MIT1 sphingolipid biosynthetic process  3.3 5.0  3.1 5.2  5.7 2.3 
orf19.431 ZCF2 regulation of transcription, DNA-dependent 3.3 4.1  2.7 3.7  4.8 2.2 
orf19.246 
  
3.3 3.3  5.6 6.6  23.7 8.2 
orf19.6313.2 MVB12 cellular response to alkalinity 3.3 1.5  3.7 4.6  0.5 1.6 
orf19.5118 SDS24 cell separation during cytokinesis  3.3 6.6  3.0 2.5  7.3 2.4 
orf19.1449 
  
3.3 2.6  5.5 8.4  15.9 39.3 
orf19.5879 
 
phosphatidic acid biosynthetic process  3.3 2.9  1.5 1.2  3.3 2.8 
orf19.5751 ORM1 response to drug  3.3 3.6  1.6 1.7  3.4 1.8 
orf19.2568 IFU5 
 
3.3 3.4  4.6 4.0  6.0 2.9 
orf19.192 
  
3.3 3.8  3.7 3.7  12.2 3.9 
orf19.5113 ADH2 NADH oxidation  3.3 9.7  11.4 16.0  23.0 10.1 
orf19.5862 AFP99 
 
3.3 2.0  2.1 2.7  13.0 10.1 
orf19.5345 
 
ER-associated protein catabolic process  3.2 3.5  2.6 2.7  4.9 3.8 
orf19.6648 SDA1 actin cytoskeleton organization  3.2 6.8  1.6 3.2  6.5 8.8 
orf19.962 
  
3.2 2.8  2.1 3.6  2.2 7.3 
orf19.5010 DIM1 rRNA modification  3.2 2.3  2.5 6.8  3.6 4.7 
orf19.6236 
 
ribosomal small subunit biogenesis 3.2 3.2  2.7 5.0  3.1 5.7 
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        Change in Fold Expression 
   
SC5314+FLC
/SC5314 
 cas5Δ/Δ+FLC
/cas5Δ/Δ 
 upc2Δ/Δ+FLC/
upc2Δ/Δ 
orf19 
Designation 
CGD 
Name Processa Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
orf19.1578 
 
endonucleolytic cleavage of rRNA 3.2 3.2  1.3 2.0  2.4 2.2 
orf19.7469 ARG1 arginine biosynthetic process  3.2 2.8  11.5 17.1  7.6 5.7 
orf19.4391 
  
3.2 1.5  3.9 7.0  1.0 0.7 
orf19.2831 RPC31  tRNA transcription from RNA polymerase III promoter 3.2 13.3  2.9 2.4  2.4 3.9 
orf19.4883 
 
signal transduction 3.2 3.5  4.4 4.6  22.5 12.4 
orf19.7219 FTR1 high-affinity iron ion transport 3.2 7.8  0.5 1.1  0.1 0.0 
orf19.4492 
 
nuclear division  3.2 3.6  2.3 3.7  1.5 3.1 
orf19.2712  HCA4 rRNA processing 3.2 3.3  4.1 3.7  3.2 5.1 
orf19.4031 
 
carbohydrate metabolic process 3.2 4.0  2.0 2.9  2.9 1.7 
orf19.4979 KNS1 protein amino acid phosphorylation  3.2 3.3  2.2 3.2  22.9 19.0 
orf19.857 FMO2 oxidation-reduction process 3.1 2.6  3.5 4.9  4.8 3.2 
orf19.4015 CAG1 cellular morphogenesis during conjugation with cellular fusion  3.1 3.6  0.8 0.7  4.4 3.3 
orf19.3984 
  
3.1 6.2  5.6 6.0  8.0 5.6 
orf19.1642 
 
endonucleolytic cleavage of rRNA 3.1 2.6  6.4 3.4  3.3 5.9 
orf19.2785 ATP7 ATP synthesis coupled proton transport  3.1 3.1  2.0 2.6  1.3 1.5 
orf19.4593 RGA2 hyphal growth  3.1 4.2  2.9 4.9  5.7 3.3 
orf19.2414 
  
3.1 3.3  1.1 0.6  0.7 1.7 
orf19.414 
 
translation 3.1 3.0  4.9 12.3  1.6 4.8 
orf19.6678 
  
3.1 5.1  1.2 1.4  3.4 3.1 
orf19.296 
  
3.1 1.7  1.5 0.9  1.2 1.0 
orf19.2943 
 
amino acid transport  3.1 4.6  2.3 3.4  6.4 2.3 
orf19.3910 
  
3.1 2.6  1.1 0.9  7.6 5.3 
orf19.1719 SGA1 glycogen catabolic process  3.1 2.5  3.7 3.3  4.0 1.5 
orf19.3813 
  
3.1 3.1  1.4 1.8  6.3 3.4 
orf19.6248 
  
3.1 12.1  0.7 1.2  25.0 3.1 
orf19.113 CIP1 response to oxidative stress 3.0 3.7  10.2 5.3  11.2 6.5 
orf19.6126 KGD2 2-oxoglutarate metabolic process  3.0 4.0  3.5 5.1  4.3 2.9 
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        Change in Fold Expression 
   
SC5314+FLC
/SC5314 
 cas5Δ/Δ+FLC
/cas5Δ/Δ 
 upc2Δ/Δ+FLC/
upc2Δ/Δ 
orf19 
Designation 
CGD 
Name Processa Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
orf19.5799 
  
3.0 2.5  13.8 11.3  6.7 1.8 
orf19.6348 
 
ubiquitin-dependent protein catabolic process 3.0 2.4  1.3 1.4  0.6 1.2 
orf19.4191 RLP24 ribosomal large subunit biogenesis 3.0 3.6  1.9 3.0  1.2 4.9 
orf19.288 MET13 methionine metabolic process  3.0 4.3  3.0 4.2  4.0 1.9 
orf19.7380 
  
3.0 3.2  1.8 2.5  1.6 1.3 
orf19.3707 YHB1 nitric oxide catabolic process  3.0 2.8  0.9 0.6  1.3 2.0 
orf19.1980 GIT4 phospholipid transport  3.0 2.1  1.5 1.8  3.4 3.1 
orf19.24 RTA2 lipid translocation  3.0 5.5  9.4 11.1  2.0 1.1 
orf19.872 
  
3.0 2.0  2.1 4.1  3.6 2.4 
orf19.3540 MAK5 rRNA processing  3.0 2.9  1.9 3.4  3.5 4.1 
orf19.515 
  
3.0 2.2  2.9 5.3  4.8 16.5 
orf19.3544 
 
oxidation-reduction process 3.0 3.2  2.5 2.6  7.2 4.7 
orf19.4183 MUC1 
 
3.0 3.5  4.8 3.6  9.9 3.1 
orf19.3762 
  
2.9 1.8  1.4 1.3  1.6 4.5 
orf19.2905 
  
2.9 3.2  2.9 2.3  11.9 14.5 
orf19.2386 
 
endonucleolytic cleavage of rRNA 2.9 1.7  3.0 4.9  2.9 6.4 
orf19.5169 
  
2.9 2.2  9.5 9.7  2.9 2.0 
orf19.4793 
  
2.9 2.0  1.5 2.9  2.6 2.3 
orf19.1369 
 
metabolic process 2.9 2.3  1.2 1.0  4.1 3.5 
orf19.3661 
 
protein deubiquitination 2.9 3.0  2.4 2.3  4.1 1.9 
orf19.5026 
 
regulation of transcription, DNA-dependent 2.9 3.2  5.1 10.3  7.0 2.6 
orf19.2185 NSA1 ribosomal large subunit biogenesis  2.9 2.6  1.8 3.1  1.1 4.0 
orf19.7547 
 
protein ubiquitination  2.9 3.0  1.1 1.4  3.9 2.6 
orf19.2167 
 
ribosomal large subunit biogenesis 2.9 1.8  2.9 4.8  1.6 3.2 
orf19.1774 
 
oxidation-reduction process 2.9 2.7  3.2 6.0  17.3 2.3 
orf19.6758 
 
response to salt stress  2.9 1.9  3.7 2.6  2.9 2.8 
orf19.4510 IFA4 
 
2.9 3.7  2.2 2.2  2.5 2.7 
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        Change in Fold Expression 
   
SC5314+FLC
/SC5314 
 cas5Δ/Δ+FLC
/cas5Δ/Δ 
 upc2Δ/Δ+FLC/
upc2Δ/Δ 
orf19 
Designation 
CGD 
Name Processa Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
orf19.376 
  
2.9 3.4  1.1 1.5  7.6 5.5 
orf19.35 
 
protein phosphorylation 2.9 3.3  2.3 2.9  1.9 1.6 
orf19.3736 KAR4 G1 phase of mitotic cell cycle  2.8 2.6  1.2 1.0  2.6 1.5 
orf19.2752 ADR1 filamentous growth  2.8 4.4  5.5 11.9  8.2 3.9 
orf19.4043 
 
response to stress  2.8 4.5  1.6 1.7  5.4 3.0 
orf19.3756 CHR1 nuclear mRNA splicing, via spliceosome  2.8 3.1  3.2 3.5  2.0 3.7 
orf19.5295 
  
2.8 1.8  2.1 2.0  22.1 16.6 
orf19.4657 
 
regulation of lipid biosynthetic process  2.8 2.2  3.5 6.1  1.4 0.6 
orf19.7229 IML2 
 
2.8 3.3  1.4 1.4  3.8 1.9 
orf19.4479 
 
endonucleolytic cleavage of rRNA 2.8 2.7  1.7 3.8  2.5 4.0 
orf19.4383 
 
response to DNA damage stimulus 2.8 2.6  0.9 0.8  1.4 2.2 
orf19.3848 
  
2.8 1.8  1.8 4.3  1.6 1.1 
orf19.4211 FET3 high-affinity iron ion transport 2.8 6.2  1.6 1.7  0.7 0.2 
orf19.287 
  
2.8 2.9  1.7 2.3  1.4 1.5 
orf19.3240 ERG27 ergosterol biosynthetic process  2.8 2.4  2.3 2.8  1.4 1.1 
orf19.2285 
 
response to drug  2.8 1.5  5.0 2.8  2.9 83.5 
orf19.5547 
  
2.8 2.4  2.0 1.8  0.8 1.1 
orf19.7520 POT1 fatty acid beta-oxidation  2.8 2.3  4.8 6.9  3.6 5.1 
orf19.1388 
 
ribosomal large subunit biogenesis  2.8 2.1  2.7 5.2  1.3 6.9 
orf19.4255 ECM331 
 
2.7 5.7  5.4 5.7  5.0 1.5 
orf19.1411 
 
oxidation-reduction process 2.7 4.8  1.1 0.9  1.4 1.1 
orf19.2154 HXK1 hyphal growth  2.7 2.8  1.4 2.2  3.1 1.6 
orf19.3015 ARX1 ribosomal large subunit biogenesis  2.7 3.9  1.3 1.7  3.7 2.8 
orf19.4887 ECM21 ubiquitin-dependent endocytosis 2.7 3.1  0.8 1.0  4.0 5.0 
orf19.3239 CTF18 double-strand break repair via homologous recombination 2.7 2.4  1.0 1.1  1.4 0.8 
orf19.4093 PES1 filamentous growth  2.7 3.5  2.3 2.3  0.6 1.3 
orf19.2344 ASR1 
 
2.7 1.7  10.9 7.9  7.1 2.5 
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        Change in Fold Expression 
   
SC5314+FLC
/SC5314 
 cas5Δ/Δ+FLC
/cas5Δ/Δ 
 upc2Δ/Δ+FLC/
upc2Δ/Δ 
orf19 
Designation 
CGD 
Name Processa Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
orf19.2458 
 
cellular response to glucose starvation 2.7 2.6  3.8 5.8  7.8 6.5 
orf19.1714 PGA44 
 
2.7 2.3  1.6 0.8  201.7 19.2 
orf19.183 HIS3 histidine biosynthetic process  2.7 1.7  4.7 4.1  8.4 7.4 
orf19.419 
  
2.7 6.4  4.7 3.5  30.5 8.7 
orf19.2319 
 
rRNA processing 2.7 2.3  2.5 3.3  1.5 2.0 
orf19.5991 
 
ribosomal large subunit assembly  2.7 4.4  2.7 3.7  6.1 7.5 
orf19.6674 BTS1 terpenoid biosynthetic process  2.7 2.1  1.3 1.4  3.3 2.3 
orf19.4346 
 
COPII vesicle coating 2.7 2.7  1.9 2.3  1.7 1.0 
orf19.1809 FOX2 fatty acid beta-oxidation  2.7 4.0  6.8 7.7  6.0 5.7 
orf19.6608 
  
2.7 4.7  1.5 1.3  5.8 9.0 
orf19.2090 
 
maturation of SSU-rRNA 2.7 3.3  1.8 2.9  2.8 4.4 
orf19.2768 AMS1 oligosaccharide catabolic process  2.7 3.9  2.1 1.5  2.9 2.7 
orf19.5251 ZCF30 regulation of transcription from RNA polymerase II promoter  2.7 3.1  3.0 4.0  4.6 3.1 
orf19.4961 STP2 amino acid import  2.7 3.2  1.6 2.4  2.8 1.9 
orf19.4531 
 
transport  2.7 4.4  5.5 12.3  1.5 0.6 
orf19.4204 
  
2.6 2.2  4.1 4.5  0.8 1.6 
orf19.6955 HBR3 maturation of rRNA 2.6 2.3  2.3 4.3  6.8 6.4 
orf19.2710 
 
chromosome segregation  2.6 1.8  1.0 0.9  1.0 2.5 
orf19.6941 
 
lipid storage  2.6 3.6  2.8 2.8  7.2 6.1 
orf19.6659 GAP6 amino acid transport 2.6 3.0  1.4 1.7  2.1 1.8 
orf19.6830 
 
metabolic process 2.6 2.7  4.4 6.5  8.9 5.3 
orf19.921 HMS1 filamentous growth 2.6 2.8  2.0 2.6  0.8 1.3 
orf19.517 HAP31 regulation of carbohydrate metabolic process  2.6 1.5  2.6 4.8  2.9 3.8 
orf19.4114 FAA2-1 lipid metabolic process  2.6 2.4  3.5 3.5  6.9 6.4 
orf19.6843 
 
mitotic sister chromatid segregation 2.6 3.0  2.7 3.1  9.2 10.1 
orf19.1596 FGR28 filamentous growth 2.6 2.9  1.3 1.8  1.8 1.9 
orf19.4013 
  
2.6 2.2  0.6 0.6  0.3 0.4 
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        Change in Fold Expression 
   
SC5314+FLC
/SC5314 
 cas5Δ/Δ+FLC
/cas5Δ/Δ 
 upc2Δ/Δ+FLC/
upc2Δ/Δ 
orf19 
Designation 
CGD 
Name Processa Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
orf19.3512 
 
cell wall organization 2.6 2.8  0.9 1.2  8.0 6.6 
orf19.3865 RFX1 negative regulation of transcription from RNA pol II promoter  2.6 2.6  6.5 5.9  21.5 9.7 
orf19.7456 
  
2.6 2.6  3.6 4.9  2.2 0.6 
orf19.2942 DIP5 amino acid transport  2.6 2.5  1.8 2.8  3.6 2.0 
orf19.2432 HAC1 cell wall organization  2.6 4.3  2.5 2.8  13.2 5.4 
orf19.4731 
 
intra-Golgi vesicle-mediated transport  2.6 2.6  2.0 2.4  1.2 1.5 
orf19.5299 ECM1 cell wall organization  2.6 4.8  2.7 3.5  1.5 5.3 
orf19.7398 
 
ribosomal large subunit biogenesis  2.6 2.4  2.4 3.9  3.0 3.8 
orf19.3021 
  
2.6 2.0  1.2 0.9  2.4 2.2 
orf19.809 
 
maturation of rRNA 2.6 1.8  2.2 3.4  2.9 7.1 
orf19.5710 
 
NLS-bearing substrate import into nucleus  2.6 3.2  4.0 2.3  3.5 2.2 
orf19.5876 
  
2.6 2.3  1.8 1.6  7.3 7.1 
orf19.5459 
 
mRNA polyadenylation  2.6 2.3  4.2 4.3  3.9 2.3 
orf19.3080 
 
mitotic sister chromatid cohesion  2.6 2.9  4.7 4.8  11.8 4.9 
orf19.996 
 
filamentous growth 2.6 3.3  3.5 3.5  7.0 4.3 
orf19.6143 
 
oxidation-reduction process 2.6 2.6  3.6 3.4  11.5 6.8 
orf19.6999 
 
oxidation-reduction process 2.6 1.7  2.2 2.6  4.0 1.4 
orf19.496 
 
mismatch repair  2.6 2.3  1.6 2.3  1.1 0.6 
orf19.2059 
  
2.6 2.3  0.2 0.3  2.3 17.6 
orf19.1867 
 
malate transport 2.6 4.2  0.7 0.6  15.1 62.1 
orf19.3737 
  
2.5 2.4  4.6 5.7  8.0 4.1 
orf19.1865 
 
reciprocal meiotic recombination  2.5 2.7  2.0 2.8  3.3 1.5 
orf19.6605 
  
2.5 2.1  3.8 4.1  5.7 4.4 
orf19.281 
  
2.5 2.2  1.5 1.9  3.8 3.2 
orf19.5145 SSP96 oxidation-reduction process 2.5 1.7  1.2 2.6  18.0 9.3 
orf19.6322 ARD fatty acid catabolic process  2.5 2.8  2.7 2.9  3.7 4.7 
orf19.5963 
 
protein amino acid glycosylation  2.5 2.7  2.4 4.4  2.1 1.0 
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        Change in Fold Expression 
   
SC5314+FLC
/SC5314 
 cas5Δ/Δ+FLC
/cas5Δ/Δ 
 upc2Δ/Δ+FLC/
upc2Δ/Δ 
orf19 
Designation 
CGD 
Name Processa Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
orf19.4507 
  
2.5 2.3  1.7 1.3  2.5 2.3 
orf19.2350 
 
filamentous growth  2.5 4.1  0.6 1.0  0.9 0.6 
orf19.2978 
  
2.5 1.7  4.5 5.9  1.1 1.3 
orf19.2398 
  
2.5 3.8  1.3 1.7  4.5 3.0 
orf19.5023 DAL7 anion transport  2.5 4.2  3.9 4.0  6.2 5.5 
orf19.4870 DBP3 rRNA processing  2.5 3.1  1.1 2.4  2.0 3.8 
orf19.278 
  
2.5 2.7  1.4 1.5  2.2 1.9 
orf19.7267 SAM35 mitochondrion organization 2.5 2.1  2.0 2.3  5.2 3.1 
orf19.1625 
  
2.5 2.6  2.4 3.2  1.6 2.0 
orf19.2772 HOS3 histone deacetylation  2.5 2.6  2.2 2.2  1.4 1.1 
orf19.6102 RCA1 DNA metabolic process  2.5 3.4  1.2 1.2  1.1 1.4 
orf19.4495 NDH51 biofilm formation  2.5 3.3  2.4 3.4  2.7 1.6 
orf19.3008 COQ4 ubiquinone biosynthetic process  2.5 1.8  1.6 1.7  0.4 0.8 
orf19.6997 ATO5 cellular response to alkalinity 2.5 2.6  0.8 0.7  2.7 2.9 
orf19.4264 
  
2.5 3.2  1.2 1.0  0.8 3.2 
orf19.7115 SAC7 actin filament reorganization during cell cycle  2.5 3.5  8.6 7.9  6.9 3.1 
orf19.4590 RFX2 adhesion to host  2.5 4.5  1.5 3.3  23.4 8.1 
orf19.93 
 
development of symbiont in host 2.5 2.4  2.4 2.8  1.8 2.5 
orf19.6057 
 
pantothenate biosynthetic process  2.5 1.8  0.9 1.0  0.2 0.2 
orf19.4477 CSH1 biofilm formation  2.5 2.3  2.2 2.1  3.9 2.3 
orf19.5938 SEN1 rRNA processing  2.5 5.2  1.5 2.5  8.0 1.9 
orf19.2066.1 ATP18 ATP synthesis coupled proton transport 2.5 2.3  2.0 2.6  2.5 2.8 
orf19.6709 
  
2.5 2.6  3.1 2.8  7.3 4.8 
orf19.7650 LTV1 response to osmotic stress 2.5 2.9  1.7 2.4  1.8 3.1 
orf19.203 STB3 positive regulation of transcription from RNA polymerase II  2.5 3.6  3.5 2.9  7.0 3.1 
orf19.2838 
 
 response to drug  2.5 2.9  0.8 0.7  1.6 0.9 
orf19.7154 UTP18 endonucleolytic cleavage of rRNA 2.4 1.5  1.6 3.1  2.1 2.9 
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SC5314+FLC
/SC5314 
 cas5Δ/Δ+FLC
/cas5Δ/Δ 
 upc2Δ/Δ+FLC/
upc2Δ/Δ 
orf19 
Designation 
CGD 
Name Processa Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
orf19.6003 
 
intracellular signal transduction 2.4 2.1  1.9 2.5  0.9 0.7 
orf19.2909 ERG26 ergosterol biosynthetic process 2.4 1.7  0.9 0.9  0.7 1.0 
orf19.3734 GEF2 transmembrane transport 2.4 4.0  1.5 1.6  10.1 4.1 
orf19.3867 RPL7 exonucleolytic trimming of rRNA 2.4 2.0  1.3 2.9  1.2 2.7 
orf19.5588 PGA60 
 
2.4 3.3  1.3 1.9  3.1 1.3 
orf19.2887 
  
2.4 2.7  3.6 4.2  5.8 2.2 
orf19.2954 
  
2.4 2.9  1.5 2.1  1.8 1.7 
orf19.6062.3 
 
cristae formation 2.4 2.9  2.7 2.9  3.2 2.5 
orf19.7610 PTP3 osmosensory signaling pathway 2.4 2.5  3.3 3.3  2.7 1.4 
orf19.2707.1 QCR9 iron-sulfur cluster assembly  2.4 2.1  1.3 4.5  0.7 1.3 
orf19.2190 VRP1 actin cortical patch localization  2.4 2.4  3.5 5.1  3.1 2.0 
orf19.2623 ECM22 sterol biosynthetic processs 2.4 4.0  1.8 2.3  4.1 1.9 
orf19.3298 CCH1 calcium ion transport  2.4 3.5  2.0 1.6  7.6 3.2 
orf19.5752 
 
ubiquitin-dependent protein catabolic process 2.4 1.8  1.5 1.4  2.7 2.5 
orf19.6790 
 
mRNA splice site selection 2.4 3.0  3.5 5.5  7.1 1.3 
orf19.5591 ADO1 purine base metabolic process 2.4 2.9  1.1 1.5  0.7 0.8 
orf19.6905 
  
2.4 3.3  0.5 0.4  1.2 1.4 
orf19.804 
 
transport 2.4 1.6  1.6 2.1  2.3 3.4 
orf19.4522 
 
response to drug  2.4 1.8  1.7 2.3  3.2 3.7 
orf19.7680 CTA26 positive regulation of transcription, DNA-dependent 2.4 2.4  3.0 4.3  3.2 8.3 
orf19.2459 
  
2.4 3.0  1.9 2.5  2.9 2.2 
orf19.4191.1 
 
protein polyubiquitination 2.4 2.0  2.2 1.6  2.0 1.9 
orf19.5368 
 
ER-associated protein catabolic process 2.4 1.8  3.6 4.3  4.1 2.0 
orf19.1949 VPS1 biofilm formation  2.4 2.6  3.4 2.8  5.6 2.4 
orf19.3705 PTC6 protein amino acid dephosphorylation  2.4 2.5  1.7 1.9  2.1 1.7 
orf19.3109 
  
2.4 2.9  0.9 1.6  7.8 3.2 
orf19.6043 
 
aerobic respiration  2.4 2.2  3.1 2.8  4.7 2.6 
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SC5314+FLC
/SC5314 
 cas5Δ/Δ+FLC
/cas5Δ/Δ 
 upc2Δ/Δ+FLC/
upc2Δ/Δ 
orf19 
Designation 
CGD 
Name Processa Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
orf19.7281 PDK2 response to drug  2.4 2.0  4.3 3.9  1.9 1.6 
orf19.3276 PWP2 cytokinesis  2.4 3.8  1.4 2.4  3.7 2.6 
orf19.6514 CUP9 cellular copper ion homeostasis  2.4 2.3  2.4 3.1  4.9 2.2 
orf19.3974 PUT2 glutamate biosynthetic process  2.4 3.4  3.0 3.3  3.1 1.2 
orf19.6638 PTC4 protein dephosphorylation 2.4 2.1  1.2 2.1  0.9 1.2 
orf19.6690 
  
2.4 2.3  0.7 0.6  0.6 0.7 
orf19.6417 TSR1 rRNA processing  2.4 3.6  1.5 3.5  5.2 3.1 
orf19.4897 
 
phospholipid transport  2.4 2.4  1.3 1.2  1.0 1.4 
orf19.1307 
  
2.4 2.4  2.0 1.7  8.5 6.1 
orf19.4144 
  
2.4 3.2  1.2 1.6  0.9 0.9 
orf19.147 YAK1 filamentous growth  2.4 2.4  1.2 2.0  2.3 1.7 
orf19.501 
 
rRNA processing 2.4 3.3  1.0 1.4  3.2 2.3 
orf19.6548 ISU1 cellular iron ion homeostasis  2.4 2.1  4.8 6.5  7.7 5.8 
orf19.5282 
  
2.4 2.7  0.5 0.4  1.9 5.4 
orf19.7578 
 
ER to Golgi vesicle-mediated transport 2.3 2.5  1.8 2.1  3.2 3.2 
orf19.1546 
  
2.3 1.5  1.8 1.5  0.4 0.9 
orf19.6842 TUS1 fungal-type cell wall organization 2.3 3.0  1.6 1.6  3.8 2.6 
orf19.4815 YTM1 filamentous growth 2.3 3.2  0.6 1.4  3.2 2.8 
orf19.3135 
 
ER-associated protein catabolic process  2.3 2.6  1.2 1.1  1.7 1.6 
orf19.2938 
 
mitochondrial respiratory chain complex III assembly 2.3 1.7  1.8 2.7  1.7 1.2 
orf19.5961 
 
proteasome regulatory particle assembly 2.3 2.0  1.3 1.2  1.7 3.1 
orf19.2423 ZCF11 filamentous growth  2.3 2.1  2.5 3.8  2.1 1.9 
orf19.6557 
  
2.3 2.1  1.4 1.4  1.7 2.1 
orf19.2527 
 
single-species biofilm formation on inanimate substrate 2.3 2.3  1.7 3.0  3.0 4.8 
orf19.2876 CBF1 chromosome segregation 2.3 3.2  0.5 0.5  0.4 2.0 
orf19.6953 IRS4 fungal-type cell wall organization  2.3 2.0  4.5 5.7  14.3 7.6 
orf19.7247 RIM101 cellular response to iron ion starvation 2.3 3.4  4.7 6.9  10.1 6.0 
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CGD 
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Exp1 Exp2 
orf19.3746 IFC1 oligopeptide transport  2.3 2.7  1.3 0.6  0.2 0.0 
orf19.6376 PTC5 protein amino acid dephosphorylation  2.3 3.6  2.4 2.9  3.3 2.0 
orf19.2210 
  
2.3 4.3  1.0 1.9  8.0 3.8 
orf19.3169 
 
establishment of mitotic sister chromatid cohesion  2.3 2.2  1.5 1.5  2.6 3.2 
orf19.6938 MEU1 glutamate biosynthetic process  2.3 2.3  1.8 2.8  2.7 1.4 
orf19.6971 DIE2 protein amino acid N-linked glycosylation 2.3 2.1  1.2 1.4  1.7 1.3 
orf19.6026 ERG2 ergosterol biosynthetic process  2.3 1.5  2.6 4.7  1.3 0.4 
orf19.1557 
 
protein methylation 2.3 2.0  1.1 1.1  2.5 3.0 
orf19.1939 
  
2.3 1.6  0.6 0.8  3.3 1.9 
orf19.5552 
 
regulation of transcription from RNA polymerase II promoter 2.3 3.7  1.7 1.8  3.5 2.7 
orf19.345 
 
response to oxidative stress 2.3 1.9  5.6 4.8  1.3 1.4 
orf19.951 
  
2.3 2.4  0.4 0.4  0.8 1.2 
orf19.5713 YMX6 glucose catabolic process to ethanol  2.3 1.8  1.8 1.6  2.2 1.8 
orf19.5611 
 
ergosterol metabolic process  2.3 1.5  12.7 8.9  4.9 10.2 
orf19.2917 
 
rRNA processing  2.3 2.3  1.3 2.9  4.0 3.2 
orf19.3921 
  
2.3 2.1  1.2 1.6  1.8 2.0 
orf19.6624 
 
regulation of Rab GTPase activity 2.3 2.2  3.0 5.8  2.9 2.3 
orf19.2962 
  
2.3 2.2  0.7 0.8  33.6 13.7 
orf19.1531 
 
mRNA cleavage  2.3 1.8  1.1 1.5  2.2 2.0 
orf19.3726 
  
2.3 2.2  1.6 2.6  1.6 1.7 
orf19.7550 IFA14 
 
2.3 1.7  1.0 0.7  4.0 9.6 
orf19.5644 
 
ascospore wall assembly 2.3 3.5  1.1 1.0  2.7 1.9 
orf19.6385 ACO1 citrate metabolic process  2.3 2.7  1.9 2.6  2.4 1.4 
orf19.2079 PHHB filamentous growth  2.3 2.9  1.3 1.3  1.8 5.7 
orf19.2030 
  
2.3 2.3  2.9 2.7  4.7 2.8 
orf19.3732 ERG25 ergosterol biosynthetic process 2.3 1.5  4.4 6.5  7.9 2.4 
orf19.4411 HOS1 chromatin organization  2.3 2.2  1.6 1.7  3.0 2.7 
 133 
Table A-1. (Continued) 
     
 
  
 
        Change in Fold Expression 
   
SC5314+FLC
/SC5314 
 cas5Δ/Δ+FLC
/cas5Δ/Δ 
 upc2Δ/Δ+FLC/
upc2Δ/Δ 
orf19 
Designation 
CGD 
Name Processa Exp1 Exp2 
 
Exp1 Exp2 
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orf19.415 
 
cristae formation 2.2 2.3  1.7 2.1  1.2 1.0 
orf19.6411 
 
phospholipid metabolic process  2.2 2.8  1.7 1.3  2.3 1.6 
orf19.1839 RPA190 transcription from RNA polymerase I promoter 2.2 4.6  1.3 2.2  2.9 1.8 
orf19.3675 GAL7 galactose catabolic process via UDP-galactose  2.2 1.9  2.0 1.8  2.0 0.9 
orf19.899 
  
2.2 1.9  1.8 1.9  4.2 3.2 
orf19.2003 HNM1 choline transport  2.2 1.9  2.5 3.8  7.1 1.7 
orf19.706 NMD3 ribosomal large subunit assembly  2.2 3.1  1.8 3.3  4.7 3.3 
orf19.5131 
 
negative regulation of gluconeogenesis  2.2 2.5  1.5 1.0  2.8 2.9 
orf19.6578 
 
phosphate transport  2.2 3.1  3.5 3.0  2.0 0.9 
orf19.3150 GRE2 response to osmotic stress  2.2 1.6  3.9 2.9  2.4 2.5 
orf19.7011 
 
maturation of SSU-rRNA  2.2 4.7  1.1 2.3  4.8 3.9 
orf19.944 IFG3 oxidation-reduction process 2.2 2.6  4.0 4.4  5.1 2.6 
orf19.6713 
  
2.2 3.7  2.7 2.5  0.9 0.3 
orf19.6229 CAT1 hyphal growth  2.2 1.5  5.5 6.1  4.9 2.2 
orf19.4970 
  
2.2 4.9  2.5 1.6  228.3 47.3 
orf19.7513 ALK2 oxidation-reduction process 2.2 3.5  4.5 6.4  40.9 20.2 
orf19.4584 PHO114 phosphate metabolic process  2.2 1.5  2.3 2.1  2.4 1.9 
orf19.2204.2 
 
cell wall organization  2.2 2.6  1.4 1.5  2.8 1.8 
orf19.3444 
 
drug transport 2.2 3.3  1.6 1.2  2.2 3.1 
orf19.2575 
  
2.2 2.3  1.1 1.9  2.0 2.5 
orf19.4795 
  
2.2 2.6  3.4 4.8  11.5 5.1 
orf19.3724 
 
endonucleolytic cleavage of rRNA 2.2 1.7  3.0 4.0  1.4 2.7 
orf19.7320 LIP7 lipid catabolic process  2.2 2.5  3.6 3.8  16.6 9.0 
orf19.669 PRM1 plasma membrane fusion during cytogamy  2.2 2.8  0.6 0.4  1.2 3.2 
orf19.3245 
  
2.2 2.3  1.2 1.1  2.5 1.6 
orf19.7472 IFF4 cell-substrate adhesion 2.2 2.3  1.6 1.7  4.3 2.2 
orf19.318  
 
iron-sulfur cluster assembly 2.2 2.0  2.9 4.5  2.0 1.6 
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orf19.2781 
 
protein amino acid phosphorylation  2.2 2.1  4.6 2.5  27.0 4.6 
orf19.7546 
 
maturation of rRNA)  2.2 1.5  2.8 5.3  8.7 5.0 
orf19.4591 CAT2 acetyl-CoA metabolic process 2.2 2.6  4.3 6.5  5.2 2.8 
orf19.188 
  
2.2 2.0  6.1 4.8  0.9 1.7 
orf19.5640 PEX5 fatty acid beta-oxidation  2.2 2.6  0.9 0.9  2.2 2.3 
orf19.7618 
 
endonucleolytic cleavageof rRNA 2.2 1.6  1.3 3.1  9.9 7.4 
orf19.6956 DAL9 anion transport  2.2 2.5  1.6 1.8  1.6 1.3 
orf19.2091 
 
oxidation-reduction process 2.2 2.3  1.9 3.4  0.8 0.9 
orf19.732 
 
fatty acid catabolic process  2.2 2.2  2.4 4.1  14.2 21.9 
orf19.2726 
 
actin cytoskeleton organization 2.2 1.5  6.0 5.0  7.2 3.7 
orf19.1902 NOC4 endonucleolytic cleavage of rRNA 2.2 1.9  1.6 3.0  2.1 4.3 
orf19.1701 RIK1 pyridoxine biosynthetic process  2.2 1.5  4.4 4.6  6.5 3.6 
orf19.3863 
  
2.2 28.3  6.2 35.3  157.2 36.4 
orf19.7359 CRZ1 calcium-mediated signaling  2.1 3.3  3.3 6.4  5.9 2.6 
orf19.3885 
 
metabolic process 2.1 2.2  4.3 8.3  75.7 17.7 
orf19.6594 PLB3 phosphatidylserine catabolic process  2.1 3.4  1.1 0.9  3.4 2.8 
orf19.7204 
 
oxidation-reduction process 2.1 2.5  2.1 2.3  3.3 4.3 
orf19.5610 ARG3 arginine biosynthetic process  2.1 1.7  4.2 5.2  2.0 1.3 
orf19.2175 
 
positive regulation of apoptosis  2.1 2.7  1.8 1.4  1.4 2.3 
orf19.6706 GYP7 vesicle-mediated transport  2.1 2.4  1.9 1.8  3.0 2.3 
orf19.2176 IFM3 oxidation-reduction process 2.1 1.8  1.7 2.1  3.6 3.6 
orf19.3621 
  
2.1 3.5  1.3 0.7  3.7 3.1 
orf19.5426 
 
cell budding 2.1 2.5  2.3 2.4  5.9 4.3 
orf19.7061 
 
metabolic process 2.1 1.7  1.2 1.3  1.0 2.1 
orf19.4012 PCL5 filamentous growth 2.1 6.0  3.4 3.2  13.1 7.5 
orf19.5198 NOP4 rRNA processing  2.1 1.8  2.0 3.1  1.1 3.5 
orf19.5601 
  
2.1 2.0  2.5 2.2  1.6 2.6 
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orf19.1682 
  
2.1 3.0  1.7 2.1  1.5 1.3 
orf19.4229 
 
diadenosine polyphosphate catabolic process  2.1 2.0  3.0 2.9  3.3 4.4 
orf19.2062 SOD4 evasion or tolerance 2.1 3.2  3.3 3.6  3.6 4.9 
orf19.1440 
  
2.1 2.6  1.7 2.4  0.8 0.9 
orf19.7517 CHT1 cytokinesis, completion of separation  2.1 2.5  1.8 1.5  14.0 3.4 
orf19.6811 
 
iron ion transport  2.1 1.8  2.0 1.9  3.1 1.9 
orf19.4982 
 
lipid metabolic process  2.1 2.3  0.9 0.6  0.7 0.8 
orf19.2192 GDH2 nitrogen compound metabolic process  2.1 1.9  1.5 2.6  2.4 1.1 
orf19.3154 
  
2.1 2.3  2.0 3.3  0.6 0.6 
orf19.692 
  
2.1 1.9  1.6 1.9  3.2 4.2 
orf19.5958 CDR2 drug export  2.1 2.5  0.9 1.0  2.5 1.7 
orf19.6983 
  
2.1 9.1  1.0 1.3  0.4 0.0 
orf19.124 CIC1 protein catabolic process  2.1 2.0  1.5 3.8  1.7 4.2 
orf19.6132 
  
2.1 2.0  1.7 2.1  1.4 1.7 
orf19.1482 HSK3 mitotic spindle organization in nucleus 2.1 1.6  2.3 1.7  1.1 1.3 
orf19.1300 
 
filamentous growth 2.1 1.8  2.1 2.3  0.3 0.6 
orf19.4090 
 
fucose transport  2.1 1.7  1.1 0.8  3.8 4.5 
orf19.5845 RNR3 DNA replication  2.1 2.7  4.5 5.3  1.4 1.2 
orf19.4278 
 
negative regulation of transcription from RNA pol II promoter 2.1 2.3  1.8 1.8  2.4 1.9 
orf19.6902 DBP7 ribosomal large subunit assembly  2.1 2.0  1.0 2.0  9.9 10.3 
orf19.6139 FRE7 siderophore-iron transport 2.1 4.9  9.5 7.8  37.7 25.9 
orf19.2825 
 
iron-sulfur cluster assembly 2.1 1.5  2.1 1.9  1.5 2.2 
orf19.4862 
 
vesicle-mediated transport 2.1 1.6  1.5 1.8  3.9 2.1 
orf19.5089 TERT telomere capping  2.1 2.3  1.8 1.6  3.1 1.4 
orf19.272 FAA21 lipid metabolic process 2.1 3.0  6.6 8.3  11.5 7.4 
orf19.1549 
  
2.1 1.8  2.0 3.0  1.1 1.6 
orf19.4215 FET34 high-affinity iron ion transport  2.1 5.2  0.2 0.5  0.0 0.1 
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orf19.5924 ZCF31 cellular response to drug 2.1 2.3  1.8 1.9  2.5 2.0 
orf19.1426 
  
2.1 2.8  2.5 3.5  2.6 1.0 
orf19.6517 RAD14 nucleotide-excision repair, DNA damage recognition 2.1 1.7  2.7 3.2  2.8 2.6 
orf19.26 
 
misfolded or incompletely synthesized protein catabolic process  2.1 2.0  1.5 1.8  1.8 2.1 
orf19.5492 
 
nuclear mRNA splicing, via spliceosome 2.1 1.9  2.2 3.9  1.5 3.2 
orf19.396 EAF6 histone acetylation  2.1 1.5  1.3 1.2  0.7 1.4 
orf19.3611 
  
2.1 2.2  2.1 3.1  1.1 1.4 
orf19.7512 
 
oxidation-reduction process 2.1 1.8  1.5 1.6  5.2 3.0 
orf19.500 
 
tRNA methylation  2.1 2.3  1.5 2.6  2.9 2.6 
orf19.2202 
  
2.1 1.8  5.5 6.4  15.1 10.1 
orf19.1813 FLC2 heme transport 2.1 1.7  2.5 3.0  7.1 1.9 
orf19.3669 SHA3 filamentous growth  2.1 2.4  1.6 2.9  4.5 2.5 
orf19.5097 CAT8 filamentous growth 2.1 1.7  3.6 4.8  8.1 4.7 
orf19.795 VPS36 hyphal growth 2.0 2.5  0.6 0.6  0.9 1.5 
orf19.7385 
  
2.0 2.4  1.3 1.7  85.7 31.9 
orf19.4975 HYR1 single-species biofilm formation in or on host organism 2.0 1.8  1.4 1.5  4.0 2.7 
orf19.5677 DUR4 urea transport  2.0 2.5  1.2 0.5  2.8 3.6 
orf19.6268 
  
2.0 1.8  1.9 2.0  1.9 1.5 
orf19.7222 PAM16 protein import into mitochondrial matrix 2.0 1.6  1.6 2.1  1.8 2.1 
orf19.7436 AAF1 cell adhesion 2.0 4.4  1.0 1.2  2.1 1.2 
orf19.6178 FBP1 gluconeogenesis  2.0 2.0  1.7 1.7  2.3 4.1 
orf19.3127 CZF1 filamentous growth  2.0 2.9  2.8 2.9  3.2 2.0 
orf19.1114 
 
mitochondrial respiratory chain complex IV assembly 2.0 1.9  2.5 3.3  3.5 3.6 
orf19.6274 PBR1 biofilm formation  2.0 1.7  1.0 2.7  2.3 1.2 
orf19.5270 
  
2.0 2.3  1.4 1.8  2.5 5.4 
orf19.2667 RPF1 maturation of rRNA 2.0 1.8  1.0 2.0  1.9 4.5 
orf19.1270 FRE3 oxidation-reduction process 2.0 1.5  1.2 1.9  48.0 7.4 
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orf19.1633 UTP4 maturation of rRNA 2.0 1.5  1.2 3.5  0.9 1.6 
orf19.4121 
 
fatty acid metabolic process  2.0 2.4  5.6 4.4  10.9 15.2 
orf19.4356 HGT3 carbohydrate transport  2.0 1.9  2.6 2.1  3.4 1.5 
orf19.1264 CFL2 cellular iron ion homeostasis  2.0 6.0  0.6 0.5  0.2 0.8 
orf19.6518 
 
oxidation-reduction process 2.0 2.6  2.9 2.3  83.1 56.9 
orf19.512 
 
ribosomal small subunit biogenesis  2.0 5.4  1.5 2.3  3.5 2.3 
orf19.3578 
  
2.0 1.5  1.7 4.1  4.1 5.8 
orf19.5824 
  
2.0 1.9  1.9 5.1  3.3 3.9 
orf19.3151 
 
cellular metabolic process 2.0 1.9  2.3 1.8  3.1 2.7 
orf19.3478 NIP7 rRNA processing  2.0 1.5  0.7 1.9  0.9 1.5 
orf19.1710 ALI1 oxidation-reduction process 2.0 1.9  1.9 2.7  0.7 0.8 
orf19.6928 SAP9 fungal-type cell wall organization  2.0 2.3  3.2 2.6  2.1 1.2 
orf19.3338 
  
2.0 4.0  3.4 5.1  5.2 13.2 
orf19.4928 SEC2 exocytosis  2.0 2.1  0.4 0.4  1.1 2.6 
orf19.2397.3 
 
filamentous growth 2.0 4.3  0.9 1.2  3.3 5.9 
orf19.7282 PEX13 protein import into peroxisome matrix  2.0 1.6  2.6 2.0  2.3 2.1 
orf19.7006 
 
reciprocal meiotic recombination 2.0 3.1  1.5 2.1  4.2 2.1 
orf19.4766 ARG81 arginine metabolic process  2.0 1.9  1.6 1.7  1.3 1.4 
orf19.1598 ERG24 ergosterol biosynthetic process  2.0 1.6  2.2 2.2  0.9 0.7 
orf19.5231.2 ATP19 ATP synthesis coupled proton transport  2.0 2.2  1.3 1.9  0.7 1.4 
orf19.5815 SCT2 phospholipid biosynthetic process 2.0 2.3  1.3 1.1  2.8 1.5 
orf19.1415 FRE10 iron ion transport  2.0 4.2  0.9 2.3  0.2 0.1 
orf19.1030 
 
meiotic recombination checkpoint  2.0 2.4  0.9 1.4  1.0 5.4 
orf19.1224 FRP3 mmonium transport  2.0 1.5  0.9 1.3  2.5 1.4 
orf19.5255 PXA2 fatty acid transport  2.0 1.5  3.3 5.6  8.9 4.3 
orf19.2622 YPT31 exocytosis  2.0 1.7  2.1 3.2  1.4 1.8 
orf19.1140 
  
2.0 1.5  1.6 2.1  1.0 1.4 
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orf19.3412 ATG15 multivesicular body membrane disassembly 2.0 2.6  0.7 1.0  3.2 2.5 
orf19.4187 
 
mitochondrial genome maintenance  2.0 1.8  1.5 1.2  3.2 4.3 
orf19.7062 RPA135 transcription from RNA polymerase I promoter 2.0 5.6  0.9 1.6  3.8 2.7 
orf19.6068 SVF1 response to oxidative stress 2.0 2.0  2.5 4.7  4.0 2.4 
orf19.73 
 
proteolysis 2.0 1.7  7.6 5.4  14.4 3.9 
orf19.2998 TSR2 maturation of rRNA 2.0 2.4  1.5 2.6  2.5 3.5 
orf19.2650 
  
2.0 1.5  1.6 2.0  1.2 1.5 
orf19.2016 
 
ergosterol biosynthetic process  2.0 2.0  1.3 1.4  1.0 1.5 
orf19.2570 MCI4 respiratory electron transport chain 2.0 1.7  1.2 2.0  1.5 2.1 
orf19.7107 
 
ribosomal large subunit biogenesis  2.0 2.2  0.6 1.2  3.2 3.3 
orf19.7261 
 
vesicle-mediated transport  2.0 2.3  1.8 1.8  2.7 1.9 
orf19.994 
  
2.0 2.7  0.7 1.3  3.4 1.7 
orf19.7316 
 
response to drug  2.0 2.3  0.7 0.8  2.6 2.2 
orf19.5491 ATP14 ATP synthesis coupled proton transport 1.9 2.3  1.3 1.8  1.3 1.6 
orf19.2005 REG1 glycogen metabolic process  1.9 2.2  2.3 3.3  3.1 1.8 
orf19.4792 
 
termination of G-protein coupled receptor signaling pathway 1.9 1.6  1.0 1.7  11.5 5.3 
orf19.3617 GTR1 chromatin silencing at telomere  1.9 2.3  1.5 1.7  1.1 3.4 
orf19.5170 ENA21 sodium ion transport  1.9 2.5  3.0 3.2  4.3 2.8 
orf19.6225.1 
 
mitochondrial respiratory chain complex IV assembly 1.9 1.9  0.9 0.7  0.7 1.6 
orf19.5006.1 
 
Golgi to plasma membrane transport 1.9 1.5  1.6 1.5  4.5 3.2 
orf19.4746 JIP5 ribosomal large subunit biogenesis 1.9 1.7  1.9 4.4  1.0 2.2 
orf19.2115 
  
1.9 2.8  0.9 1.5  4.6 1.7 
orf19.4055 
 
filamentous growth 1.9 2.5  0.9 0.7  1.9 1.4 
orf19.972 
 
DNA repair 1.9 2.9  0.8 0.6  2.1 2.4 
orf19.4014 
 
budding cell bud growth  1.9 1.6  0.8 0.8  2.5 2.6 
orf19.6881 YTH1 mRNA cleavage 1.9 2.0  0.9 0.9  0.8 1.5 
orf19.6686 ENP2 rRNA processing  1.9 1.6  3.5 6.3  9.1 8.1 
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orf19.4791 
  
1.9 1.9  1.2 1.0  4.3 3.1 
orf19.4016 
 
aerobic respiration  1.9 2.8  1.7 2.4  1.6 1.3 
orf19.1250 
 
maturation of rRNA 1.9 1.5  1.5 2.3  2.2 3.6 
orf19.6369 RIO2 maturation of rRNA 1.9 1.9  1.4 2.1  1.9 2.2 
orf19.1770 CYC1 mitochondrial electron transport, ubiquinol to cytochrome c  1.9 2.2  1.4 1.7  0.6 0.7 
orf19.4549 FGR38 filamentous growth  1.9 2.5  1.1 1.1  2.3 1.2 
orf19.4941 TYE7 positive regulation of glycolysis  1.9 1.9  1.3 1.5  1.5 1.3 
orf19.4401 YVH1 hyphal growth  1.9 1.8  1.1 2.3  2.7 3.8 
orf19.909 STP4 regulation of transcription, DNA-dependent 1.9 1.5  4.0 4.6  3.2 3.1 
orf19.1791 
 
maturation of rRNA 1.9 2.5  1.7 3.0  0.9 1.5 
orf19.2818 
 
generation of catalytic spliceosome for second transesterification step  1.9 1.6  1.8 3.4  5.2 2.6 
orf19.7150 NRG1 filamentous growth  1.9 1.8  0.8 1.3  1.4 0.7 
orf19.7034 
 
negative regulation of translation 1.9 2.1  3.3 3.7  1.5 1.1 
orf19.6185 
  
1.9 1.9  2.6 3.4  1.1 0.9 
orf19.3778 
 
ribosomal large subunit assembly  1.9 2.5  0.7 1.4  3.0 2.4 
orf19.1313 CDR3 drug export  1.9 2.1  0.9 1.0  2.4 1.7 
orf19.5553 
 
response to oxidative stress  1.9 2.3  1.3 1.8  2.3 2.4 
orf19.3241 
  
1.9 2.0  1.9 1.8  3.4 2.2 
orf19.2050 
 
sterol metabolic process  1.9 2.2  1.2 1.3  2.9 1.8 
orf19.925 SAM51 protein complex assembly 1.9 2.8  2.3 3.4  1.1 0.9 
orf19.5367 RDH54 DNmeiotic sister chromatid segregation 1.9 2.2  2.1 2.3  2.1 0.9 
orf19.151 TPO5 ployamine transport  1.9 1.9  0.9 1.1  2.8 3.3 
orf19.2984 MST1 mitochondrial threonyl-tRNA aminoacylation 1.9 2.0  1.0 1.1  0.7 1.0 
orf19.6852 
  
1.9 1.7  1.3 1.2  1.0 1.4 
orf19.2517 
 
drug transport 1.9 1.6  2.0 1.8  2.3 2.0 
orf19.4937 CHS3 cell wall chitin biosynthetic process  1.9 2.0  1.9 2.5  6.3 2.4 
orf19.753 
 
protein O-linked glycosylation 1.9 1.9  1.8 2.6  9.0 6.7 
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SC5314+FLC
/SC5314 
 cas5Δ/Δ+FLC
/cas5Δ/Δ 
 upc2Δ/Δ+FLC/
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orf19 
Designation 
CGD 
Name Processa Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
orf19.3228 
 
pseudohyphal growth 1.9 1.8  0.8 1.2  1.4 0.8 
orf19.2906 PGA41 
 
1.9 1.6  1.5 1.0  4.9 2.3 
orf19.1570 ERG7 ergosterol biosynthetic process 1.9 1.8  1.5 1.4  1.7 1.3 
orf19.6460 PEX1 protein import into peroxisome matrix, receptor recycling 1.9 1.8  2.4 2.7  1.9 1.7 
orf19.6727 RIT1 charged-tRNA amino acid modification  1.9 2.2  1.1 1.1  1.9 3.4 
orf19.1619 
 
mRNA 3'-end processing 1.9 2.7  3.7 2.7  1.7 1.6 
orf19.5203 
  
1.9 2.2  2.7 2.7  1.4 1.4 
orf19.2446 
 
pantothenate biosynthetic process 1.9 2.0  2.4 2.4  2.6 2.8 
orf19.6090 
 
single-species biofilm formation on inanimate substrate 1.9 2.4  0.6 0.6  0.9 4.5 
orf19.3769 
 
zinc ion transport  1.9 1.6  1.7 2.4  6.4 3.5 
orf19.6967 USO6 ER to Golgi vesicle-mediated transport 1.9 1.7  1.3 1.1  1.3 1.4 
orf19.4286 
  
1.9 2.9  0.3 0.4  2.3 3.8 
orf19.3658 
 
protein folding in endoplasmic reticulum 1.9 1.7  1.2 1.4  2.0 0.7 
orf19.3536 
 
protein amino acid N-linked glycosylation  1.9 1.5  2.1 4.1  2.0 1.0 
orf19.3659 
 
transcription from RNA polymerase II promoter  1.9 1.9  1.4 1.7  2.0 2.0 
orf19.7567 
  
1.9 2.1  1.1 1.0  0.2 0.2 
orf19.2137 
 
translation 1.9 2.3  0.6 0.8  0.9 2.3 
orf19.4871 ERO1 protein thiol-disulfide exchange 1.9 1.9  0.9 0.6  1.8 1.7 
orf19.2821 
  
1.9 2.6  1.2 2.0  1.3 1.7 
orf19.1317 OSH3 filamentous growth  1.9 1.9  2.6 2.9  4.3 3.4 
orf19.6607 
  
1.9 1.9  2.2 2.5  0.6 1.9 
orf19.5921 
 
transport 1.9 1.7  2.7 2.8  5.7 4.0 
orf19.5847 
 
transcription from RNA polymerase III promoter 1.9 2.7  1.4 2.4  4.6 2.5 
orf19.6382 
 
transport  1.9 2.7  1.4 1.8  7.3 2.3 
orf19.2039 MSF1 mitochondrial phenylalanyl-tRNA aminoacylation  1.9 1.8  1.8 2.6  1.1 1.4 
orf19.6165 KGD1 2-oxoglutarate metabolic process  1.9 3.6  2.7 3.5  3.2 2.0 
orf19.367 CNH1 cell morphogenesis  1.9 2.1  1.4 1.5  3.1 2.0 
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SC5314+FLC
/SC5314 
 cas5Δ/Δ+FLC
/cas5Δ/Δ 
 upc2Δ/Δ+FLC/
upc2Δ/Δ 
orf19 
Designation 
CGD 
Name Processa Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
orf19.1687 
 
maturation of 5.8S rRNA from tricistronic rRNA transcript 1.9 2.3  2.6 4.7  3.5 2.3 
orf19.2609 CET1 mRNA capping  1.9 2.0  1.4 1.7  1.1 1.5 
orf19.2064 
 
regulation of transcription, DNA-dependent  1.9 3.0  0.9 0.8  3.3 3.0 
orf19.1252 YME1 chronological cell aging  1.9 3.0  1.0 0.7  1.1 1.3 
orf19.3131 OYE32 cell redox homeostasis 1.9 1.7  3.4 2.8  2.3 1.7 
orf19.3881 
  
1.9 2.0  0.7 0.6  0.5 0.5 
orf19.6346 
 
protein export from nucleus  1.9 1.5  1.6 1.6  0.8 2.1 
orf19.719 
 
fungal-type cell wall organization 1.8 3.3  1.0 1.0  1.5 1.3 
orf19.4119 SPO72 autophagic vacuole formation  1.8 2.0  1.7 1.3  4.2 3.1 
orf19.782 
 
lipid homeostasis 1.8 1.7  2.1 2.6  4.9 2.7 
orf19.7590 
 
ATP synthesis coupled electron transport 1.8 2.8  2.0 3.6  1.2 0.8 
orf19.518 
 
tRNA methylation  1.8 1.9  1.3 2.1  1.1 1.0 
orf19.6418 
 
ribosomal large subunit biogenesis 1.8 2.3  1.1 1.6  3.2 4.4 
orf19.2256 
  
1.8 1.5  2.1 2.8  1.5 3.4 
orf19.4569 
  
1.8 2.0  0.8 0.8  2.1 2.5 
orf19.4330 
  
1.8 1.9  2.0 2.3  1.3 1.8 
orf19.5848 
  
1.8 2.1  1.8 2.4  7.1 4.3 
orf19.3290 
 
electron transport chain 1.8 2.0  1.8 2.3  1.0 1.1 
orf19.1144 
  
1.8 2.0  1.8 1.3  2.2 1.6 
orf19.828 
 
translation 1.8 1.5  1.8 2.1  0.2 0.4 
orf19.4393 CIT1 acetyl-CoA catabolic process  1.8 1.9  4.2 6.6  2.3 1.1 
orf19.913.2 
 
aerobic respiration 1.8 1.9  1.5 2.4  0.7 1.6 
orf19.2057 
 
protein complex assembly 1.8 2.9  1.7 1.7  1.8 1.4 
orf19.2590 
 
biotin biosynthetic process 1.8 2.8  1.6 1.4  0.0 0.2 
orf19.5232 CSI2 filamentous growth  1.8 1.7  1.3 2.6  1.3 2.0 
orf19.3759 
 
regulation of transcription from RNA polymerase II promoter  1.8 1.5  1.7 3.3  4.4 3.6 
orf19.2812 
  
1.8 1.8  0.8 1.0  1.6 1.4 
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CGD 
Name Processa Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
orf19.2044 PGA27 
 
1.8 2.0  1.5 2.2  3.1 1.6 
orf19.1954 PUS4 tRNA modification  1.8 2.0  2.0 2.3  2.4 2.6 
orf19.3573 PEX6 protein import into peroxisome matrix 1.8 1.7  2.9 2.5  2.6 1.3 
orf19.3310 
  
1.8 1.9  0.8 0.6  2.9 3.3 
orf19.2674 
 
regulation of transcription, DNA-dependent 1.8 20.1  1.1 1.2  1.2 1.5 
orf19.5798 LIG4 filamentous growth 1.8 2.6  0.9 0.8  1.0 1.0 
orf19.6319 
 
protein deubiquitination  1.8 2.1  2.0 2.0  1.1 0.9 
orf19.2565 
 
mitochondrion inheritance  1.8 2.6  1.3 1.4  5.4 4.3 
orf19.5629 QCR7 aerobic respiration  1.8 2.0  1.4 2.3  0.9 1.6 
orf19.881 DFG16 filamentous growth 1.8 2.1  1.2 1.2  2.5 2.2 
orf19.199 
  
1.8 1.8  3.8 5.2  8.8 3.2 
orf19.1888 
 
ER-associated protein catabolic process  1.8 1.8  0.9 1.0  1.6 2.3 
orf19.4372 
 
transmembrane transport 1.8 3.0  0.6 0.6  3.5 3.3 
orf19.409 
 
mitochondrial respiratory chain complex IV assembly 1.8 1.8  1.5 2.1  2.1 2.1 
orf19.4175 TOK1 cellular potassium ion homeostasis  1.8 3.4  2.3 2.5  4.3 4.8 
orf19.6353 
  
1.8 2.0  0.7 0.6  2.0 2.6 
orf19.4488 
 
ATP-dependent chromatin remodeling  1.8 2.0  2.1 2.6  0.9 1.4 
orf19.1574 
 
RNA polymerase II transcriptional preinitiation complex assembly 1.8 1.8  2.9 2.6  2.1 2.4 
orf19.1631 ERG6 ergosterol biosynthetic process  1.8 1.7  3.5 4.9  0.4 0.5 
orf19.2516 
 
protein folding  1.8 1.7  3.3 3.5  1.5 2.0 
orf19.6736 
 
maturation of SSU-rRNA 1.8 1.5  1.6 2.1  0.5 1.1 
orf19.1864 
  
1.8 1.5  1.3 1.2  1.5 2.1 
orf19.4539 
 
small GTPase mediated signal transduction  1.8 1.7  0.9 0.5  1.5 2.3 
orf19.2009 PEX12 protein import into peroxisome matrix  1.8 2.1  2.4 3.0  3.0 3.1 
orf19.3065 DAO1 oxidation-reduction process 1.8 2.0  3.6 3.0  3.0 3.2 
orf19.6047 TUF1 mitochondrial translation 1.8 2.8  1.5 1.4  0.3 0.3 
orf19.874 
 
misfolded or incompletely synthesized protein catabolic process 1.8 1.5  1.1 1.0  0.5 1.0 
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CGD 
Name Processa Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
orf19.5159 DUG3 glutathione catabolic process 1.8 3.6  0.9 0.7  1.3 1.3 
orf19.5412 
 
cell wall organization 1.8 1.6  2.3 2.5  4.2 3.7 
orf19.6152 
  
1.8 1.6  3.6 3.8  3.0 2.4 
orf19.6530 
 
SRP-dependent cotranslational protein targeting to membrane 1.8 2.4  1.7 2.9  6.6 4.0 
orf19.7561 DEF1 telomere maintenance 1.8 4.8  1.3 2.5  2.4 2.7 
orf19.6209 
 
monocarboxylic acid transport  1.8 1.6  2.0 2.0  2.6 1.6 
orf19.5095 
 
sterol transport 1.8 2.2  1.8 2.1  2.4 1.4 
orf19.4885 MIR1 phosphate transport  1.8 2.7  1.4 2.1  1.9 1.3 
orf19.2808 ZCF16 
 
1.8 2.5  1.9 2.4  4.8 3.4 
orf19.4051 HTS1 histidyl-tRNA aminoacylation  1.8 1.7  2.2 2.9  0.9 0.8 
orf19.3811 GYP1 vesicle-mediated transport 1.8 1.6  0.9 1.2  0.8 0.9 
orf19.5356 
 
fungal-type cell wall organization 1.8 2.9  1.5 2.7  12.5 3.9 
orf19.351 
  
1.8 2.7  1.6 1.8  8.7 6.0 
orf19.5392 NGT1 N-acetylglucosamine transport  1.8 2.0  1.6 1.6  44.3 29.7 
orf19.5806 ALD5 acetate biosynthetic process  1.8 1.7  2.7 2.3  2.0 1.0 
orf19.6558 
 
ER to Golgi vesicle-mediated transport  1.8 1.8  1.8 2.8  2.6 2.3 
orf19.75 SEC5 protein complex assembly  1.8 2.0  3.2 1.8  2.1 1.6 
orf19.5238 
 
metabolic process 1.8 2.5  1.8 1.9  2.8 4.2 
orf19.4396 
 
cristae formation  1.8 1.9  1.8 2.3  1.0 0.9 
orf19.2646 ZCF13 aerobic respiration  1.8 3.0  2.3 3.6  3.2 2.8 
orf19.2753 ZCF15 regulation of transcription, DNA-dependent 1.8 2.1  2.3 3.7  5.9 3.4 
orf19.607 
 
transcription-coupled nucleotide-excision repair 1.8 2.0  2.1 1.8  2.5 2.5 
orf19.4054 CTA24 positive regulation of transcription, DNA-dependent 1.8 2.5  2.0 2.0  0.5 1.0 
orf19.516 
 
cell cycle  1.8 2.0  1.2 1.7  1.1 1.0 
orf19.920 RMT2  arginine metabolic process 1.8 1.6  1.3 1.1  1.8 2.7 
orf19.173 
 
regulation of transcription, DNA-dependent  1.8 4.2  1.3 2.0  2.3 1.6 
orf19.7534 MIS12 folic acid-containing compound biosynthetic process 1.8 5.2  1.3 2.5  3.2 1.7 
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Exp1 Exp2 
 
Exp1 Exp2 
orf19.4066 
 
phospholipid biosynthetic process 1.8 1.6  2.2 2.2  1.7 0.7 
orf19.5662 PEP7 filamentous growth  1.8 1.6  1.0 0.7  3.1 4.8 
orf19.7173 
  
1.8 2.6  1.3 0.8  3.8 3.3 
orf19.2699 ABP1 actin cortical patch assembly 1.8 1.9  5.2 3.8  2.4 1.1 
orf19.255 ZCF1 regulation of transcription, DNA-dependent 1.8 5.7  3.3 4.7  9.2 2.3 
orf19.209 DFG10 pseudohyphal growth  1.8 1.5  1.4 1.4  3.3 2.4 
orf19.4275 RAD9 hyphal growth 1.8 1.5  1.1 2.7  1.1 1.4 
orf19.6639 
 
mitochondrial fission 1.8 1.5  2.6 3.3  2.1 1.8 
orf19.1957 CYC3 hyphal growth 1.8 2.4  1.6 2.8  2.0 2.5 
orf19.4862.2 PET100 aerobic respiration  1.7 1.8  0.8 0.9  0.4 1.4 
orf19.212 VPS28 fungal-type cell wall organization  1.7 2.1  0.5 0.5  1.0 1.3 
orf19.27 
  
1.7 1.5  1.5 1.5  2.4 3.4 
orf19.4758 
 
oxidation-reduction process 1.7 2.8  2.3 2.9  1.5 1.3 
orf19.6211 
 
chromosome segregation 1.7 3.1  1.2 1.2  2.1 1.2 
orf19.6698 
 
mitochondrial asparaginyl-tRNA aminoacylation  1.7 1.6  1.4 1.5  0.7 0.9 
orf19.1434 
 
nucleotide-excision repair  1.7 2.7  0.8 1.0  0.8 0.9 
orf19.1356 
 
wobble position uridine thiolation 1.7 2.1  1.8 3.2  3.1 2.4 
orf19.1753 PUS7 enzyme-directed rRNA pseudouridine synthesis 1.7 2.7  1.6 3.1  2.4 2.3 
orf19.4511 
  
1.7 1.8  1.5 1.7  2.8 1.6 
orf19.2143 
 
negative regulation of transposition, RNA-mediated 1.7 2.4  1.4 2.8  8.2 3.5 
orf19.4614 
 
peroxisome degradation  1.7 1.8  1.6 1.5  3.8 3.3 
orf19.3962 HAS1 ribosomal small subunit biogenesis  1.7 2.3  0.7 0.8  1.1 2.4 
orf19.6445 ECI1 filamentous growth  1.7 1.5  3.3 3.0  2.5 4.0 
orf19.5940 ZCF32 lysine biosynthetic process via aminoadipic acid  1.7 1.6  1.5 2.2  2.1 1.7 
orf19.322 
  
1.7 2.2  2.1 1.4  7.0 1.1 
orf19.4864 
 
triglyceride metabolic process 1.7 1.6  1.8 1.6  8.7 6.4 
orf19.5236 
 
protein amino acid glycosylation 1.7 2.2  0.5 0.4  1.0 1.8 
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Name Processa Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
orf19.254 
  
1.7 2.6  2.3 2.6  2.9 1.7 
orf19.4760 
 
response to drug  1.7 1.5  2.8 4.2  1.5 2.9 
orf19.7114 CSA1 cellular iron ion homeostasis  1.7 3.2  1.5 1.5  0.7 0.6 
orf19.5384 CHS8 cell wall chitin biosynthetic process  1.7 1.8  1.7 1.9  4.2 2.3 
orf19.7544 TLO1 
 
1.7 1.6  2.2 1.7  0.9 1.3 
orf19.1795 PUF3 aerobic respiration  1.7 2.1  1.6 1.8  1.5 1.1 
orf19.3586 
 
fungal-type cell wall organization 1.7 1.9  3.4 3.5  7.5 3.2 
orf19.3342 
 
protein deubiquitination 1.7 2.0  1.1 0.9  2.4 2.5 
orf19.3605 PEX17 
 
1.7 1.8  1.8 1.5  4.7 3.0 
orf19.2387 
 
prolyl-tRNA aminoacylation  1.7 1.5  1.4 2.0  0.7 0.7 
orf19.2908 
 
oxidation-reduction process 1.7 1.5  1.1 0.8  1.1 1.3 
orf19.3221 CPA2 arginine biosynthetic process  1.7 3.9  2.7 3.5  5.2 2.2 
orf19.3237 
 
protein monoubiquitination  1.7 2.1  1.4 1.4  1.8 2.1 
orf19.847 YIM1 mitochondrial protein processing during import 1.7 1.9  1.7 1.6  2.5 1.2 
orf19.843 
 
protein amino acid dephosphorylation 1.7 1.7  1.2 1.9  2.6 1.2 
orf19.211 
 
DNA repair 1.7 2.4  0.7 0.7  1.5 2.4 
orf19.7092 
  
1.7 1.5  1.4 1.5  1.0 1.0 
orf19.5311 
  
1.7 3.2  2.3 1.9  3.3 1.2 
orf19.117 
 
Golgi to plasma membrane transport  1.7 1.5  2.5 2.5  3.9 3.6 
orf19.1801 CBR1 oxidation-reduction process 1.7 1.5  1.3 1.7  1.6 1.3 
orf19.7374 CTA4 positive regulation of transcription from RNA pol II promoter  1.7 2.2  0.8 1.1  0.8 1.0 
orf19.2248 ARE2 ergosterol metabolic process  1.7 1.6  0.7 0.7  1.1 1.2 
orf19.6544 LPI9 chromosome segregation  1.7 2.3  1.9 1.9  2.0 1.5 
orf19.7527 
  
1.7 2.1  1.0 1.0  2.3 1.9 
orf19.3689 
 
fructose metabolic process 1.7 2.7  2.2 2.6  4.6 3.0 
orf19.2791 BBC1 actin cytoskeleton organization  1.7 2.4  3.1 2.8  2.9 1.8 
orf19.3171 ACH1 acetate metabolic process  1.7 2.0  1.9 2.4  3.9 0.9 
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orf19.3757 ATP20 ATP synthesis coupled proton transport 1.7 1.9  1.2 1.5  1.1 1.1 
orf19.273 
 
sterol biosynthetic process  1.7 1.5  1.3 1.7  2.2 1.4 
orf19.2665 MSN5 protein export from nucleus  1.7 2.5  1.2 1.0  2.3 1.5 
orf19.3029 
 
endocytosis  1.7 1.8  3.4 3.0  2.6 2.7 
orf19.5636 RBT5 cellular iron ion homeostasis  1.7 1.6  1.8 1.5  0.2 0.2 
orf19.3233 HSE1 ascospore-type prospore assembly 1.7 1.5  1.9 2.1  4.9 3.9 
orf19.2077 ZCF9 arginine metabolic process  1.7 1.6  1.1 0.9  3.1 3.2 
orf19.6479 SEC1 vesicle docking during exocytosis  1.7 1.7  1.9 2.0  1.6 1.6 
orf19.23 RTA3 fatty acid transport  1.7 2.7  4.8 5.4  2.6 1.1 
orf19.5912 MAK21 ribosomal large subunit assembly  1.7 3.5  1.3 2.1  2.5 3.1 
orf19.6741 
 
fungal-type cell wall organization 1.7 1.7  1.7 2.5  0.9 1.1 
orf19.1191 
 
ER-associated protein catabolic process 1.7 2.7  1.6 1.9  7.0 2.3 
orf19.3026 MAS1 mitochondrial protein processing during import 1.7 1.6  1.6 1.5  0.9 0.8 
orf19.6187 
  
1.7 1.7  2.1 3.0  0.9 0.7 
orf19.5854.1 
 
bile acid and bile salt transport 1.7 2.2  1.4 2.8  2.0 4.5 
orf19.4357 
 
misfolded or incompletely synthesized protein catabolic process 1.7 1.8  0.9 0.8  0.6 1.3 
orf19.1210 
 
amino acid transmembrane export from vacuole 1.7 2.7  1.5 1.2  2.2 1.2 
orf19.540 
 
cellular protein modification process 1.7 1.7  0.9 0.6  2.7 2.3 
orf19.6794 FESUR1 oxidation-reduction process 1.7 2.1  1.6 2.1  2.0 1.5 
orf19.7160 
 
response to osmotic stress  1.7 1.9  1.1 1.5  1.9 3.3 
orf19.6522 
 
anion transport  1.7 2.2  1.5 1.4  5.4 3.3 
orf19.2242 PRB1 proteolysis  1.7 1.5  0.7 0.6  2.5 2.5 
orf19.1940 
 
ubiquinone biosynthetic process 1.7 1.5  1.0 1.0  0.4 0.7 
orf19.563 RRP15 maturation of rRNA 1.7 1.5  1.5 4.0  2.2 5.9 
orf19.2479 UGA4 gamma-aminobutyric acid transport  1.7 2.9  2.6 6.6  18.2 9.3 
orf19.1622 YCG1 meiotic chromosome condensation 1.7 2.1  2.3 3.9  1.3 1.7 
orf19.6347 
 
DNA replication  1.7 1.5  1.7 2.8  1.0 1.9 
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Exp1 Exp2 
 
Exp1 Exp2 
orf19.7675 
 
translation 1.7 1.9  1.8 2.6  0.8 0.8 
orf19.7490 
 
transmembrane transport 1.7 2.2  1.0 1.8  6.1 3.8 
orf19.3565 
  
1.7 1.7  2.5 2.1  1.6 1.5 
orf19.5518 
  
1.7 1.6  1.4 1.4  5.1 2.1 
orf19.4950 AKR1 endocytosis 1.7 1.8  1.7 1.7  5.1 2.6 
orf19.6726 
 
RNA elongation from RNA polymerase II promoter  1.7 1.8  2.4 3.0  2.9 2.7 
orf19.723 BCR1 filamentous growth  1.7 2.1  3.3 3.3  6.3 2.8 
orf19.111 CAN2 amino acid transmembrane transport 1.7 13.0  0.7 1.5  1.2 3.5 
orf19.4318 MIG1 carbon utilization  1.7 2.1  0.7 1.0  2.1 2.3 
orf19.4747 HEM14 heme biosynthetic process  1.7 2.0  0.6 0.4  0.1 0.2 
orf19.2346 
  
1.7 2.1  2.0 2.0  4.8 2.3 
orf19.3519 SUA72 transcription initiation from RNA polymerase II promoter 1.7 1.7  1.1 1.1  1.7 2.0 
orf19.6990 
 
response to stress  1.7 1.6  1.1 0.9  1.5 1.6 
orf19.1367 MTW1 chromosome segregation  1.7 1.5  1.1 1.0  0.9 2.2 
orf19.164 
  
1.7 2.5  1.2 0.9  4.6 5.1 
orf19.5884 
 
rRNA metabolic process 1.7 2.8  1.3 2.2  4.8 2.9 
orf19.3133 GUT2 NADH oxidation  1.7 1.8  1.1 1.1  2.2 1.6 
orf19.4721 
 
mRNA processing 1.7 1.5  1.0 1.0  0.7 1.9 
orf19.7379 FAA2 lipid metabolic process  1.7 3.1  1.3 1.2  4.4 2.8 
orf19.1785 
  
1.7 2.2  1.4 1.2  2.9 2.1 
orf19.2734 
 
oxidation-reduction process 1.6 1.6  1.9 2.3  5.6 7.4 
orf19.135 EXO84 Golgi to plasma membrane transport  1.6 2.2  1.9 2.6  2.8 2.0 
orf19.69 
  
1.6 2.3  1.3 1.4  0.8 1.4 
orf19.5250 
  
1.6 1.5  3.8 3.2  4.3 4.5 
orf19.7529 EPL1 histone acetylation  1.6 2.5  1.0 1.1  2.0 1.5 
orf19.2839 CIRT4B regulation of transcription, DNA-dependent 1.6 2.6  0.4 0.3  0.7 0.6 
orf19.1586 FGR22 filamentous growth  1.6 1.7  3.1 4.1  4.0 1.6 
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/cas5Δ/Δ 
 upc2Δ/Δ+FLC/
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orf19 
Designation 
CGD 
Name Processa Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
orf19.4640 PWP1 rRNA processing  1.6 2.3  1.2 1.5  2.2 1.6 
orf19.5419 ATP5 ATP synthesis coupled proton transport 1.6 1.9  1.3 1.6  1.3 1.3 
orf19.1255 ZCF5 carbohydrate metabolic process  1.6 2.0  2.2 1.7  6.4 4.2 
orf19.5029 MODF 
 
1.6 2.1  1.3 1.3  2.0 1.5 
orf19.285 
 
mRNA stabilization 1.6 1.5  1.0 1.0  1.5 2.8 
orf19.4788 ARG5,6 arginine biosynthetic process 1.6 2.8  2.8 3.1  4.0 2.9 
orf19.2439.1 
 
aerobic respiration  1.6 2.6  1.0 1.2  0.8 1.2 
orf19.5543 
 
Golgi to endosome transport  1.6 1.5  3.6 3.1  10.1 5.3 
orf19.1124 
  
1.6 2.0  7.9 6.7  7.8 4.6 
orf19.2031 VPS24 protein targeting to vacuole 1.6 1.9  2.5 3.2  6.1 6.5 
orf19.5537 WSC2 cellular cell wall organization  1.6 2.0  3.8 5.0  12.1 5.6 
orf19.6652 DBP8 endonucleolytic cleavage of rRNA 1.6 2.5  1.9 3.0  3.8 4.1 
orf19.6105 MVD ergosterol biosynthetic process  1.6 1.9  1.6 1.4  1.5 0.9 
orf19.7629 
  
1.6 1.8  1.7 1.7  3.5 2.1 
orf19.5660 
 
protein ubiquitination 1.6 1.5  1.9 1.6  2.6 2.7 
orf19.1698 
 
actin cytoskeleton organization 1.6 1.9  1.5 1.8  2.1 0.8 
orf19.4739 MSS116 RNA splicing 1.6 1.6  1.5 2.5  1.2 1.5 
orf19.1467 COX13 aerobic respiration 1.6 1.7  1.0 1.2  0.6 1.1 
orf19.5953 
 
regulation of cell size  1.6 2.4  0.9 1.5  1.2 1.5 
orf19.5705 NAM2 mitochondrial translation  1.6 2.0  1.3 1.9  0.7 0.7 
orf19.6797 
  
1.6 2.1  1.7 1.8  2.6 1.4 
orf19.4906 
 
G1/S transition of mitotic cell cycle 1.6 1.7  1.1 1.6  4.6 2.9 
orf19.3706 
 
oxidation-reduction process 1.6 1.5  1.4 1.5  3.3 2.1 
orf19.7365 
 
anti-apoptosis 1.6 1.5  1.5 1.6  1.9 1.7 
orf19.1133 MSB1 cell adhesion 1.6 1.9  3.6 4.5  2.7 1.6 
orf19.7521 REP1 response to drug 1.6 3.7  2.2 7.2  4.5 1.3 
orf19.3223 ATP3 ATP synthesis coupled proton transport  1.6 2.1  1.2 1.3  1.5 1.5 
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Designation 
CGD 
Name Processa Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
orf19.166 ASG1 positive regulation of transcription from RNA pol II promoter  1.6 3.8  1.4 2.5  1.5 1.5 
orf19.2104 
 
iron-sulfur cluster assembly  1.6 1.6  2.5 3.1  2.1 2.0 
orf19.1945 AUR1 sphingolipid metabolic process  1.6 2.3  1.3 2.1  7.1 3.8 
orf19.6481 YPS7 response to pheromone during conjugation with cellular fusion  1.6 2.3  0.4 0.4  0.9 1.0 
orf19.1223 DBF2 cytokinesis  1.6 1.9  2.4 2.6  0.9 0.9 
orf19.5247 
  
1.6 1.5  1.0 1.4  1.5 1.7 
orf19.5767 
 
nuclear mRNA splicing, via spliceosome  1.6 1.6  1.1 1.1  2.3 2.6 
orf19.922 ERG11 ergosterol biosynthetic process 1.6 1.5  1.2 1.0  0.8 0.7 
orf19.2881 MNN4 cell wall mannoprotein biosynthetic process  1.6 2.4  1.2 1.6  2.3 1.3 
orf19.5535 
 
anion transport  1.6 1.5  1.6 2.1  1.6 1.3 
orf19.4159 
 
transport  1.6 1.5  3.0 4.7  1.2 1.0 
orf19.2314 
 
rRNA processing  1.6 1.5  2.7 4.2  1.5 7.5 
orf19.5296 
 
mitochondrial respiratory chain complex IV assembly 1.6 1.6  1.1 1.3  0.7 1.3 
orf19.5335 SGS1 double-strand break repair via homologous recombination 1.6 1.9  1.4 2.4  2.9 1.3 
orf19.4478 
 
mitochondrial aspartyl-tRNA aminoacylation 1.6 1.8  1.0 0.9  0.5 0.8 
orf19.879 
 
intracellular mRNA localization 1.6 2.2  1.4 1.1  2.5 2.6 
orf19.59 REI1 budding cell bud growth  1.6 1.8  2.6 4.4  1.0 4.6 
orf19.5139 
  
1.6 1.8  1.2 1.4  3.2 1.4 
orf19.6973 
 
proteolysis  1.6 2.1  2.2 2.3  2.2 1.9 
orf19.2296 
  
1.6 2.2  2.6 3.0  1.7 0.8 
orf19.3616 ERG9 ergosterol biosynthetic process 1.6 1.7  1.2 1.0  0.9 1.1 
orf19.2343 VPS23 hyphal growth  1.6 1.8  2.5 1.7  2.8 2.5 
orf19.6196 
 
chromosome segregation 1.6 1.5  2.7 2.8  2.3 3.2 
orf19.4363 SGD1 hyperosmotic response  1.6 1.7  1.9 3.7  2.1 2.8 
orf19.4504 
 
fermentation  1.6 2.7  3.7 3.1  4.5 6.1 
orf19.399 
 
sphingolipid metabolic process  1.6 2.0  1.2 1.1  3.8 2.4 
orf19.7519 
  
1.6 1.9  1.1 1.1  1.4 1.6 
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CGD 
Name Processa Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
orf19.1297 
 
early endosome to Golgi transport  1.6 2.7  5.7 4.1  6.3 10.2 
orf19.2663 
  
1.6 1.9  1.0 1.2  1.2 0.9 
orf19.2670 
 
fatty acid biosynthetic process  1.6 1.8  0.4 0.4  0.4 0.7 
orf19.5058 SMI1 cellular bud neck  1.6 2.1  1.6 1.3  0.7 1.2 
orf19.781 DUR31 urea transport 1.6 1.6  2.0 3.0  6.4 3.3 
orf19.3311 IFD3 cellular aldehyde metabolic process  1.6 1.6  2.1 2.2  2.7 3.3 
orf19.3991 
 
cellular lipid metabolic process  1.6 1.5  1.4 1.7  2.5 1.9 
orf19.2410 SYS3 Golgi to plasma membrane protein transport  1.6 1.9  3.8 3.1  2.0 2.7 
orf19.5539 
 
retrograde vesicle-mediated transport, Golgi to ER 1.6 1.6  0.7 0.8  1.6 2.9 
orf19.886 PAN1 axial cellular bud site selection 1.6 1.9  2.4 4.4  1.7 1.1 
orf19.4688 DAG7 cellular response to drug 1.6 1.6  2.3 2.6  3.5 1.7 
orf19.1464 BMT5 glycosphingolipid biosynthetic process 1.6 2.1  1.5 1.5  2.5 1.3 
orf19.3360 
  
1.6 2.0  0.9 1.0  1.8 2.1 
orf19.2068 
  
1.6 1.5  1.3 1.8  0.6 0.6 
orf19.3508 
 
nicotinamide nucleotide metabolic process 1.6 1.9  1.8 1.7  1.7 1.2 
orf19.4896 
 
transcription from RNA polymerase I promoter 1.6 2.0  2.2 3.5  1.3 2.5 
orf19.6550 
  
1.6 1.6  1.0 1.0  1.5 1.7 
orf19.3535 
  
1.6 1.8  1.4 2.2  8.0 5.5 
orf19.6898.1 
  
1.6 1.6  1.1 1.5  0.6 0.9 
orf19.7599 UTP5 maturation of rRNA 1.6 1.5  1.3 2.6  2.1 1.7 
orf19.7270 
  
1.6 2.1  1.6 1.4  2.2 1.0 
orf19.5892 
 
protein monoubiquitination  1.6 2.7  1.3 1.0  3.1 2.4 
orf19.6045 
 
phosphatidylcholine biosynthetic process  1.6 1.9  0.9 1.0  1.9 1.6 
orf19.5110 OPY2 cell cycle arrest in response to pheromone  1.6 2.3  2.9 3.5  13.6 4.9 
orf19.4771 
 
protein amino acid glycosylation  1.6 1.8  1.2 1.3  6.5 8.1 
orf19.7350 RCT1 
 
1.6 1.6  1.6 1.7  1.4 1.1 
orf19.5989 
 
mRNA cleavage  1.6 2.0  2.0 2.0  1.7 1.4 
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orf19.522 
 
cellular chaperone-mediated protein complex assembly 1.6 1.7  2.0 2.2  1.1 1.1 
orf19.2736 HFL2 negative regulation of transcription from RNA pol II promoter  1.6 2.1  1.1 1.3  1.6 1.4 
orf19.6217 PGA63 ER to Golgi vesicle-mediated transport 1.6 2.8  2.5 3.3  1.6 0.6 
orf19.260 SLD1 plasma membrane organization  1.6 1.5  1.3 1.5  1.0 1.4 
orf19.1881 
 
glycerophospholipid biosynthetic process  1.6 2.1  1.1 1.4  1.9 1.3 
orf19.1648 RAD50 response to oxidative stress  1.6 1.7  2.2 1.7  1.8 1.4 
orf19.5407 SOF1 maturation of rRNA 1.6 1.6  1.4 2.2  2.2 3.8 
orf19.2644 QCR2 aerobic respiration  1.6 2.4  1.4 1.6  1.3 1.1 
orf19.3579 ATP4 ATP synthesis coupled proton transport 1.6 1.8  1.4 2.0  0.9 1.4 
orf19.418 KOG1 regulation of cell growth  1.6 2.0  1.4 1.6  3.0 1.4 
orf19.6942 ORC3 DNA replication initiation  1.6 1.7  1.9 2.5  1.5 1.4 
orf19.4670 CAS5 fungal-type cell wall organization  1.6 2.8  0.1 0.3  4.7 3.3 
orf19.6643 MCT1 fatty acid metabolic process 1.6 1.5  3.0 3.0  2.6 1.6 
orf19.5893 RIP1 aerobic respiration  1.6 2.2  1.4 1.9  0.7 0.8 
orf19.3122 ARR3 arsenite transport  1.6 1.9  1.6 1.3  3.3 3.2 
orf19.5005 OSM2 metabolic process  1.6 1.5  2.6 3.6  2.6 1.9 
orf19.3553 RPF2 ribosomal large subunit assembly 1.6 1.8  1.1 2.2  1.0 1.5 
orf19.603 IMP4 translation 1.5 1.6  1.5 3.2  2.4 3.5 
orf19.7481 MDH1 tricarboxylic acid cycle 1.5 1.6  1.4 1.4  1.9 1.0 
orf19.109 
 
mitochondrial tyrosyl-tRNA aminoacylation 1.5 1.6  1.3 1.2  0.5 0.5 
orf19.1374 
  
1.5 3.1  1.3 1.4  3.8 4.9 
orf19.3138 NOP1 rRNA methylation  1.5 2.4  1.2 1.5  0.7 0.7 
orf19.1301 
  
1.5 2.0  3.8 3.2  1.1 2.0 
orf19.5500 MAK16 maturation of rRNA 1.5 1.9  3.5 6.1  0.9 6.1 
orf19.5357 AKL1 actin cortical patch assembly  1.5 1.8  1.9 1.9  3.4 2.1 
orf19.1515 CHT4 chitin catabolic process 1.5 1.5  1.0 0.7  5.5 4.8 
orf19.5797 PI-PLC filamentous growth  1.5 2.0  2.7 3.9  4.1 1.5 
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Exp1 Exp2 
orf19.1589 
 
regulation of transcription, DNA-dependent 1.5 2.3  1.5 3.2  4.7 4.9 
orf19.7225 
  
1.5 1.5  1.7 2.1  1.7 3.6 
orf19.4750 
  
1.5 1.8  2.3 4.2  2.4 1.1 
orf19.5326 
 
glucose metabolic process  1.5 1.9  0.6 0.7  1.3 3.4 
orf19.6531 NUC2 oxidation-reduction process 1.5 2.0  1.7 2.2  1.2 1.0 
orf19.3546 PEX2 protein import into peroxisome matrix 1.5 1.7  1.7 2.1  3.5 2.0 
orf19.3841 
 
autophagic vacuole formation  1.5 2.6  2.2 2.8  9.1 5.3 
orf19.4418 FMT1 methionyl-tRNA aminoacylation  1.5 1.5  1.5 2.7  0.9 1.9 
orf19.4106 
  
1.5 2.1  3.2 4.6  4.7 3.5 
orf19.2073 
 
drug transmembrane transport 1.5 1.6  0.6 0.5  2.1 2.8 
orf19.633 
 
metabolic process 1.5 1.6  0.8 0.5  0.3 1.1 
orf19.6464 
  
1.5 1.8  1.0 1.2  3.3 2.4 
orf19.7537 BNR1 cell separation during cytokinesis 1.5 2.3  1.8 2.3  4.4 2.8 
orf19.2046 POT1-2 fatty acid beta-oxidation  1.5 2.2  0.5 0.4  1.6 1.9 
orf19.5504 
  
1.5 2.1  1.5 1.8  3.2 2.0 
orf19.314 
 
histone deacetylation  1.5 1.8  1.4 1.7  1.9 1.5 
orf19.6194 
  
1.5 1.6  1.2 1.3  0.6 0.9 
orf19.7357 
 
coenzyme A biosynthetic process  1.5 1.7  2.0 2.6  2.7 2.5 
orf19.6117 
 
transmembrane transport 1.5 2.3  0.6 0.4  3.3 3.3 
orf19.2786 
 
vesicle-mediated transport  1.5 2.2  1.4 1.7  1.6 1.6 
orf19.1956 
 
reciprocal meiotic recombination  1.5 1.8  1.7 2.5  0.8 1.0 
orf19.2789 
  
1.5 1.8  1.3 1.3  1.6 1.7 
orf19.6014 RRS1 response to drug 1.5 1.7  1.3 2.3  2.7 4.2 
orf19.5365 
  
1.5 1.7  1.6 2.4  0.9 0.9 
orf19.1658 
  
1.5 1.7  2.5 3.5  3.3 2.1 
orf19.6996 
 
protein amino acid O-linked glycosylation  1.5 2.9  1.0 2.5  1.4 2.1 
orf19.7664 
  
1.5 1.7  0.7 1.6  1.3 2.4 
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orf19.6837 FMA1 oxidation-reduction process 1.5 1.5  0.7 0.7  0.9 1.6 
orf19.2608 ADH5 biofilm formation  1.5 1.7  1.7 1.5  1.2 1.2 
orf19.2308 
 
fructose 2,6-bisphosphate metabolic process  1.5 1.6  0.7 1.0  1.4 1.9 
orf19.729.1 RGD3 intracellular signal transduction 1.5 2.0  1.0 0.8  2.3 2.2 
orf19.3969 SFL2 filamentous growth  1.5 2.4  1.2 1.2  0.7 0.6 
orf19.3782.2 
 
cristae formation 1.5 1.8  1.1 1.5  0.6 0.5 
orf19.6140 FRE30 
 
1.5 4.8  9.5 6.1  23.3 15.4 
orf19.1047 ERB1 rRNA processing 1.5 1.9  1.0 1.6  1.2 2.2 
orf19.1373 INP51 fungal-type cell wall organization 1.5 1.8  2.1 2.4  3.7 2.7 
orf19.2691 
  
1.5 1.5  0.5 0.7  0.4 0.7 
orf19.6989 
  
1.5 2.5  1.6 1.4  3.2 3.7 
orf19.6621 MHP1 filamentous growth 1.5 2.4  1.0 0.9  1.3 1.0 
orf19.6527 
 
conjugation with cellular fusion 1.5 1.8  0.8 0.7  4.4 2.7 
orf19.1325 ECM38 
 
1.5 1.9  1.6 1.2  1.9 1.5 
orf19.7509.1 ATP17 ATP synthesis coupled proton transport 1.5 1.5  1.1 1.1  1.3 1.9 
orf19.6601 
  
1.5 3.0  4.1 7.2  6.2 8.4 
orf19.649 
  
1.5 2.2  1.2 1.5  3.0 2.3 
orf19.6448 
  
1.5 2.3  1.9 2.2  1.2 0.6 
orf19.6512 EXO70 Golgi to plasma membrane transport 1.5 1.8  2.6 2.4  2.0 1.7 
orf19.916 
 
apoptotic process 1.5 1.7  1.8 1.8  3.7 2.3 
orf19.4033 PRP22 generation of catalytic spliceosome for second transesterification step 1.5 1.8  1.9 2.3  2.6 2.8 
orf19.1563 ECM3 cell wall organization 1.5 1.5  0.4 0.6  1.2 1.5 
orf19.3461 
  
1.5 1.6  2.2 2.9  1.7 1.1 
orf19.1077 ATM1 cellular iron ion homeostasis 1.5 2.8  4.5 2.9  3.2 3.4 
orf19.4918 
 
regulation of transcription, DNA-dependent 1.5 1.7  1.7 1.9  2.4 1.5 
orf19.4759 COX5 aerobic respiration  1.5 2.2  1.5 1.6  0.9 1.2 
orf19.3758 
  
1.5 1.6  1.0 0.9  1.6 2.0 
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orf19.5167 IFM1 mitochondrial translation  1.5 1.7  1.9 3.2  0.8 1.4 
orf19.7551 ALO1 response to oxidative stress  1.5 2.8  0.7 0.6  1.7 1.3 
orf19.6225 PCL7 regulation of cyclin-dependent protein kinase activity  1.5 2.0  0.8 0.8  1.5 1.3 
orf19.5660.1 
 
ATP synthesis coupled proton transport 1.5 1.8  1.1 1.6  1.2 1.6 
orf19.1816 ALS3 biofilm formation  1.5 3.1  1.3 1.3  2.6 1.1 
orf19.1981 IMP2 mitochondrial protein processing during import  1.5 1.5  1.8 2.3  1.3 2.0 
orf19.7619 
 
mitochondrion organization 1.5 1.9  2.1 2.6  3.6 3.5 
orf19.191 KIC1 cell wall organization  1.5 1.9  1.2 1.2  1.7 1.3 
orf19.4634 
 
protein urmylation  1.5 3.2  2.1 2.4  3.2 3.8 
orf19.7661 HMI1 mitochondrial genome maintenance 1.5 1.6  1.4 1.0  2.0 1.9 
orf19.2309 
 
RNA processing  1.5 1.6  1.8 4.0  1.2 1.3 
orf19.6979 
 
cellular manganese ion homeostasis  1.5 5.7  3.8 2.5  5.3 2.9 
orf19.3827 
 
misfolded or incompletely synthesized protein catabolic process 1.5 1.6  1.4 2.3  6.2 3.6 
orf19.1371 
  
1.5 1.6  1.3 1.7  0.8 0.6 
orf19.1900 
 
nucleolus organization  1.5 1.6  2.4 3.8  1.1 1.5 
orf19.7187 MAM33 aerobic respiration 1.5 2.3  1.7 1.3  1.1 1.5 
orf19.7027 
  
1.5 2.2  0.7 1.3  2.4 2.2 
orf19.4805 
 
Golgi to plasma membrane transport 1.5 1.5  1.3 2.5  2.5 1.3 
orf19.4127 
 
actin cortical patch localization  1.5 1.8  1.8 1.8  1.6 1.2 
orf19.783 
 
intracellular protein transport 1.5 2.2  2.0 3.4  7.4 3.2 
orf19.3309 
  
1.5 1.7  0.8 0.6  3.2 2.8 
orf19.738 MYO5 cell wall organization  1.5 2.0  1.9 1.9  2.7 1.4 
orf19.4645 BEM1 cell budding 1.5 1.9  1.5 1.6  0.4 0.6 
orf19.3201 MTLA1 cell differentiation  1.5 1.5  1.8 2.1  2.4 4.5 
orf19.1671 UTR2 cell wall organization  1.5 1.6  1.9 2.5  3.8 2.6 
orf19.3302 
 
regulation of glycogen biosynthetic process  1.5 2.1  0.7 0.8  1.1 0.9 
orf19.5619 
  
1.5 2.9  1.4 1.6  5.7 3.8 
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SC5314+FLC
/SC5314 
 cas5Δ/Δ+FLC
/cas5Δ/Δ 
 upc2Δ/Δ+FLC/
upc2Δ/Δ 
orf19 
Designation 
CGD 
Name Processa Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
orf19.6297 
 
tRNA pseudouridine synthesis 1.5 1.8  1.5 2.0  2.4 2.6 
orf19.5134 
  
1.5 2.2  0.9 2.0  1.7 6.0 
orf19.2006.1 COX17 intracellular copper ion transport  1.5 1.6  1.8 1.2  0.7 1.0 
orf19.5234 RBD1 filamentous growth  1.5 1.8  1.0 1.2  4.3 2.7 
orf19.5168 
 
maturation of SSU-rRNA 1.5 1.7  1.6 2.4  1.9 2.3 
orf19.4764 
 
mRNA 3'-end processing 1.5 1.5  1.9 1.8  2.5 1.1 
orf19.7569 SIK1 rRNA processing 1.5 2.2  1.3 1.7  0.6 0.9 
orf19.1776 
 
coenzyme A biosynthetic process  1.5 1.5  1.6 1.9  0.6 1.0 
orf19.3083 
 
DNA recombination  1.5 1.8  1.0 1.6  0.8 0.3 
orf19.4457 BNI4 filamentous growth 1.5 2.0  1.4 1.9  2.2 1.0 
orf19.3603 
 
multicellular organismal development 1.5 1.5  2.8 2.8  1.6 1.5 
orf19.6070 ENA2 potassium ion transport  1.5 2.1  0.9 1.7  11.7 6.1 
orf19.6854 ATP1 ATP biosynthetic process 1.5 2.0  1.2 1.0  1.2 1.0 
orf19.3195 HIP1 amino acid transmembrane transport 1.5 2.6  0.6 0.7  0.7 0.8 
orf19.1187 CPH2 filamentous growth  1.5 2.2  1.4 1.7  3.5 2.1 
orf19.3004 
  
1.5 2.0  0.6 0.6  0.9 1.4 
orf19.4317 GRE3 response to oxidative stress 1.5 1.5  0.8 0.6  0.3 0.7 
orf19.2443 RGD1 osmosensory signaling pathway  1.5 1.6  1.4 1.2  1.6 1.7 
a Descriptions are from the Candida Genome Database (http://www.candidagenome.org). 
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Table A-2. Genes downregulated by at least 0.5-fold by fluconazole in SC5314 
 
      Change in Fold Expression 
   
SC5314+FLC
/SC5314 
 
cas5Δ/Δ+FLC
/cas5Δ/Δ 
 
upc2Δ/Δ+FLC/
upc2Δ/Δ 
orf19 
Designation 
CGD 
Name Processa Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
orf19.5673 OPT7 oligopeptide transport  0.0 0.1  0.2 0.2  0.0 0.0 
orf19.2475 PGA26 filamentous growth 0.1 0.0  0.2 0.2  0.1 0.2 
orf19.946 MET14 methionine metabolic process  0.1 0.1  1.1 2.5  0.4 0.2 
orf19.689 PLB1 pathogenesis  0.1 0.0  0.0 0.0  0.0 0.0 
orf19.2337 ALP1 basic amino acid transport  0.1 0.1  0.3 0.4  0.4 0.3 
orf19.5017 DUR32  transmembrane transport 0.1 0.1  0.7 0.6  0.9 0.2 
orf19.3475 
  
0.1 0.1  0.4 0.4  2.0 2.1 
orf19.2738 SUL2 sulfate transport  0.1 0.3  1.7 1.2  5.4 0.8 
orf19.5399 IFF11 pathogenesis 0.1 0.1  0.0 0.0  0.0 0.0 
orf19.1887 
 
sterol metabolic process 0.1 0.1  0.4 0.5  0.6 0.5 
orf19.7330 
 
thiamin biosynthetic process  0.1 0.2  0.4 0.3  0.1 0.2 
orf19.6679 
  
0.1 0.3  1.0 2.8  1.0 1.5 
orf19.386 SAM4 L-methionine biosynthetic process from S-adenosylmethionine 0.2 0.1  0.3 0.3  0.1 0.1 
orf19.1442 PLB4.5 phosphoinositide metabolic process  0.2 0.3  0.4 0.3  0.0 0.0 
orf19.769 IFE1 oxidation-reduction process 0.2 0.1  1.0 1.2  0.1 0.1 
orf19.4526 HSP30 negative regulation of ATPase activity 0.2 0.1  2.6 1.2  0.8 1.5 
orf19.4669 AAT22 aspartate catabolic process 0.2 0.1  0.3 0.4  0.0 0.0 
orf19.385 GCV2 glycine catabolic process  0.2 0.3  1.2 2.5  0.9 0.1 
orf19.1368 
  
0.2 0.3  0.2 0.1  0.1 0.1 
orf19.2618 MET2 homoserine metabolic process  0.2 0.2  0.8 0.9  0.6 0.3 
orf19.5103 
  
0.2 0.3  0.1 0.1  0.1 0.2 
orf19.6770 
 
actin cortical patch assembly 0.2 0.2  0.1 0.1  0.2 0.2 
orf19.6086 LEU4 leucine biosynthetic process 0.2 0.3  0.6 0.8  0.1 0.1 
orf19.7284 ASR2 
 
0.2 0.1  1.7 1.7  0.3 0.3 
orf19.7098 
 
oxidation-reduction process 0.2 0.1  0.9 0.8  0.6 0.9 
orf19.1447 
  
0.2 0.3  1.0 2.7  0.7 0.3 
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        Change in Fold Expression 
   
SC5314+FLC
/SC5314 
 cas5Δ/Δ+FLC
/cas5Δ/Δ 
 upc2Δ/Δ+FLC/
upc2Δ/Δ 
orf19 
Designation 
CGD 
Name Processa Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
orf19.768 SYG1 signal transduction 0.2 0.4  0.1 0.1  0.4 0.6 
orf19.5870 CTP1 mitochondrial citrate transport 0.2 0.2  0.2 0.4  0.1 0.3 
orf19.6570 NUP nucleoside transport 0.2 0.1  0.7 0.3  0.1 0.1 
orf19.7553 
  
0.2 0.5  3.6 3.2  0.7 1.2 
orf19.4664 NAT4 cellular developmental process 0.2 0.2  0.1 0.1  0.0 0.1 
orf19.7586 CHT3 cellular bud site selection  0.2 0.3  0.2 0.2  0.0 0.0 
orf19.3897 
  
0.2 0.3  1.5 1.2  0.2 0.5 
orf19.3916 
  
0.2 0.2  0.9 0.6  0.4 0.5 
orf19.3048 
  
0.2 0.3  0.5 0.9  0.9 0.3 
orf19.3106 MET16 methionine metabolic process 0.2 0.3  0.8 1.4  1.2 0.6 
orf19.4456 GAP4 amino acid transport 0.2 0.3  0.5 0.7  0.9 0.6 
orf19.923 THR1 homoserine metabolic process 0.2 0.2  0.2 0.2  0.1 0.2 
orf19.4438 RME1 meiosis 0.2 0.4  0.4 0.3  0.0 0.2 
orf19.6077 
  
0.2 0.3  0.3 0.3  0.9 0.5 
orf19.7199 
  
0.3 0.2  0.1 0.2  0.1 0.2 
orf19.4907 
 
regulation of cell size 0.3 0.4  0.5 0.4  0.3 0.2 
orf19.4651 PGA53 
 
0.3 0.2  0.4 0.4  0.2 0.2 
orf19.3664 HSP31 protein refolding 0.3 0.2  1.0 0.8  0.3 0.7 
orf19.7310 
 
reciprocal meiotic recombination 0.3 0.3  2.5 2.6  1.1 0.5 
orf19.5992 WOR2 cellular developmental process 0.3 0.2  0.5 0.4  0.9 0.6 
orf19.4889 
 
drug transport 0.3 0.2  0.7 1.0  0.6 0.5 
orf19.7025 MCM1 hyphal growth  0.3 0.4  0.5 0.6  0.5 0.7 
orf19.4142 
  
0.3 0.3  1.5 6.2  2.7 1.1 
orf19.2602 OPT1 nitrogen utilization  0.3 0.2  0.8 0.5  0.1 0.1 
orf19.1333 SNG3 response to drug 0.3 0.3  0.2 0.2  0.5 0.4 
orf19.4375 
 
chromatin silencing at rDNA 0.3 0.3  0.4 0.5  0.4 0.8 
orf19.1075 
  
0.3 0.5  1.5 1.4  2.5 1.4 
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        Change in Fold Expression 
   
SC5314+FLC
/SC5314 
 cas5Δ/Δ+FLC
/cas5Δ/Δ 
 upc2Δ/Δ+FLC/
upc2Δ/Δ 
orf19 
Designation 
CGD 
Name Processa Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
orf19.2018 
 
peptidyl-diphthamide biosynthetic process 0.3 0.3  2.1 4.1  2.0 2.3 
orf19.5663 RCH1 calcium ion import 0.3 0.2  0.9 0.8  1.3 1.6 
orf19.2246 
  
0.3 0.1  0.6 0.8  0.7 2.1 
orf19.3433 OYE23 oxidation-reduction process 0.3 0.5  0.5 0.2  0.1 0.1 
orf19.473 TPO4 drug transport 0.3 0.3  0.9 1.0  0.5 0.4 
orf19.5484 SER1 purine base biosynthetic process 0.3 0.3  0.8 0.9  0.4 0.5 
orf19.5615 AYR2 phosphatidic acid biosynthetic process  0.3 0.2  0.3 0.2  0.2 0.2 
orf19.21 
 
ethanol metabolic process  0.3 0.3  0.2 0.2  0.3 0.8 
orf19.5805 DLD1 aerobic respiration 0.3 0.5  1.1 1.5  0.9 0.5 
orf19.1510 SRD1 
 
0.3 0.4  0.8 1.4  1.8 0.8 
orf19.1159 
  
0.3 0.5  1.6 2.9  4.0 1.1 
orf19.3915 
 
glutathione catabolic process 0.3 0.4  0.4 0.5  0.4 0.3 
orf19.6656 DUR3 urea transport 0.3 0.3  0.3 0.3  0.4 0.3 
orf19.6636 
  
0.3 0.2  0.4 0.4  0.2 0.2 
orf19.1443 PLB4 phosphoinositide metabolic process  0.3 0.4  0.5 0.4  0.1 0.0 
orf19.1182 
 
Golgi to vacuole transport 0.3 0.3  0.7 1.0  0.8 0.5 
orf19.1968.1 
 
N-terminal protein amino acid acetylation 0.3 0.3  1.1 1.6  0.4 0.3 
orf19.5032 SIM1 cell wall organization 0.3 0.4  0.6 1.0  0.8 1.0 
orf19.1901 MCM3 DNA replication initiation 0.3 0.4  1.1 2.1  0.2 0.1 
orf19.2396 IFR2 oxidation-reduction process 0.3 0.2  0.9 0.6  0.2 0.1 
orf19.1253 PHO4 cellular response to phosphate starvation 0.3 0.2  1.0 1.5  0.8 0.6 
orf19.2639 
 
mitochondrial genome maintenance 0.3 0.2  1.0 2.5  0.1 0.6 
orf19.4192 CDC14 hyphal growth  0.3 0.2  0.6 0.8  0.3 0.5 
orf19.6817 FCR1 filamentous growth 0.3 0.4  0.1 0.1  0.3 0.2 
orf19.4733 YMC2 transport  0.3 0.3  0.9 0.9  0.9 0.4 
orf19.139 TRA1 histone acetylation 0.3 0.4  2.3 1.1  0.7 0.4 
orf19.6580 
  
0.3 0.3  0.5 0.5  0.1 0.2 
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        Change in Fold Expression 
   
SC5314+FLC
/SC5314 
 cas5Δ/Δ+FLC
/cas5Δ/Δ 
 upc2Δ/Δ+FLC/
upc2Δ/Δ 
orf19 
Designation 
CGD 
Name Processa Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
orf19.4816 
  
0.3 0.2  0.4 0.3  0.5 0.6 
orf19.1517 ARO3 aromatic amino acid family biosynthetic process 0.3 0.3  0.7 1.1  0.2 0.2 
orf19.5316 FGR29  filamentous growth 0.3 0.5  0.9 0.9  0.7 0.5 
orf19.5519 GCV1 glycine metabolic process 0.3 0.2  1.0 1.0  1.1 0.6 
orf19.2452 
  
0.3 0.2  0.2 0.5  0.2 0.1 
orf19.1116 
  
0.3 0.2  0.2 0.1  0.2 0.3 
orf19.1390 PMI1 fungal-type cell wall organization 0.3 0.3  0.4 0.4  0.3 0.2 
orf19.5267 
  
0.3 0.3  0.2 0.3  0.0 0.0 
orf19.2989 GOR1 glyoxylate catabolic process 0.3 0.3  0.5 0.4  0.2 0.2 
orf19.1697 
 
cytoplasmic translation 0.3 0.4  1.0 1.9  0.5 0.9 
orf19.2600 SPC98 microtubule nucleation 0.4 0.4  1.6 3.7  1.7 1.3 
orf19.655 PHO84 phosphate transport 0.4 0.5  0.6 0.5  0.1 0.6 
orf19.6001 SAP3 adhesion to host  0.4 0.2  0.1 0.1  0.1 1.1 
orf19.5496 AVT1 
 
0.4 0.4  0.3 0.5  0.5 0.7 
orf19.335 
 
chromosome segregation  0.4 0.3  0.6 0.6  0.7 0.8 
orf19.1621 GPA2 hyphal growth 0.4 0.5  0.7 0.8  0.9 1.0 
orf19.4718 TRP5 tryptophan biosynthetic process  0.4 0.4  0.8 1.1  0.3 0.5 
orf19.4068 
  
0.4 0.4  1.1 1.1  0.5 0.4 
orf19.6022 NRM1 cellular response to hydroxyurea 0.4 0.4  1.9 2.5  0.3 0.2 
orf19.1258 
  
0.4 0.2  0.9 1.2  1.0 0.4 
orf19.1756 GPD1 glycerol metabolic process 0.4 0.4  0.2 0.2  0.1 0.2 
orf19.7218 RBE1 pathogenesis 0.4 0.3  0.2 0.4  0.0 0.0 
orf19.3648 
 
DNA repair  0.4 0.3  1.0 1.2  0.4 0.4 
orf19.7166 
  
0.4 0.1  0.5 0.6  0.3 0.4 
orf19.5051 
  
0.4 0.2  1.3 2.3  0.6 0.9 
orf19.3230 BOI2 budding cell apical bud growth 0.4 0.4  1.0 1.4  1.5 0.9 
orf19.6951 
 
calcium-mediated signaling 0.4 0.5  0.7 0.9  1.1 0.5 
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SC5314+FLC
/SC5314 
 cas5Δ/Δ+FLC/
cas5Δ/Δ 
 upc2Δ/Δ+FLC/
upc2Δ/Δ 
orf19 
Designation 
CGD 
Name Processa Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
orf19.7190 OGG1 base-excision repair, AP site formation 0.4 0.4  3.5 5.1  1.6 0.6 
orf19.2335 
 
response to drug  0.4 0.3  0.3 0.3  0.2 0.2 
orf19.6782 BMT1 beta-1,2-oligomannoside metabolic process 0.4 0.4  1.0 0.8  0.1 0.1 
orf19.5760 IHD1 
 
0.4 0.5  0.1 0.3  0.1 0.4 
orf19.3160 HSP12 cell adhesion  0.4 0.3  1.7 1.4  0.5 0.5 
orf19.3618 YWP1 cell-cell adhesion 0.4 0.3  0.7 0.7  0.1 0.0 
orf19.6146 CLG1 cell cycle 0.4 0.5  0.6 1.0  1.5 1.0 
orf19.2187 ALG7 aerobic respiration 0.4 0.4  0.4 0.7  0.5 0.4 
orf19.4520 
 
D-gluconate metabolic process 0.4 0.2  0.6 0.6  0.5 0.6 
orf19.4390 
  
0.4 0.3  1.1 1.8  0.3 0.2 
orf19.3146 
  
0.4 0.4  0.7 0.7  0.2 0.2 
orf19.568 SPE2 pantothenate biosynthetic process 0.4 0.2  1.4 2.0  2.1 1.4 
orf19.6424 
 
G2/M transition of mitotic cell cycle  0.4 0.2  0.3 0.5  0.3 0.9 
orf19.5789 ADE8 adenine biosynthetic process 0.4 0.2  1.3 1.9  0.6 0.6 
orf19.6691 
 
drug transmembrane transport 0.4 0.4  0.6 1.3  1.8 1.4 
orf19.7564 DPB2 DNA repair 0.4 0.3  1.1 2.6  0.6 0.3 
orf19.5612 BMT4 beta-1,2-oligomannoside metabolic process  0.4 0.3  0.7 0.6  1.0 0.6 
orf19.6562 RNH35 DNA replication, removal of RNA primer 0.4 0.3  0.2 0.4  0.2 0.3 
orf19.3810 
 
folic acid and derivative biosynthetic process 0.4 0.3  1.1 1.9  1.2 0.7 
orf19.4783 
  
0.4 0.2  0.3 0.2  0.2 0.3 
orf19.3099 TRP4 tryptophan biosynthetic process 0.4 0.4  0.8 1.9  0.2 0.3 
orf19.2529 
 
GPI anchor biosynthetic process 0.4 0.4  0.9 1.4  0.8 0.6 
orf19.3430 
  
0.4 0.4  0.7 0.9  0.3 0.3 
orf19.4910 FGR41 filamentous growth 0.4 0.4  0.1 0.2  0.0 0.0 
orf19.3469 
 
regulation of transcription involved in G1/S phase 0.4 0.4  0.6 0.8  0.9 0.6 
orf19.4241 
  
0.4 0.3  0.5 0.6  0.6 0.7 
orf19.5369 
 
heme biosynthetic process 0.4 0.4  0.7 0.8  0.7 0.7 
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SC5314+FLC
/SC5314 
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/cas5Δ/Δ 
 upc2Δ/Δ+FLC/
upc2Δ/Δ 
orf19 
Designation 
CGD 
Name Processa Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
orf19.6008 
  
0.4 0.4  0.4 0.5  0.1 0.1 
orf19.1757 
 
regulation of transcription, DNA-dependent 0.4 0.2  1.6 3.3  0.7 0.6 
orf19.3591 APE3 vacuolar protein catabolic process 0.4 0.4  0.6 0.7  0.9 0.5 
orf19.7637 YHB4 response to stress 0.4 0.5  0.3 0.2  1.0 1.5 
orf19.3139 
 
oxidation-reduction process 0.4 0.3  0.3 0.3  0.1 0.3 
orf19.1167 
 
sulfur compound catabolic process  0.4 0.1  1.4 1.1  0.3 0.2 
orf19.7106 VPS70 protein targeting to vacuole 0.4 0.5  1.0 1.1  3.9 1.0 
orf19.5455 
 
microautophagy 0.4 0.2  0.4 0.3  0.3 0.3 
orf19.7667 IAH1 filamentous growth 0.4 0.4  0.5 0.5  0.2 0.4 
orf19.4195.1 FCA1 cytosine metabolic process 0.4 0.3  0.2 0.3  0.2 0.4 
orf19.4177 HIS5 histidine biosynthetic process  0.4 0.5  1.1 1.2  0.9 0.9 
orf19.7149 
 
endocytosis 0.4 0.4  0.9 0.9  0.4 0.3 
orf19.6977 GPI1 GPI anchor biosynthetic process 0.4 0.5  0.4 0.3  0.2 0.4 
orf19.4666 
  
0.4 0.5  1.0 1.8  1.1 1.1 
orf19.5280 MUP1 sulfur amino acid transport 0.4 0.4  0.5 0.6  0.3 0.4 
orf19.4499 RIM2 mitochondrial genome maintenance 0.4 0.3  0.7 1.0  0.3 0.6 
orf19.5495 
  
0.4 0.5  1.3 1.4  1.3 0.7 
orf19.1049 
  
0.4 0.4  0.7 1.0  0.4 0.5 
orf19.5057 
  
0.4 0.3  5.8 1.9  1.8 0.7 
orf19.1332 SNG4 
 
0.4 0.3  0.4 0.4  0.7 0.6 
orf19.3192 STI1 protein complex assembly 0.4 0.5  0.6 0.8  0.5 0.5 
orf19.2041 
 
chromatin remodeling 0.4 0.5  1.0 1.1  0.5 0.4 
orf19.2936 
  
0.4 0.3  1.2 1.6  1.9 0.7 
orf19.1559 HOM2 methionine metabolic process 0.4 0.3  0.5 0.4  0.3 0.5 
orf19.5136 
  
0.4 0.5  0.1 0.1  0.1 0.3 
orf19.1971 TRY3 positive regulation of cell-substrate adhesion 0.4 0.5  0.5 0.3  0.2 0.7 
orf19.3104 YDC1 ceramide metabolic process 0.4 0.3  0.7 0.6  1.0 0.5 
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SC5314+FLC
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/cas5Δ/Δ 
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orf19 
Designation 
CGD 
Name Processa Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
orf19.6010 CDC5 signal transduction during filamentous growth 0.4 0.3  1.0 1.3  0.2 0.2 
orf19.7023 
 
chromatin remodeling 0.4 0.3  0.5 0.5  0.1 0.4 
orf19.5071 NRP1 
 
0.4 0.5  0.6 1.7  1.0 0.8 
orf19.4284 BUR2 mitotic sister chromatid segregation 0.4 0.3  1.7 4.8  0.4 2.5 
orf19.34 GIT1 phospholipid transport  0.4 0.1  0.7 0.1  0.2 0.0 
orf19.3016 
 
meiotic chromosome segregation 0.4 0.3  0.8 0.9  0.9 1.0 
orf19.7324 THI13 thiamin biosynthetic process 0.4 0.5  1.0 0.8  0.8 0.8 
orf19.5839 PDR17 sterol biosynthetic process 0.4 0.3  0.9 1.7  0.9 0.6 
orf19.3394 
  
0.4 0.4  0.4 0.4  0.8 0.7 
orf19.6489 FMP45 cellular cell wall organization 0.4 0.3  3.1 2.1  32.8 9.5 
orf19.5745 ALS9 cell adhesion 0.4 0.4  0.2 0.1  0.3 0.3 
orf19.3688 
 
cell wall mannoprotein biosynthetic process 0.4 0.5  1.3 1.5  0.7 1.4 
orf19.3252 DAL81 positive regulation of cell adhesion 0.4 0.3  1.3 1.6  0.8 0.9 
orf19.4026 HIS1 histidine biosynthetic process 0.4 0.4  0.7 0.7  0.4 0.7 
orf19.103 KAR5 karyogamy involved in conjugation with cellular fusion 0.4 0.4  1.0 1.5  0.7 2.6 
orf19.6948 CCC1 cellular calcium ion homeostasis 0.4 0.3  0.7 0.7  1.7 0.9 
orf19.3446 
 
protein import into nucleus 0.4 0.3  0.5 0.6  0.2 0.7 
orf19.514 SNP3 nuclear mRNA splicing, via spliceosome  0.4 0.2  0.4 0.5  0.1 0.3 
orf19.7479 NTH1 trehalose catabolic process 0.4 0.5  0.3 0.3  0.3 0.5 
orf19.687 
  
0.4 0.2  0.8 1.3  0.7 0.5 
orf19.908 FEN12 fatty acid elongation 0.4 0.3  0.5 0.8  0.3 0.3 
orf19.3211 RCF3 leading strand elongation 0.4 0.4  0.8 1.2  0.3 0.4 
orf19.708 
 
microtubule nucleation 0.4 0.4  0.7 0.9  0.5 0.4 
orf19.348 SKN2 1,6-beta-glucan biosynthetic process 0.4 0.3  1.4 1.3  3.2 2.3 
orf19.756 SAP7 pathogenesis 0.4 0.4  0.9 0.6  13.6 6.6 
orf19.3322 DUT1 DNA replication  0.4 0.4  0.8 0.8  0.3 0.2 
orf19.1168 ZCF3 filamentous growth 0.4 0.1  1.5 2.2  0.5 1.0 
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CGD 
Name Processa Exp1 Exp2 
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orf19.4447 YMC1 mitochondrial transport  0.4 0.4  0.4 0.6  0.4 0.5 
orf19.7279 
 
nitrogen compound metabolic process 0.4 0.2  1.0 1.3  0.4 0.3 
orf19.927 
 
telomere maintenance  0.4 0.2  1.3 1.8  1.0 1.6 
orf19.2686 
 
nitrogen compound metabolic process 0.4 0.5  1.1 1.1  0.7 0.4 
orf19.6786 
  
0.4 0.0  3.0 9.2  0.7 1.5 
orf19.5242 CDC6  DNA replication initiation 0.4 0.5  0.7 2.2  0.1 0.1 
orf19.5736 ALS5 cell adhesion 0.4 0.3  0.7 1.1  3.0 2.2 
orf19.7100 
 
amino acid transport 0.4 0.4  0.6 0.8  1.0 0.5 
orf19.1832 FCY23 vitamin transport 0.4 0.4  1.1 2.7  0.7 0.4 
orf19.4301 
 
chromatin silencing at rDNA 0.4 0.4  1.0 2.8  1.1 0.2 
orf19.7293 MPS1 mitotic cell cycle spindle assembly checkpoint  0.4 0.5  1.6 4.5  0.8 0.7 
orf19.321 
 
amino acid transport 0.4 0.5  0.4 0.4  0.9 0.6 
orf19.6416 
 
cellular response to oxidative stress 0.4 0.4  2.2 3.3  3.8 2.0 
orf19.4280 
  
0.4 0.5  0.3 0.4  0.2 0.5 
orf19.333 FCY2 drug transport 0.4 0.4  0.2 0.3  0.1 0.2 
orf19.398 
  
0.4 0.4  1.3 1.2  1.2 1.3 
orf19.4998 ROB1 cellular amino acid catabolic process 0.4 0.4  0.3 0.4  0.1 0.3 
orf19.7344 
 
chromosome segregation 0.4 0.4  1.8 3.5  0.6 1.2 
orf19.7427 
  
0.4 0.3  0.7 1.1  1.9 1.3 
orf19.1308 
 
drug transport  0.4 0.3  1.1 1.6  1.0 0.5 
orf19.660 
  
0.4 0.4  2.0 3.5  1.8 2.1 
orf19.1318 
  
0.4 0.2  0.8 1.3  0.6 0.6 
orf19.4161 
 
DNA repair 0.4 0.4  2.4 4.3  0.6 0.3 
orf19.4665 
  
0.4 0.4  0.6 0.7  0.7 0.6 
orf19.7554 
 
drug transport  0.5 0.3  1.1 2.0  10.9 11.4 
orf19.1240 
  
0.5 0.5  0.6 0.5  0.7 0.5 
orf19.6784 PGA32 cellular cell wall organization 0.5 0.4  0.9 1.4  0.4 0.2 
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        Change in Fold Expression 
   
SC5314+FLC
/SC5314 
 cas5Δ/Δ+FLC
/cas5Δ/Δ 
 upc2Δ/Δ+FLC/
upc2Δ/Δ 
orf19 
Designation 
CGD 
Name Processa Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
orf19.28 
 
thiamin pyrophosphate transport 0.5 0.3  0.7 0.8  0.5 1.0 
orf19.2951 HOM6 methionine metabolic process  0.5 0.4  0.6 0.6  0.5 0.6 
orf19.1238 TUB4 microtubule nucleation 0.5 0.4  1.1 1.3  0.7 0.8 
orf19.7083 DCC1 mitotic sister chromatid cohesion 0.5 0.4  0.9 1.6  0.5 0.5 
orf19.2336 
  
0.5 0.4  0.6 0.8  0.6 0.9 
orf19.5074 
 
protein sumoylation 0.5 0.4  1.0 1.4  0.7 0.5 
orf19.1948 
  
0.5 0.4  0.8 0.8  0.4 0.4 
orf19.4046 
  
0.5 0.5  0.5 0.4  0.7 1.0 
orf19.3788 SPC34 mitotic spindle organization in nucleus 0.5 0.3  1.2 1.2  0.8 1.3 
orf19.1613 ILV2 branched chain family amino acid biosynthetic process 0.5 0.5  0.5 0.7  0.2 0.2 
orf19.3042 
  
0.5 0.4  1.0 3.3  1.1 3.5 
orf19.4040 ILV3 branched chain family amino acid biosynthetic process 0.5 0.5  0.4 0.3  0.1 0.2 
orf19.1847 ARO10 aromatic amino acid family catabolic process to alcohol  0.5 0.4  0.8 0.6  0.5 0.1 
orf19.5917.3 
 
mRNA export from nucleus 0.5 0.4  0.4 0.4  0.2 0.2 
orf19.2849 AQY1 response to osmotic stress 0.5 0.5  0.6 0.5  0.0 0.0 
orf19.6177 
  
0.5 0.3  0.8 0.9  0.2 0.4 
orf19.6858 EDC3 cytoplasmic mRNA processing body assembly 0.5 0.4  1.8 2.0  0.6 1.1 
orf19.547 
 
DNA replication, removal of RNA primer 0.5 0.3  1.8 8.1  1.3 0.5 
orf19.1796 
 
metabolic process 0.5 0.4  0.3 0.3  0.3 0.5 
orf19.6671 LAP4 vacuolar protein catabolic process 0.5 0.3  0.9 0.7  0.8 0.6 
orf19.6189 
 
cellular modified amino acid biosynthetic process 0.5 0.5  0.5 0.6  1.0 1.1 
orf19.4233 THR4 threonine metabolic process 0.5 0.5  0.5 0.4  0.2 0.4 
orf19.2547 
  
0.5 0.2  1.7 2.7  0.9 1.0 
orf19.704 SOL3 tRNA processing 0.5 0.3  0.7 0.5  0.4 0.4 
orf19.6936 RAD53 hyphal growth 0.5 0.3  0.9 1.3  0.7 0.6 
orf19.1626 
 
peptidyl-lysine modification to hypusine 0.5 0.4  0.3 0.4  0.1 0.3 
orf19.6751 
 
tRNA methylation 0.5 0.3  0.7 1.6  0.5 1.3 
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        Change in Fold Expression 
   
SC5314+FLC
/SC5314 
 cas5Δ/Δ+FLC
/cas5Δ/Δ 
 upc2Δ/Δ+FLC/
upc2Δ/Δ 
orf19 
Designation 
CGD 
Name Processa Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
orf19.7244 
 
regulation of transcription, DNA-dependent 0.5 0.5  0.8 0.9  0.3 0.6 
orf19.6291 
 
chromosome organization 0.5 0.4  2.0 2.5  1.0 0.7 
orf19.802 UGA1 gamma-aminobutyric acid catabolic process 0.5 0.5  1.5 2.0  0.5 0.6 
orf19.105 HAL22 methionine biosynthetic process 0.5 0.5  0.9 0.7  0.7 0.5 
orf19.1802 
 
translational termination  0.5 0.5  0.2 0.2  0.1 0.2 
orf19.7375 
 
nuclear mRNA splicing, via spliceosome 0.5 0.3  1.3 1.8  1.1 2.1 
orf19.7358 SAM50 protein complex assembly 0.5 0.1  0.7 1.2  0.5 0.4 
orf19.5647 SUB2 RNA elongation from RNA polymerase II promoter  0.5 0.5  0.4 0.4  0.3 0.4 
orf19.2637 
 
response to unfolded protein  0.5 0.3  0.5 0.6  0.4 0.4 
orf19.4809 ERG12 ergosterol biosynthetic process 0.5 0.4  0.5 0.9  0.5 0.5 
orf19.6365 PTP1 protein amino acid dephosphorylation 0.5 0.4  0.4 0.5  0.9 1.1 
orf19.2969 RAD16 nucleotide-excision repair, DNA damage recognition 0.5 0.5  0.4 0.4  0.3 0.7 
orf19.5825 NCB2 negative regulation of transcription from RNA polymerase II  0.5 0.2  0.7 0.7  0.4 0.6 
orf19.7152 
 
cysteine biosynthetic process 0.5 0.5  0.8 0.7  0.7 0.6 
orf19.6692 MNN7 protein amino acid glycosylation 0.5 0.4  0.9 1.1  0.9 0.6 
orf19.3972 
 
ER to Golgi vesicle-mediated transport  0.5 0.4  1.2 1.6  1.3 1.0 
orf19.5528 MOB1 mitosis 0.5 0.5  0.3 0.2  0.5 0.6 
orf19.3914 
 
translational initiation 0.5 0.3  0.9 1.0  0.3 0.4 
orf19.3089 
 
cardiolipin metabolic process 0.5 0.3  1.2 1.9  0.9 1.0 
orf19.5841 
  
0.5 0.5  0.7 0.8  0.8 1.0 
orf19.5919 MEA1 actin cortical patch localization 0.5 0.3  1.1 1.4  0.8 0.5 
orf19.5665 
 
dehydro-D-arabinono-1,4-lactone biosynthetic process 0.5 0.5  0.8 1.0  1.0 0.7 
orf19.6755 DLD2 aerobic respiration 0.5 0.5  0.6 0.4  0.4 0.5 
orf19.1358 GCN4 filamentous growth 0.5 0.5  0.6 0.6  0.2 0.3 
orf19.5034 YBP1 response to oxidative stress 0.5 0.5  0.7 0.9  0.8 0.9 
orf19.3870 ADE13 purine base metabolic process 0.5 0.4  1.0 0.9  0.2 0.2 
orf19.4148 
  
0.5 0.3  0.8 0.7  0.2 0.3 
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        Change in Fold Expression 
   
SC5314+FLC
/SC5314 
 cas5Δ/Δ+FLC
/cas5Δ/Δ 
 upc2Δ/Δ+FLC/
upc2Δ/Δ 
orf19 
Designation 
CGD 
Name Processa Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
orf19.4612 
  
0.5 0.2  0.2 0.3  0.8 3.7 
orf19.3141 
 
ER to Golgi vesicle-mediated transport  0.5 0.5  1.1 1.7  0.7 0.6 
orf19.2763 
 
meiotic telomere clustering 0.5 0.4  1.7 1.7  0.8 0.9 
orf19.1115 GUK1 GMP metabolic process 0.5 0.5  0.7 1.1  0.2 0.2 
orf19.6399 ATS1 budding cell bud growth 0.5 0.4  0.9 0.9  1.5 1.5 
orf19.4774 AOX1 aerobic respiration 0.5 0.4  1.3 1.2  1.6 1.1 
orf19.6237 RAC1 filamentous growth  0.5 0.3  0.8 1.1  0.5 0.6 
orf19.2092 
 
methionine biosynthetic process 0.5 0.5  0.6 0.8  0.8 0.7 
orf19.6737 
  
0.5 0.4  1.0 1.2  0.9 0.6 
orf19.5572 
 
protein amino acid N-linked glycosylation 0.5 0.5  0.4 0.4  1.1 0.8 
orf19.5648 
  
0.5 0.3  0.8 1.2  0.5 0.7 
orf19.3471 
 
regulation of mitotic metaphase/anaphase transition 0.5 0.4  0.7 0.5  0.3 0.7 
orf19.1986 ARO2 aromatic amino acid family biosynthetic process 0.5 0.5  0.5 0.6  0.2 0.3 
orf19.939 NAM7 intracellular mRNA localization 0.5 0.5  1.2 1.4  0.9 0.7 
orf19.6628 
 
chromosome segregation 0.5 0.4  1.2 1.1  0.3 0.9 
orf19.3364 
  
0.5 0.4  0.7 0.7  0.4 0.5 
orf19.3965 
 
double-strand break repair via homologous recombination 0.5 0.5  0.5 0.8  0.7 0.6 
orf19.3449.2  
 
cardiolipin biosynthetic process 0.5 0.3  0.7 0.7  0.3 0.4 
orf19.2693 GST2 regulation of nitrogen utilization 0.5 0.3  1.1 0.7  0.5 0.3 
orf19.3964 ASH2 chromatin silencing at telomere 0.5 0.4  1.1 1.9  0.8 0.7 
orf19.2213 
  
0.5 0.4  1.8 3.0  0.7 1.4 
orf19.1235 HOM3 methionine metabolic process  0.5 0.5  0.3 0.6  0.2 0.4 
orf19.6952 
 
gene silencing by RNA 0.5 0.5  0.5 0.4  0.4 0.6 
orf19.1852 
  
0.5 0.4  0.6 1.0  0.3 0.4 
orf19.6167 AYR1 phosphatidic acid biosynthetic process 0.5 0.5  0.6 0.9  0.8 0.6 
orf19.390 CDC42 cell budding 0.5 0.5  0.8 1.0  0.9 0.7 
orf19.7499 
 
nicotinate nucleotide salvage 0.5 0.5  0.3 0.4  0.4 0.5 
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        Change in Fold Expression 
   
SC5314+FLC
/SC5314 
 cas5Δ/Δ+FLC
/cas5Δ/Δ 
 upc2Δ/Δ+FLC/
upc2Δ/Δ 
orf19 
Designation 
CGD 
Name Processa Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
orf19.7545 
  
0.5 0.5  0.6 1.0  0.8 1.0 
orf19.1600 
  
0.5 0.3  0.8 2.5  1.0 0.4 
orf19.6929 
  
0.5 0.3  0.4 0.4  0.2 0.3 
orf19.7484 ADE1 adenine biosynthetic process  0.5 0.3  0.8 0.8  0.3 0.3 
orf19.3894 
 
response to drug 0.5 0.2  2.5 5.1  2.9 3.8 
orf19.7615 
 
ER to Golgi vesicle-mediated transport 0.5 0.2  1.4 3.3  1.4 1.2 
orf19.4523 
 
folic acid and derivative biosynthetic process 0.5 0.3  0.4 0.3  0.4 1.0 
orf19.7017 YOX1 regulation of mitotic cell cycle 0.5 0.4  2.2 3.1  2.0 1.3 
orf19.6400 
 
inositol metabolic process 0.5 0.5  1.2 1.5  1.3 1.2 
orf19.2533.1 
 
cotranslational protein targeting to membrane 0.5 0.3  0.9 1.1  0.4 0.6 
orf19.3459 
 
ascospore formation 0.5 0.5  0.8 0.7  1.0 0.7 
orf19.7097 
 
response to drug 0.5 0.4  0.9 1.3  0.7 0.8 
orf19.4880 
  
0.5 0.5  1.3 1.2  1.0 0.5 
orf19.6976 
 
folic acid transport 0.5 0.3  2.1 2.5  1.0 0.4 
orf19.3395 
 
drug transport 0.5 0.4  0.3 0.2  0.6 0.4 
orf19.2870 
  
0.5 0.4  4.1 4.6  1.5 1.1 
orf19.1959 
 
protein deubiquitination 0.5 0.3  1.3 2.3  0.3 1.1 
orf19.4580 
  
0.5 0.3  0.3 0.2  0.1 0.5 
orf19.2546 TRP2 tryptophan biosynthetic process 0.5 0.5  0.6 0.6  0.2 0.4 
orf19.6875 VPS35 protein retention in Golgi apparatus 0.5 0.5  0.8 0.7  0.6 0.5 
orf19.5211 IDP1 glutamate biosynthetic process 0.5 0.5  0.9 0.9  0.3 0.3 
orf19.6017 
  
0.5 0.4  1.4 1.2  0.4 0.6 
orf19.6316 
 
L-amino acid transport 0.5 0.3  0.8 0.8  0.8 0.5 
orf19.6885 SPO7 meiosis  0.5 0.5  1.0 1.5  1.7 1.3 
orf19.1782 
  
0.5 0.3  0.5 0.6  0.2 0.3 
orf19.3872 
  
0.5 0.4  0.5 0.5  1.1 1.0 
orf19.2267 RFA2 DNA strand elongation during DNA replication 0.5 0.5  0.9 0.8  0.4 0.3 
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SC5314+FLC
/SC5314 
 cas5Δ/Δ+FLC
/cas5Δ/Δ 
 upc2Δ/Δ+FLC/
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orf19 
Designation 
CGD 
Name Processa Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
orf19.7454 TAF60 chromatin organization 0.5 0.4  1.1 1.3  0.7 0.7 
orf19.4036 APM1 filamentous growth 0.5 0.5  1.2 1.8  1.2 0.9 
orf19.2581 
 
cellular metabolic process 0.5 0.5  0.7 1.3  0.4 0.6 
orf19.4749 
  
0.5 0.5  1.0 1.1  0.8 0.3 
orf19.4616 POL30 base-excision repair 0.5 0.5  0.6 0.6  0.2 0.2 
orf19.3442 
 
oxidation-reduction process 0.5 0.5  0.5 0.4  0.5 0.8 
orf19.985 
  
0.5 0.4  1.4 1.9  0.6 0.7 
orf19.2040 
 
hydrogen peroxide-mediated programmed cell death 0.5 0.3  1.2 1.4  1.1 1.4 
orf19.7638 PRO1 proline biosynthetic process 0.5 0.5  0.3 0.3  0.5 1.0 
orf19.4205.1 
 
nuclear mRNA splicing, via spliceosome 0.5 0.4  0.4 0.6  0.4 0.6 
orf19.2461 PRN4 
 
0.5 0.3  1.4 1.2  1.6 2.0 
orf19.2949 
 
intracellular signal transduction 0.5 0.5  1.6 2.3  1.0 0.6 
orf19.6650 
  
0.5 0.4  1.1 1.5  1.8 2.1 
orf19.7095 
  
0.5 0.5  0.3 0.4  0.5 0.5 
orf19.6635 
  
0.5 0.4  1.1 1.0  0.9 1.7 
orf19.1913 
  
0.5 0.4  0.5 0.7  0.4 0.7 
orf19.5628 
 
dicarboxylic acid transport 0.5 0.3  0.2 0.2  0.3 0.5 
orf19.4022 SDH4 succinate metabolic process 0.5 0.5  0.5 1.0  0.3 0.6 
orf19.3761 CDC54 DNA replication initiation  0.5 0.5  2.1 3.6  0.3 0.1 
orf19.3679 
 
nicotinamide nucleotide metabolic process 0.5 0.4  0.6 0.5  0.6 0.6 
orf19.4553 
  
0.5 0.5  1.0 1.3  1.2 0.7 
orf19.511 
 
nicotinamide riboside metabolic process 0.5 0.4  0.6 0.8  0.4 0.6 
orf19.7175 HLJ1 ER-associated protein catabolic process 0.5 0.5  0.7 1.0  0.8 0.8 
orf19.95 
  
0.5 0.5  1.6 3.2  0.9 0.4 
orf19.3040 EHT1 medium-chain fatty acid biosynthetic process  0.5 0.5  0.3 0.2  0.2 0.3 
orf19.5505 HIS7 histidine biosynthetic process 0.5 0.4  1.0 1.1  0.4 0.5 
orf19.4748 
 
nuclear mRNA splicing, via spliceosome  0.5 0.4  0.8 0.9  0.4 0.9 
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CGD 
Name Processa Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
orf19.434 PRD1 proteolysis 0.5 0.5  0.6 0.4  0.4 0.4 
orf19.7631 SLD5 DNA-dependent DNA replication 0.5 0.4  1.6 1.4  1.0 0.5 
orf19.6779 PRO2 proline biosynthetic process 0.5 0.4  1.5 1.8  0.9 0.8 
orf19.1973 HAP5 filamentous growth 0.5 0.3  1.2 1.4  0.4 0.6 
orf19.1681 
  
0.5 0.5  0.9 0.8  3.0 3.6 
orf19.3844 MRP8 translation 0.5 0.5  0.6 0.5  0.7 1.3 
orf19.306 USO5 ER to Golgi vesicle-mediated transport  0.5 0.5  1.8 2.0  1.3 1.7 
orf19.4270 
 
protein amino acid O-linked glycosylation  0.5 0.5  1.4 1.2  1.1 0.9 
orf19.993 
  
0.5 0.2  0.9 0.9  0.4 0.3 
orf19.2898 
 
protein targeting to vacuole  0.5 0.4  1.5 1.8  6.3 3.1 
orf19.3534 RHO3 hyphal growth 0.5 0.4  0.9 1.2  1.3 0.9 
orf19.4817 RAM2 protein geranylgeranylation 0.5 0.3  0.5 0.5  0.3 0.6 
orf19.244 DCG1 nitrogen compound metabolic process 0.5 0.3  1.0 0.9  0.6 0.4 
orf19.7370 
  
0.5 0.4  1.5 2.4  2.5 1.6 
orf19.4575 
  
0.5 0.3  0.5 0.8  0.2 0.2 
orf19.7304 
  
0.5 0.5  0.9 0.9  0.8 0.4 
orf19.3715 ASF1 DNA replication-dependent nucleosome assembly 0.5 0.5  1.0 2.1  0.3 0.2 
orf19.424 TRP99 response to oxidative stress 0.5 0.4  1.0 1.1  0.6 0.7 
orf19.2923 
 
drug transport 0.5 0.5  0.5 0.4  0.9 0.7 
orf19.6813 
  
0.5 0.3  1.0 1.0  0.4 0.2 
orf19.2087 SAS2 chromatin silencing at telomere 0.5 0.4  1.3 2.2  0.7 0.7 
orf19.6563 
  
0.5 0.5  1.0 1.3  1.7 1.1 
orf19.3043 
 
lipid metabolic process 0.5 0.4  0.9 1.0  0.9 0.8 
orf19.4796 
 
negative regulation of translation 0.5 0.4  1.0 1.5  0.3 0.5 
orf19.1999 
  
0.5 0.4  0.5 0.3  0.6 1.1 
orf19.1828 BUD16 cellular bud site selection 0.5 0.3  1.3 3.1  1.0 0.9 
orf19.5487 CDC46 DNA replication initiation 0.5 0.4  0.9 2.3  0.2 0.1 
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CGD 
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orf19.4024 RIB5 riboflavin biosynthetic process 0.5 0.4  0.8 1.0  0.5 0.7 
orf19.5363 
 
dolichol-linked oligosaccharide biosynthetic process 0.5 0.5  0.5 0.6  0.5 0.6 
orf19.7414 ALS6 cell adhesion 0.5 0.4  0.7 1.1  0.7 0.6 
orf19.1795.1 
 
protein targeting to ER 0.5 0.5  0.2 0.3  0.3 0.5 
a Descriptions are from the Candida Genome Database (http://www.candidagenome.org). 
Red indicates those identified to be fluconazole repressed and dependent on Cas5 or Upc2. 
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APPENDIX B.  CAS5 SUPPLEMENTAL DATA 
 
 
Table B-1. TF disruptant clones displaying a reduction in FLC MIC in RPMI, 
rescreened in YPD 
 
  orf19 
Designation 
MIC (µg/ml)  MFC (µg/ml) 
Clone ID CGD RPMI YPD  RPMI YPD 
WT -- -- 0.25 0.5  >4 >64 
TF3 RPN4 orf19.1069 0.0625 0.25  0.125 32 
TF4 -- orf19.1253 SGa 0.5  SG >64 
TF33 CAS5 orf19.4670 0.125 0.25  4 2 
TF45 GAL4 orf19.5338 0.125 0.5  >4 >64 
TF59 ACE2 orf19.6124 0.03125 0.5  2 >64 
TF77 UPC2 orf19.391 0.03125 0.125  1 1 
TF82 STP4 orf19.909 0.125 0.5  >4 >64 
TF95 NDT80 orf19.2119 0.03125 0.5  >4 >64 
TF103 HFL1 orf19.3063 NGa NG  NG NG 
TF104 CZF1 orf19.3127 0.0625 0.5  0.25 8 
TF126 RIM101 orf19.7247 0.0625 0.5  >4 4 
TF127 ISW2 orf19.7401 0.0625 0.25  >4 16 
TF155 DAL81 orf19.3252 0.0625 0.5  4 >64 
TF158 RAP1 orf19.1773 0.03125 0.5  >4 >64 
TF159 -- orf19.1757 0.03125 0.5  >4 >64 
TF160 -- orf19.2743 0.03125 0.5  >4 >64 
TF163 RFX1 orf19.3865 0.0078125 0.25  >4 >64 
TF164 RGT1 orf19.2747 0.0625 0.5  >4 >64 
TF165 PPR1 orf19.3986 0.03125 0.25  >4 >64 
a Abbreviations: Slow growth (SG), No growth (NG) 
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Table B-2. Genes downregulated by at least 0.5-fold by fluconazole which are dependent upon Cas5 and Upc2 
 
      Change in Fold Expression         
 
   
SC5314+FLC/ 
SC5314 (A) 
 cas5Δ/Δ+FLC/ 
cas5Δ/Δ (B) 
 upc2Δ/Δ+FLC/ 
upc2Δ/Δ (C) 
 CAS5 Ratio 
(B/A) 
 UPC2 Ratio 
(C/A) 
   
    
Processa 
orf19 
Designation 
CGD 
Name Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
Lipid metabolic 
process 
orf19.1887 
 
0.1 0.1  0.4 0.5  0.6 0.5  2.8 3.2  4.4 3.3 
orf19.3043 
 
0.5 0.4  0.9 1.0  0.9 0.8  1.6 2.6  1.6 2.0 
 
orf19.3089 
 
0.5 0.3  1.2 1.9  0.9 1.0  2.5 5.7  1.9 2.9 
 
orf19.3104 YDC1 0.4 0.3  0.7 0.6  1.0 0.5  1.8 2.0  2.3 1.6 
     
 
  
 
  
 
  
 
  Cell wall 
organization 
orf19.5032 SIM1 0.3 0.4  0.6 1.0  0.8 1.0  1.8 2.7  2.5 2.6 
orf19.6489 FMP45 0.4 0.3  3.1 2.1  32.8 9.5  7.3 6.9  78.0 31.0 
     
 
  
 
  
 
  
 
  Iron ion transport orf19.6948 CCC1 0.4 0.3  0.7 0.7  1.7 0.9  1.7 2.1  4.0 2.7 
     
 
  
 
  
 
  
 
  Drug transport orf19.1308 
 
0.4 0.3  1.1 1.6  1.0 0.5  2.4 5.8  2.3 1.6 
 
orf19.4889 
 
0.3 0.2  0.7 1.0  0.6 0.5  2.6 4.3  2.3 2.2 
 
orf19.6691 
 
0.4 0.4  0.6 1.3  1.8 1.4  1.6 3.7  4.7 4.0 
 
orf19.7554 
 
0.5 0.3  1.1 2.0  10.9 11.4  2.5 6.1  24.1 34.1 
     
 
  
 
  
 
  
 
  Transport orf19.1182 
 
0.3 0.3  0.7 1.0  0.8 0.5  2.1 3.6  2.5 1.9 
 
orf19.2337 ALP1 0.1 0.1  0.3 0.4  0.4 0.3  3.2 7.5  5.0 6.1 
 
orf19.2738 SUL2 0.1 0.3  1.7 1.2  5.4 0.8  12.8 4.7  40.5 3.1 
 
orf19.2898 
 
0.5 0.4  1.5 1.8  6.3 3.1  2.8 4.8  11.7 8.1 
 
orf19.3972 
 
0.5 0.4  1.2 1.6  1.3 1.0  2.5 3.7  2.7 2.4 
 
orf19.4456 GAP4 0.2 0.3  0.5 0.7  0.9 0.6  1.9 2.2  3.6 1.8 
 
orf19.4733 YMC2 0.3 0.3  0.9 0.9  0.9 0.4  2.9 3.3  2.7 1.7 
 
orf19.5017 DUR32 0.1 0.1  0.7 0.6  0.9 0.2  6.8 4.6  8.7 1.7 
 
orf19.5663 RCH1 0.3 0.2  0.9 0.8  1.3 1.6  3.1 3.9  4.5 8.2 
 
orf19.6316 
 
0.5 0.3  0.8 0.8  0.8 0.5  1.5 3.3  1.6 1.9 
 
orf19.6563 
 
0.5 0.5  1.0 1.3  1.7 1.1  1.9 2.4  3.0 2.1 
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Table B-2. (Continued) 
 
      Change in Fold Expression         
 
   
SC5314+FLC/ 
SC5314 (A) 
 cas5Δ/Δ+FLC/ 
cas5Δ/Δ (B) 
 upc2Δ/Δ+FLC/ 
upc2Δ/Δ (C) 
 CAS5 Ratio 
(B/A) 
 UPC2 Ratio 
(C/A) 
   
    
Processa 
orf19 
Designation 
CGD 
Name Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
 
orf19.7106 VPS70 0.4 0.5  1.0 1.1  3.9 1.0  2.4 2.4  9.7 2.2 
 
orf19.7370 
 
0.5 0.4  1.5 2.4  2.5 1.6  2.8 6.9  4.6 4.5 
 
orf19.7615 
 
0.5 0.2  1.4 3.3  1.4 1.2  2.8 13.2  2.7 4.9 
     
 
  
 
  
 
  
 
  Response to stress orf19.4526 HSP30 0.2 0.1  2.6 1.2  0.8 1.5  15.6 12.6  5.2 15.9 
 
orf19.5034 YBP1 0.5 0.5  0.7 0.9  0.8 0.9  1.5 1.9  1.7 1.9 
 
orf19.6779 PRO2 0.5 0.4  1.5 1.8  0.9 0.8  2.7 4.1  1.7 1.8 
 
orf19.946 MET14 0.1 0.1  1.1 2.5  0.4 0.2  14.5 28.5  5.4 2.6 
     
 
  
 
  
 
  
 
  Response to 
chemical stimulus 
orf19.3106 MET16 0.2 0.3  0.8 1.4  1.2 0.6  3.5 5.2  4.8 2.3 
orf19.3252 DAL81 0.4 0.3  1.3 1.6  0.8 0.9  3.1 4.6  1.8 2.6 
 
orf19.3894 
 
0.5 0.2  2.5 5.1  2.9 3.8  5.0 24.2  5.7 17.7 
 
orf19.4177 HIS5 0.4 0.5  1.1 1.2  0.9 0.9  2.7 2.6  2.3 1.9 
 
orf`19.5839 PDR17 0.4 0.3  0.9 1.7  0.9 0.6  2.2 5.3  2.1 2.0 
 
orf19.6671 LAP4 0.5 0.3  0.9 0.7  0.8 0.6  2.0 2.2  1.8 1.7 
     
 
  
 
  
 
  
 
  Oxidation-
reduction process 
orf19.2040 
 
0.5 0.3  1.2 1.4  1.1 1.4  2.3 4.0  2.1 4.2 
orf19.3810 
 
0.4 0.3  1.1 1.9  1.2 0.7  2.9 5.6  3.0 2.1 
 
orf19.5665 
 
0.5 0.5  0.8 1.0  1.0 0.7  1.6 1.9  2.1 1.5 
 
orf19.7098 
 
0.2 0.1  0.9 0.8  0.6 0.9  4.4 5.7  2.7 7.0 
     
 
  
 
  
 
  
 
  Filamentous 
growth 
orf19.1253 PHO4 0.3 0.2  1.0 1.5  0.8 0.6  3.1 6.5  2.5 2.8 
orf19.1621 GPA2 0.4 0.5  0.7 0.8  0.9 1.0  2.0 1.6  2.6 1.8 
 
orf19.4036 APM1 0.5 0.5  1.2 1.8  1.2 0.9  2.3 3.5  2.3 1.7 
 
orf19.5992 WOR2 0.3 0.2  0.5 0.4  0.9 0.6  1.9 1.8  3.2 2.4 
 
orf19.7025 MCM1 0.3 0.4  0.5 0.6  0.5 0.7  1.9 1.7  1.8 1.8 
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Table B-2. (Continued) 
 
      Change in Fold Expression         
 
   
SC5314+FLC/ 
SC5314 (A) 
 cas5Δ/Δ+FLC/ 
cas5Δ/Δ (B) 
 upc2Δ/Δ+FLC/ 
upc2Δ/Δ (C) 
 CAS5 Ratio 
(B/A) 
 UPC2 Ratio 
(C/A) 
   
    
Processa 
orf19 
Designation 
CGD 
Name Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
 
orf19.7324 THI13 0.4 0.5  1.0 0.8  0.8 0.8  2.3 1.6  2.0 1.7 
     
 
  
 
  
 
  
 
  Organelle 
organization orf19.103 KAR5 0.4 0.4 
 
1.0 1.5 
 
0.7 2.6 
 
2.4 4.2 
 
1.5 7.2 
 
orf19.1238 TUB4 0.5 0.4  1.1 1.3  0.7 0.8  2.4 3.0  1.6 1.9 
 
orf19.2600 SPC98 0.4 0.4  1.6 3.7  1.7 1.3  4.5 9.8  4.8 3.5 
 
orf19.2763 
 
0.5 0.4  1.7 1.7  0.8 0.9  3.5 3.8  1.7 1.9 
 
orf19.3534 RHO3 0.5 0.4  0.9 1.2  1.3 0.9  1.7 3.0  2.4 2.3 
 
orf19.3688 
 
0.4 0.5  1.3 1.5  0.7 1.4  3.0 3.3  1.6 3.0 
 
orf19.3788 SPC34 0.5 0.3  1.2 1.2  0.8 1.3  2.6 3.6  1.8 3.7 
 
orf19.6291 
 
0.5 0.4  2.0 2.5  1.0 0.7  4.3 6.3  2.1 1.7 
 
orf19.6399 ATS1 0.5 0.4  0.9 0.9  1.5 1.5  1.9 2.6  3.0 4.2 
 
orf19.6885 SPO7 0.5 0.5  1.0 1.5  1.7 1.3  1.8 3.1  3.3 2.8 
     
 
  
 
  
 
  
 
  Cell cycle orf19.1828 BUD16 0.5 0.3  1.3 3.1  1.0 0.9  2.4 10.9  1.8 3.3 
 
orf19.3016 
 
0.4 0.3  0.8 0.9  0.9 1.0  1.9 3.0  2.1 3.6 
 
orf19.3230 BOI2 0.4 0.4  1.0 1.4  1.5 0.9  2.7 3.2  4.1 2.1 
 
orf19.5919 MEA1 0.3 1.1  1.4 0.8  0.5 2.3  4.4 1.6  1.6 
 
 
orf19.7017 YOX1 0.5 0.4  2.2 3.1  2.0 1.3  4.4 8.2  4.0 3.5 
     
 
  
 
  
 
  
 
  DNA metabolic 
process 
orf19.3964 ASH2 0.5 0.4  1.1 1.9  0.8 0.7  2.1 4.9  1.6 1.8 
orf19.547 
 
0.5 0.3  1.8 8.1  1.3 0.5  3.9 25.0  2.9 1.6 
 
orf19.7190 OGG1 0.4 0.4  3.5 5.1  1.6 0.6  9.4 13.9  4.3 1.6 
 
orf19.7310 
 
0.3 0.3  2.5 2.6  1.1 0.5  9.5 8.4  4.2 1.6 
 
orf19.927 
 
0.4 0.2  1.3 1.8  1.0 1.6  3.1 8.4  2.3 7.1 
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Table B-2. (Continued) 
 
      Change in Fold Expression         
 
   
SC5314+FLC/ 
SC5314 (A) 
 cas5Δ/Δ+FLC/ 
cas5Δ/Δ (B) 
 upc2Δ/Δ+FLC/ 
upc2Δ/Δ (C) 
 CAS5 Ratio 
(B/A) 
 UPC2 Ratio 
(C/A) 
   
    
Processa 
orf19 
Designation 
CGD 
Name Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
Carbohydrate 
metabolic process 
orf19.4270 MNN13 0.5 0.5  1.4 1.2  1.1 0.9  2.6 2.3  2.0 1.7 
orf19.5612 BMT4 0.4 0.3  0.7 0.6  1.0 0.6  1.7 2.1  2.5 2.1 
 
orf19.6400 
 
0.5 0.5  1.2 1.5  1.3 1.2  2.4 3.0  2.5 2.3 
 
orf19.6416 
 
0.4 0.4  2.2 3.3  3.8 2.0  5.0 7.4  8.5 4.4 
 
orf19.6692 MNN26 0.5 0.4  0.9 1.1  0.9 0.6  1.8 3.1  1.8 1.7 
     
 
  
 
  
 
  
 
  Other orf19.1159 
 
0.3 0.5  1.6 2.9  4.0 1.1  5.4 5.9  13.2 2.1 
 
orf19.1697 
 
0.3 0.4  1.0 1.9  0.5 0.9  2.9 5.0  1.5 2.3 
 
orf19.1757 
 
0.4 0.2  1.6 3.3  0.7 0.6  4.1 14.1  1.9 2.7 
 
orf19.2018 
 
0.3 0.3  2.1 4.1  2.0 2.3  7.2 12.4  6.9 6.9 
 
orf19.4774 AOX1 0.5 0.4  1.3 1.2  1.6 1.1  2.7 3.0  3.3 2.7 
 
orf19.5369 
 
0.4 0.4  0.7 0.8  0.7 0.7  1.8 1.9  1.9 1.7 
 
orf19.5519 GCV1 0.3 0.2  1.0 1.0  1.1 0.6  2.9 5.7  3.2 3.2 
 
orf19.568 SPE2 0.4 0.2  1.4 2.0  2.1 1.4  3.8 9.3  5.5 6.8 
 
orf19.5736 ALS5 0.4 0.3  0.7 1.1  3.0 2.2  1.5 3.2  6.8 6.3 
 
orf19.5789 ADE8 0.4 0.2  1.3 1.9  0.6 0.6  3.3 7.6  1.6 2.5 
 
orf19.6146 CLG1 0.4 0.5  0.6 1.0  1.5 1.0  1.6 2.3  4.0 2.2 
 
orf19.7375 
 
0.5 0.3  1.3 1.8  1.1 2.1  2.7 6.7  2.2 7.5 
 
orf19.756 SAP7 0.4 0.4  0.9 0.6  13.6 6.6  2.2 1.5  31.7 15.7 
     
 
  
 
  
 
  
 
  Unknown orf19.1075 
 
0.3 0.5  1.5 1.4  2.5 1.4  5.1 2.7  8.9 2.8 
 
orf19.1258 
 
0.4 0.2  0.9 1.2  1.0 0.4  2.5 5.2  2.7 1.6 
 
orf19.1510 SRD1 0.3 0.4  0.8 1.4  1.8 0.8  2.7 3.6  6.1 2.0 
 
orf19.1681 
 
0.5 0.5  0.9 0.8  3.0 3.6  1.7 1.7  5.5 7.2 
 
orf19.2246 
 
0.3 0.1  0.6 0.8  0.7 2.1  2.2 5.7  2.6 14.1 
 
orf19.2461 PRN4 0.5 0.3  1.4 1.2  1.6 2.0  2.7 4.5  3.1 7.6 
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Table B-2. (Continued) 
 
      Change in Fold Expression         
 
   
SC5314+FLC/ 
SC5314 (A) 
 cas5Δ/Δ+FLC/ 
cas5Δ/Δ (B) 
 upc2Δ/Δ+FLC/ 
upc2Δ/Δ (C) 
 CAS5 Ratio 
(B/A) 
 UPC2 Ratio 
(C/A) 
   
    
Processa 
orf19 
Designation 
CGD 
Name Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
 
Exp1 Exp2 
 
orf19.2547 
 
0.5 0.2  1.7 2.7  0.9 1.0  3.5 12.1  1.9 4.7 
 
orf19.2870 
 
0.5 0.4  4.1 4.6  1.5 1.1  8.0 11.2  3.0 2.8 
 
orf19.2936 
 
0.4 0.3  1.2 1.6  1.9 0.7  2.8 4.9  4.6 2.2 
 
orf19.3042 
 
0.5 0.4  1.0 3.3  1.1 3.5  2.1 7.6  2.4 8.0 
 
orf19.306 USO5 0.5 0.5  1.8 2.0  1.3 1.7  3.4 4.1  2.4 3.5 
 
orf19.335 
 
0.4 0.3  0.6 0.6  0.7 0.8  1.7 2.3  2.1 3.1 
 
orf19.3475 
 
0.1 0.1  0.4 0.4  2.0 2.1  3.0 3.9  17.2 20.3 
 
orf19.348 SKN2 0.4 0.3  1.4 1.3  3.2 2.3  3.3 4.9  7.5 9.0 
 
orf19.3916 
 
0.2 0.2  0.9 0.6  0.4 0.5  4.0 2.9  1.8 2.1 
 
orf19.398 
 
0.4 0.4  1.3 1.2  1.2 1.3  2.9 3.3  2.6 3.7 
 
orf19.4142 
 
0.3 0.3  1.5 6.2  2.7 1.1  5.6 19.6  9.7 3.6 
 
orf19.4666 
 
0.4 0.5  1.0 1.8  1.1 1.1  2.5 3.5  2.7 2.1 
 
orf19.5051 
 
0.4 0.2  1.3 2.3  0.6 0.9  3.6 9.9  1.7 4.0 
 
orf19.5057 
 
0.4 0.3  5.8 1.9  1.8 0.7  14.2 6.0  4.5 2.4 
 
orf19.5071 NRP1 0.4 0.5  0.6 1.7  1.0 0.8  1.5 3.7  2.5 1.8 
 
orf19.5841 
 
0.5 0.5  0.7 0.8  0.8 1.0  1.5 1.5  1.8 1.9 
 
orf19.660 
 
0.4 0.4  2.0 3.5  1.8 2.1  4.4 7.8  4.0 4.8 
 
orf19.6635 
 
0.5 0.4  1.1 1.0  0.9 1.7  2.1 2.9  1.6 4.8 
 
orf19.6650 
 
0.5 0.4  1.1 1.5  1.8 2.1  2.1 3.4  3.5 5.0 
 
orf19.6679 
 
0.1 0.3  1.0 2.8  1.0 1.5  6.5 8.7  6.8 4.5 
 
orf19.6737 
 
0.5 0.4  1.0 1.2  0.9 0.6  2.0 3.3  1.8 1.7 
 
orf19.687 
 
0.4 0.2  0.8 1.3  0.7 0.5  1.8 5.4  1.7 1.9 
 
orf19.7284 ARS2 0.2 0.1  1.7 1.7  0.3 0.3  8.2 14.7  1.6 2.8 
 
orf19.7427 
 
0.4 0.3  0.7 1.1  1.9 1.3  1.5 3.8  4.2 4.6 
 
orf19.7553 
 
0.2 0.5  3.6 3.2  0.7 1.2  15.9 6.7  3.2 2.5 
a Descriptions are from the Candida Genome Database (http://www.candidagenome.org). 
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